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Abstract
Cysteine Dioxygenase is an enzyme that catalyses the reaction of cysteine to 
cysteinesulfinic acid and is thought to regulate the intracellular concentra- 
tions of its substrate. The enzyme may also be involved in the oxidation of 
exposed sulfidrils of proteins and by implication, involved in cell signalling or 
regulation. Substrate and products of cysteine dioxygenase are known to be 
disrupted in a number of neurodegenerative diseases making the protein an 
important target for medical research. To date, the structure of the protein 
has not been solved. An understanding of its structure and reaction mecha- 
nism will further the understanding of the aetiology of a number of different 
pathologies. Its structure may also further the development of novel pharma- 
cological drugs.
Chapter 1
Introduction
Cysteine dioxygenase (CDO) is an enzyme that catalyses the reaction of L- 
cysteine to 3-sulfino-L-alanine (L-Cysteinesulfinic acid). The reaction requires 
Fe2~ and \AD~ or \ADP~as cofactors. The enzyme was originally named 
cysteine oxidase until it was establised that it uses molecular oxygen as a 
co-substrate[l]. For this reason, it has been given an enzyme clasification 
of EC 1.13.11.20 (1-Oxidoreductase, 13-Acting on single donors with incor- 
poration of molecular oxygen, 11-With incorporation of two atoms of oxygen, 
2O-cysteine dioxygenase).
The precise physiological role of this enzyme has not been establised. It 
seems to be present in all animals, exists as a single gene copy, and shows 
an extraordinary sequence homology/identity across organisms, hi man, the 
gene is cytogenetically located on the long arm of chromosome 5, in the region 
of 22-23 (5q22-q23). The human genome project has since precisely located 
the gene between 119919360 - 119931270 bp. The mRNA is 1549 bases in 
length. The gene has 5 exons of 12kb of chromosome 5 and codes for a protein 
2OO aa residues long[2].
Biochemically, CDO is believed to be the principle regulator of free intra-
10
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Figure 1.1: Reaction catalyzed by cysteine dioxygenase
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Figure 1.2: Sanger Centre genome map with locus of human CDO gene
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cellular L-cysteine by converting it to 3-sulfino-L-alanine, which is ultimately 
converted to hypotaurine and taurine. As well as being an important con- 
stituent of proteins, L-cysteine is also a NMDA agonist and an excitotoxin[3]. 
Cysteine is also a precursor to glutathione and other anti-oxidants making 
CDO a tantalising target for pharmacophore development and to study its 
neuro-physiological role.
A significant amount of research is currently devoted to elucidating the 
aetiological basis of diseases. Epidemiological and genetic investigations have 
yielded many exogenous factors and loci as the potential causes of many 
pathologies. In nearly every neuropathy, differences in the severity, age of 
onset, gestation period, etc. indicate that there are many non-genetic fac- 
tors involved in pathogenesis. Developmental genetics and cancer research 
have shown that truncations of a protein may lead to a loss of function or 
cause the protein to become constitutively active. Molecular biophysics and 
prion research are less clear on the functionality of misfolded proteins, but 
the consequences are equally deleterious. Investigation of enzyme systems 
that potentially create intracellular conditions permissive for protein denat- 
uration, misfolding, and aggregation is important not only for prion disease, 
but also for all neurodegenerative diseases.
Many neurodegenerative diseases are characterised by mitochondria! dys- 
function, oxidative stress, alterations in the redox state, protein aggregation, 
and ultimately apoptosis or necrosis. There is no concensus on which aeti- 
ological features are causative or consequential. Cysteine dioxygenase is a 
suspect gene product in many neurodegenerative diseases. Its precise neuro- 
physiological function has never been established primarily because no ap- 
propriate model system exists. However, the gene product is likely to be 
the primary regulator of intracellular L-cysteine. Its substrate, L-cysteine,
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Figure 1.3: End-products of L-cysteine involved in the anti-oxidant defence.
is a neurotoxin as well as being a precursor substrate to the neuronal anti- 
oxidant defence, glutathione. hi addition, two of its end-products, hypotau- 
rine and taurine, are molecules that have a roles in neuromodulation and 
in anti-oxidant defence, hi order to understand what physiological relevance 
cysteine dioxygenase may have with respect to cell survival, a brief summary 
of some pathologies and few regulatory systems are discussed.
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1.1 Pathologies
Different neuro-pathologies may show very different clinical symptoms. Many 
have been identified as having a genetic basis or have been shown to be 
caused by exogenous factors. Most, if not all, of these different diseases have 
a commonality in the intracellular environment of their respective cell types. 
The cell groups affected dictate the outward clinical symptoms of the disease. 
A brief review of a few neurodegenerative diseases will highlight factors in- 
volved in pathogenesis and the role CDO may play within the cell.
1.1.1 Prion Disease
There are several human prion diseases: Kuru, fatal familial insomnia (Fin), 
Gerstmann-Straussler-Scheinker disease (GSS), and Creutzfeldt-Jakob dis- 
ease (CJD) are the most documented. Prion diseases differ from other patholo- 
gies in that the diseases are not caused by virus, bacteria or other convention- 
ally accepted pathogen; they are caused by a otherwise normal protein (PrP°) 
that undergoes a conformational change that catalyses the unfolding of the 
rest of the the PrP° into a pathogenic form (PrPSc). CJD, FFI, GSS, and Kuru 
are all part of the same class of transmissible spongiform encephalopathies 
fTSEs). Prion diseases are progressively neurodegenerative and are invariably 
fatal.
Initial clinical symptoms of CJD include fatigue, vertigo, anxiety, impaired 
memory, weakness, and impaired motor function[4]. As the disease pro- 
gresses, gross impairments of higher order brain function and motor func- 
tion ensue[4I. There is tremendous neuronal loss in CJD. The cerebral cor- 
tex is the most affected and the deeper lamellae of the frontal and temporal 
lobes are particularly prone[4). The striatum (caudate and putamen), thala-
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mus, midbrain, and the superficial layers of the cerebellar cortex also show 
these changes[4). In the final stages of the disease, victims' mental abilities 
completely deteriorate and they become vegetative[41. CJD can occur spon- 
taneously but a new variant epidemic (nvCJD) has attracted international 
attention in recent years. It is believed that scrapie, a sheep TSE, was passed 
across species to bovine (becoming bovine spongiform encephalopathy, BSE) 
by feeding cattle a "meat and bone meal" (MBM) containing scrapie infected 
sheep remains. Bovine spongiform encephalopathy (BSE) was then transmit- 
ted to man (nvCJD). The epidemic was thought to have spread further by the 
practice of feeding MBM, this time containing BSE infected meat. Kuru is 
thought to have been CJD and the epidemic a century ago is believed to have 
originated from cannibalistic practices upon a spontaneous CJD victim l . Ges- 
tation periods may last several years or decades but once the disease begins 
manifesting itself clinically, the course of neurodegeneration is rapid[8|.
PrP aggregation is a common feature of all prion disease, is apparent histo- 
logically, and amyloid plaques present are putative sites harbouring PrP5c[91. 
In CJD, PrP0 is a regulator of Cu^/Zn^-superoxide dismutase. It has been 
shown that the conversion of PrP° to PrPSc is sensitive to the redox state of 
the cell and the inability to mediate proper PrPc disulfide bonds! 10). The toxic 
effects of PrPSc have been attenuated in vitro with drugs that raise intracellu- 
lar levels of glutathione[l 1]. A lowered glutathione reductase is reported in a 
PrP° knockout cell line[12]. A dysfunctional glutathione reductase may indi- 
cate a change in the ratio of reduced to oxidised glutathione and to generalised 
protein folding problems (discussed later). There is widespread labelling for
'Kuru and CJD have been known to virulent diseasesISJ. The actual discovery of a virus 
has never been published and it was not until the discovery of the prion[6] that researchers 
realised a protein was the virulent agent. It has since become accepted that Kuru is caused 
by the virulent form of the prion protein!?].
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markers of oxidative stress in prion diseases and is a proposed cause of neu- 
ronal loss[13]. Impaired activities of mitochondria! Mn-superoxide dismutase 
(SOD), ATPase and cytochrome c in animal prion models suggest mitochon- 
dria! dysfunction! 14j. Inclusion bodies in prion disease are ubiquitinated[15J.
1.1.2 Huntington's Disease
Huntington's disease (HD) is an autosomal dominant disorder. The disease 
usually progresses from slight impaired motor function to progressive de- 
mentia over a course of 15-20 years[4). There are reductions in the mass of 
the cerebral cortex, white matter, thalamus and particularly the caudate and 
putamen(4]. There is progressive degeneration of the corpus striatum and 
the globus pallidus, hypothalamus, dentate nucleus, brain stem, and Purk- 
inje neurons of the cerebellum may also be affected[41. Neurofibrillary tangles 
reminiscent of Alzheimer*s disease are sometimes present[4). Interestingly, 
a co-worker in this laboratory has shown that CDO is strongly expressed in 
Purianje neurons! 16].
Huntington's disease is one of a class of (CAG)n/Qn -expansion disorders 
that code for extended glutamine repeats! 17J. In HD, the glutamine repeat 
is found on the huntingtin protein (349 kDa). The disease will not manifest 
itself until a threshold of repeats is reached; with increasing repeats there is 
a decrease in the age of onset and an increase in the severity of the disease. 
Other (CAG)n/Qn-expansion disorders include dentatorubral pallidoluysian 
atrophy (DRPLA or Smith disease), atrophin, and spinobulbar muscular at- 
rophy (Kennedy disease). Hallmarks of HD and other (CVlG)n/Qn-expansion 
disorders are aggregates of protein in the nuclei. Inclusion bodies in HD 
and (CMG)n/Qn-expansion disorders are ubiquitinated[15]. Although the ge-
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netic evidence in (CVlG)n/Qn -expansion disorders is compelling, epidemiologi- 
cal findings amongst twins indicate that environmental differences can affect 
the influence of genetic predisposition! 18]. Oxidative stress and severe mito- 
chondria! impairments of complex n and complex III have been reported in 
HD with less severe impairments of complex IVtl91 (Figure 1.4). There is an 
accumulation of iron in the basal ganglia in HD[20]. Interestingly, a 50% re- 
duction of oxidised glutathione has been reported in HD[21). A change in in 
the ratio of oxidised to reduced glutathione may be of importance for proper 
protein structure, function, and inclusion body formation.
1.1.3 Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease charac- 
terised by dramatic cognitive decline, neurodegeneration and characteristic 
neurofibrillary tangles (NFT). Several genetic mutations have been identified 
which can predispose an individual to AD. however, many cases are idio- 
pathic.
Histologically, AD has characteristic inclusion bodies in affected areas 
called senile plaques. As with other diseases, neurofibrillary tangles and 
plaques are aggregates of insoluble, protease-resistant and misfolded pro- 
teins. Several proteins have been identified as constituents of these inclu- 
sions: ft — amyloid (A beta), al-antichymotrypsin, amyloid precursor protein 
(APP), presenilin-l(PSl), neurosin, butyrylcholinesterase, synelfin (synuclein, 
NACP), tissue factor pathway inhibitor-1 (TFPI-1), tissue inhibitor of metal- 
loproteinase (TIMP), tau, heparin sulfate glycosaminoglycan, and many more 
are likely to be discovered[22, 23, 24, 25, 26, 27, 28, 29, 30). Mutations 
in some of these proteins have been shown to cause familial AD; in idio-
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patnic cases, the number of proteins identified in proteinaceous inclusions 
and knowledge of prion proteins as infections agents may indicate that initia- 
tion of the disease is due to a more general problem of proper folding.
Research indicates that there is an alteration in the ratio of reduced to 
oxidised gjutathione in the brains of AD patients[31]. Populations of neurons 
within the brain that are prone to develop NFTs are also part of a subset 
of neurons more immunoreactive to taurine[32]. Cysteine levels are elevated 
in AD[33) and an increased cysteine to sulphate ratio in AD links a defect 
in sulphur metabolism to the two previous observations[34, 35]. Oxidative 
stress and apoptosis in AD are well documented. There are several in situ ex- 
periments that have been published linking various transition metals with the 
generation of reactive oxygen species and solubility problems with amyloid de- 
posits; aluminium is also a suspect metal. Brain magnesium levels have been 
found to be lowered in AD compared to controls[36, 37]. Experiments have 
demonstrated that amyloid plaques are sites of free radical generation and 
oxidative stress; however ^-amyloid peptides will not spontaneously generate 
free radicals without the presence of a transition metal[38].
Epidemiological studies indicate that aluminium exposure is a risk factor 
for developing AD[39]. Magnesium deficiency may also be a risk factor.
1.1.4 Multiple Sclerosis
Multiple sclerosis (MS) accounting for about one per 1000 deaths around the 
world is a leading cause of disability amongst young people[4]. Generally it 
is recognised to affect the spinal neurons and accounts for the disability of 
movement. Clinically it is characterised by apathy, depression, fatigue weight 
loss, muscle pains, weakness, numbness, paresthesia, and varying vision
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problems[4]. It is a relapsing disease but as the disease takes its course it 
is invariably chronic and degenerative[4]. The disease also affects the brain 
and often results in vertigo, incontinence, and other problems associated with 
brain stem functional.
Brain sections in MS often reveal plaques(4). A commonly involved area in 
MS is the region between the caudate nucleus and the corpus callosum, the 
striatum, pallidum and the thalamus[4). There has not been a satisfactory 
amount of work done investigating MS plaques histologicalty but inclusion 
bodies, "pole bodies", have recently been identified[40]. Both reduced and 
oxidised glutathione levels are elevated in MS[41j. It has been reported that 
glutathione reductase activity is increased and glutathione peroxidase activity 
is decreased[42). Some evidence exists that there is a decrease in the cerebral 
thiol pool[43). There are obvious implications of these reports for oxidative 
stress; they may also have implications for improper protein folding. At least 
one enzyme, a-2-macroglobulin, that has been reported in MS with an aber- 
rant structureI44). The presence of inclusion bodies indicates that there are 
many others. Although the plaques have not been well characterised im- 
munohistochemically; one paper reports that A-amyloid is a constituent(45]. 
Iron deposits have been detected in brain tissue in MS and likely contribute 
to oxidative stress[46].
Initial epidemiological studies have suggested that mercury[47] is a risk 
factor. There are varying reports linking transition metals as either being 
protective or risk factors based on soil composition. A preponderance of epi- 
demiological papers implicate a viral risk factor.
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1.1.5 Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND) is a neu- 
rodegenerative disorder that affects both the upper and lower motor neu- 
ron systems[4). Cerebral regions are often normal but in protracted cases 
there is degeneration of the precentral gyrus[4). Neuronal loss and gliosis 
are also present in the thalamus, striatum. globus pallidus, subthalamic nu- 
cleus, and substantia nigra(4]. Occasionally, inclusion bodies called "Bunina 
bodies" are found in affected neurons and are immunoreactive to cystatin C, 
an inhibitor of cysteine proteases[4, 48]. Hyalinated intraceUular inclusions 
are common in affected neurons and are immunoreactive to ubiquitin and 
neurofilaments[4). There is a unusually high incidence of ALS in the south 
Pacific indicating exogenous risk factors[4].
It has been reported that the cerebro spinal fluid in ALS showed an ele- 
vated reduced to oxidised glutathione ratio[49J. Alterations in the cysteine to 
sulphate ratio in ALS have been reported[35). Prolonged survival in animal 
models of familial ALS receiving N-acetyl-L-cysteine, a non-toxic pro-cysteine 
compound, has been documented(501. Elevated taurine levels have been re- 
ported in cervical spinal regions in ALS[51] and in the brain[52).
1.1.6 Hallervorden-Spatz Disease
Hallervorden-Spatz Disease (HSD) or also "neurodegeneration with brain iron 
accumulation type-1" (NBIA-1) is characterised histologicalry by the accumu- 
lation of iron, protein aggregation, and progressive neurodegeneration[53]. 
HSD is a very rare disease that starts to manifest itself clinically in late 
childhood[4]. As the disease progresses, victims progressively lose their ability 
to articulate themselves. Dementia and dystonia ensue[4]. The accumulation
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of iron is visually apparent upon postmortem examination with staining of 
the globus pallidus and substantia nigra|4). The globus pallidus and sub- 
stantia nigra also show neuron loss, gliosis, and inclusion bodies (most also 
test positive for iron)[4].
Inclusion bodies are immunoreactive to a-synuclein, tau, and ubiquitin[54). 
It has been reported that cysteine dioxygenase activity is decreased and there 
are accumulations of cysteine and cysteine-glutathione mixed disulfide in 
HSD[55]. An enzyme blockage in cysteine metabolism and the ability of cys- 
teine to chelate metals has been a proposed mechanism for the disorder[4]. 
While iron accumulation is apparent in HSD, iron metabolism elsewhere in 
the body appears to be normal[56j. hi addition to iron as an aetiological prob- 
lem, copper and zinc levels are also elevated in HSD[57J.
1.1.7 Pick's Disease
Pick's Disease is characterised by middle-age onset dementia with concurrent 
lobar cerebral atrophyf4]. It distinguishes itself firom AD with morphologically 
distinct inclusion bodies. Pick's bodies, as opposed to the neurofibrillary tan- 
gles associated with AD[4]. Pick's bodies are comparable in size to the cell 
nucleus and appear to be composed of differing linear fibrils[4].
Proteins identified in the inclusion bodies, "Pick bodies", in Pick's disease 
include ubiquitin[4), tau, neurofilament(581, a-synuclein[59], heme oxygenase- 
1 (HO-1)[6O) and amyloid(61]. Significant accumulations of iron and man- 
ganese have been detected in brain tissue[62). Oxidanve stress is believed to 
be an important factor in the neural demise in Pick's disease with the pres- 
ence of HO-1, an indicator of oxidative stress[60].
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1.1.8 Progressive Supranuclear Palsy
Steele-Richardson-Olsewski disease or Progressive Supranuclear Palsy (PSP) 
is a late onset disease that is accompanied with parkinsonism and a char- 
acteristic loss of the ability to gaze downward[4). The subcortical region of 
the brain is mostly affected showing signs of neuronal loss, gliosis, but other 
regions of the brain and spinal cord may also be involved[4]. The subthala- 
mic nuclei, substantia nigra, and superior colliculi are most affected, together 
with the corpus striatum, globus pallidus, thalamus, red nucleus, brain stem 
tegmentum, and dentate nuclei also showing signs of the disease[4]. There 
is striatal dopamine depletion and depigmentation of the substantia nigra(4j. 
There is a reduction of dopamine receptors in PSP which accounts for the non- 
responsiveness of levodopa therapy and distinguishes itself from Parkinson's 
disease[4).
A 50% reduction of reduced glutathione is observed in the caudate nucleus 
in PSP[21]. Glutathione is markedly increased in the substantia nigra distin- 
guishing itself again from PD[63). Taurine levels are markedly increased in 
the nucleus accumbens, substantia nigra, and globus pallidusI63]. Cellular 
concentrations of 7-aminobutyric acid, glutamic acid, and glycerophospho- 
ethanolamine levels are also impaired in various regions of the brain com- 
pared with controls[63]. Inclusion bodies are present in the brain and spinal 
cord that are immunoreactive to tau and microtubule associated protein but 
are not ubiquitinated[4j. Qxidative stress and mitochondrial disfunction have 
been reported in both clinical and in in situ models of PSP. [64, 65].
Epidemiological studies indicate there may be a link between some Caribbean 
plant toxins and developing PSP[66J. Exhaustive efforts to determine whether 
or not there are other risk factors have been explored without finding any
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links(4|.
1.1.9 Parkinson's Disease
Parkinson's disease (PD) is a progressive neurodegenerative disorder that is 
also present in a number of different neuropathies affecting the central ner- 
vous system{67]. Clinical manifestations of the disease include poverty of 
movement, tremor, a characteristic shuffle step, and loss of balance[4]. As the 
disease progresses, patients may become susceptible to infection, confined to 
bed, and dementia may develop[4). Clinical manifestations of parkinsonism 
may be primarily degenerative, encompassing features of diseases like HSD 
and PSP. or secondary to diseases like CJD[4]. The disease usually mani- 
fests itself later in life and is often fatal ten years after the onset of clinical 
symptoms(41.
Depletion of the pigmented dopaminergic neurons is a key feature of PD. 
Areas of the brain affected include the brain stem, zona compacta of the sub- 
stantia nigra, locus corelleus. reticularis, dorsal nucleus of the vagus, dorsal 
raphe nucleus, substantia insomata, hypothalamus, and globus pallidus[4]. 
In addition to neuronal loss and gliosis, inclusion bodies are present within 
cells in affected areas. Intracellular inclusions known as Lewy bodies may be 
present in many areas of the CNSJ4J.
Cysteine levels are elevated in PDJ33J. There is a depletion of glutathione in 
the substantia nigra and the ratio between reduced and oxidised glutathione 
is depressed(68, 211. An elevated cysteine to sulphate ratio in PD links a defect 
in sulfur metabolism to the two previous observations[34, 35]. Cerebral spinal 
fluid from PD patients show decreased levels of taurine(69]. Inclusion bodies 
in PD are ubiquitinated, immunoreactive for tau, o-synuclein, amyloid[70],
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and have been shown to contain iron[71]. Iron is also a component of the 
neuromelanin found in the substantia nigra[72].
Epidemiological reports have linked a higher probability of developing PD 
after prolonged exposure to lead sulfate[73), manganese, copper, lead, iron, 
mercury, zinc, and aluminium[74]. There is a lower incidence of PD amongst 
smokers[75]. Exogenous toxins such as MPTP (MPP+)[76I and cycad plant 
toxins in Guam[77] and some Caribbean fruits[66] have been demonstrated 
to cause Parkinsonism. There is abundant literature suggesting that excito- 
toxcisity (particularly NMDA mediated) is a major contributor to PD neurode- 
generation. L-cysteine excitotoxcisity is mediated via the NMDA receptor. It is 
interesting that magnesium deficiencies may contribute to the pathogenesis 
of PD[78j; Magnesium is required to block the NMDA receptor, it attenuates 
the effects of oxidative stress induced by the Fenton reaction2 in vtuo[79], and 
it quenches the Fenton reaction in s#u[80, 81].
1.2 Overview
1.2.1 Mitochondria! Dysfunction
Mitochondria are responsible for meeting the energy requirements of the cell. 
This process is established by creating a redox potential across mitochondrial 
membranes. The process of respiration leads to the generation of ROS and 
healthy cells have many defences to prevent ROS damage. Mitochondrial dys- 
function has been described in neurodegenerative disease. As an organelle 
with a symbiotic relationship with the rest of the cell, any biochemical change 
in either system will have an influence on the homoeostasis of the other. In-
2The details of the Fenton reaction are described in the section "Oxidative Stress", page 
26.
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Figure 1.4: Common mitochondrial sites documented a being impaired in dif- 
ferent neurodegenerative pathologies. (Image taken from the KEGG database)
hibiting any step in mitochondrial respiration will have a cascade effect that 
effects cellular energy requirements, change chemical equilibria, biosynthe- 
sis, etc.
1.2.2 Redox State
The redox state of a cell is difficult define because of the large number of dif- 
ferent process that contribute to the intracellular environment. For simplic- 
ity, the redox state could be represented as the ratio of a reduced to oxidised 
marker, glutathione. The ratio of reduced glutathione is tightly regulated by 
several different glutathione oxidases, reductases and peroxidases. For the 
most part, glutathione levels are maintained by a complicated processes that
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recycle the substrate. The glutathione redox state then confers its redox sta- 
tus to countless other biochemical systems within the cell.
The redox ratio is not the only important redox parameter; concentration 
of redox active compounds is equally critical. Biochemically, the redox state is 
important for maintaining enzymatic reaction kinetics. Physically, the redox 
state dictates how chemical bonds are formed and this in turn can affect the 
structural integrity of proteins themselves. The ability to scavenge radicals is 
also influenced by the redox state.
Although the exact mechanism of paracetamol toxicity is not clear, the 
toxic effects are related to a depletion of glutathione[82]. Cysteamine and N- 
acetylcysteine are two prescribed antidotes for acute poisoning. Both these 
compounds can be converted to glutathione by first being converted to L- 
cysteine. Implicit with this observation is that cysteine dioxygenase is a redox 
regulator.
1.2.3 Oxidative Stress
Qxidative stress refers to the generation of reactive oxygen species (ROS) that 
can react with and damage proteins, lipids, DMA, and RNA. The main reactive 
species include superoxide radical (O?'), hydrogen peroxide (H2O2), hydroxyl 
free radical (HO*), singlet oxygen, hypochlorous acid, peroxynitrite (ONOO~), 
and nitric acid. All ROS are generated from oxygen within the cell. Mitochon- 
dria are the principal consumers of cellular oxygen and are responsible for 
generating the majority of ROS's.
A few enzymes are present to transmute ROS into more benign oxygen 
species. Catalase reduces peroxides (hydrogen and organic) into water and
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oxygen.
#202 + #202 -> 2#20 + 02
An extracellular, cytosolic and a mitochondria! superoxide dismutase (SOD) 
catalyses the conversion of superoxide into hydrogen peroxide and oxygen.
Glutathione peroxidase plays a major role reducing ROS by catalysing perox- 
ide to water; oxidised glutathione is then reduced by NADPH via glutathione 
reductase[83].
2G/UR
All of these enzymes require a metal cofactor to coordinate the reactions. SOD 
requires a zinc, copper, iron or manganese ion depending on the particular 
isoform. Catalase requires a haem group and manganese. Glutathione per- 
oxidase requires selenium.
Mitochondria! ubisemiquinone and complex I have been recognised as po- 
tential sources of superoxide formation via electron leakage during respiration[831. 
Several other routes of ROS generation have been proposed to explain oxida- 
tive stress observed in pathological conditions such as the Fenton reaction 
or the analogous Haber-Weiss reaction. The more general Fenton reaction 
explains how a transition metal can convert superoxide and peroxide (also
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hypochlorous acid) into the less reactive but more toxic hydroxyl radical.
The hydroxyl radical's toxcisiry is due to its longevity and it is one of the 
most long-lived reactive radicals known. Because there is some disagreement 
over the mechanism of this reaction, the Haber-Weiss reaction shows the half 
reactions and illustrate the required Fe2j~ and Fe3~ cycling:
Under anaerobic conditions, the Fenton reaction is also capable of oxidis- 
ing hydroxyl groups on carbon to ketone groups. Metal chelators may not 
quench the Fenton reaction. Iron complexed with EDTA has been shown to 
be 100 fold more catalytic, hi biological systems, transition metals are tightly 
regulated but dysregulation can lead to more rapid catalysis than the transi- 
tion metal ion alone|84j. In situ experiments have demonstrated the effective- 
ness of many transition metals catalysing the Fenton reaction and damaging 
DNAJ851 and although aluminium is not a transition metal, it has been shown 
to coordinate with the reaction making iron more catalytic(861.
Chemical factors that influence the Fenton reaction have also been shown 
to influence pathogenesis. There are papers indicating magnesium as having 
a protective effect: clinical, epiderniological, and chemical. Two papers have 
demonstrated magnesium ion as stabilising iron in the Fe2+ statefSO, 81]. If 
the chemistry works similarly under physiological conditions, it may prevent
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the conversion of O%~ to the more damaging HO* and prevent the required 
cycling of Fe2^ back to Fe3~. If true, it may indicate O?~ as the principal ROS 
generated under pathological conditions.
The superoxide radical is also capable of reacting with nitric oxide to form 
peroxynitrite, a thiol reactive oxidant that stimulates mitochondria! calcium 
releaselST].
Transition metals are often implicated in the aetiologies of many diseases. 
It has been shown that thiols such as dithiothreitol (DTT), L-cysteine, glu- 
tathione, cysteamine, J-mercaptoethanol, etc. can become toxic by reducing 
transition metals obviating the need for superoxide in Fenton reactions[88]; 
this may have ramifications for exposed thiol groups on misfolded proteins 
that would otherwise be buried within the tertiary structure. Guanosine 
triphosphate (GTP) also enhances the production of hydroxyl radical forma- 
tion in the Fenton reaction[89]. Acute toxic exposures to transition metals 
have also been shown to cause neurodegenerative diseases.
1.2.4 Glutathione Metabolism
Glutathione is a biological radical scavenger and a reductant. Oxidised glu- 
tathione (GSSG) is readily converted back to the reduced form (GSH) via a 
NAD(P)H dependent glutathione reductase (EC 1.6.4.2). GSH is synthesised 
in a two step reaction by the ATP driven 7   glutamylcysteine synthase (EC 
6.3.2.2) and ATP driven glutathione synthase (EC 6.3.2.3) (Figure 1.5).
The ratio of GSH/GSSG can affect protein folding. As a nascent peptide 
is being formed, disulfide bridges are often formed that stabilise adjacent 
peptide chains. If the environment is too reducing, these disulfide bonds 
are prevented from forming. If the local environment is too oxidising, disul-
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Figure 1.5: Two step process for biosynthesis of glutathione from L-cysteine.
fide bridges will form locking the conformation of the protein. Experiments 
in situ have shown that in order for a protein to fold into its energetically 
favourable functional tertiary structure, it is necessary for an equilibrium to 
exist between reduced and oxidised disulfide bonds until the final energeti- 
cally favourable conformation is reached[90, 91].
Glutathione synthase is the rate limiting enzyme in the biosynthesis of 
GSH. Overall synthesis is primarily limited by the availability of substrates, 
namely L-cysteine[92J.
1.2.5 Intracellular Cysteine
L-Cysteine is a thiol-containing amino add whose unique chemistry is vital 
for protein synthesis, is a required substrate for the biosynthesis of many 
cellular compounds in many critical pathways, and is also a toxin. L-Cysteine 
and methionine are two sulphur containing amino acids that play a critical 
role in coordinating metal ions in redox reactions carried out in enzymes.
Although a critical requirement for the structural integrity of proteins, 
L-cysteine is also a neurotoxin. For this reason the cell keeps its relative 
concentration low. It is also a rate limiting substrate in the biosynthesis of
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glutathione. L-cysteine is also a regulator of the expression of CDO an 7- 
glutamylcysteine synthase[93].
1.2.6 Inclusion Bodies
Inclusion bodies are aggregates of misfolded and protease resistant proteins. 
They may be referred to as Lewy Bodies (LB), senile plaques, amyloid plaques, 
etc. in histology. They are the result of proteins aggregating together due 
to misfolding, over-expression, a conformational change that preferentially 
binds to other proteins, damage, etc. Inclusion bodies are often highly ubiqui- 
tinated. a tag for cellular destruction, which indicates that the cell recognises 
the state of the protein as being aberrant. Controversy exists as to whether 
the inclusion bodies are causative or a resulting final step in many diseases. 
They are present in some brains with no apparent pathological symptoms. 
In others, they are usually detectable long after clinical symptoms become 
apparent so it has often considered a late event in pathogenesis.
It is not uncommon for recombinantly expressed proteins to form inclusion 
bodies in host systems. Depending on the host system, a lack of chaperonins 
or other accessory proteins in the translation process is one proposed expla- 
nation for a yield of misfunctional/misfolded aggregated protein. In eukary- 
otic systems that produce inclusions, an inordinately high level of translation 
may exhaust the supply of chaperonins, etc. Another likely cause that has 
been established is the redox state of the cell. Prokaryotic expression sys- 
tems are more reducing than eukaryotic cells and can prevent disulfide bond 
formation because of the higher level of reduced glutathione[90J. In order 
to recover functional protein, procedures have been developed to re-fold the 
peptide chain. In situ, "protein folding" work often requires re-suspending the
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protein in a solution with a ratio between reduced and oxidised forms of glu- 
tathione (or other reductant as J-mercaptoethanol) [9O, 94].
Factors such as chaperonins and gtycosylation state influence protein fold- 
ing. There is, however, very little evidence linking chaperonin problems with 
any neurodegenerative disease. Problems with gtycosylation are often at- 
tributed to problems with oxidative stress and the redox state of the cell, 
hi nearly every neurodegenerative disease (if not every), there are disruptions 
of glutathione levels or oxidised to reduced ratios. It is known from in situ 
work with proteins that concentrations of reductant and ratios between re- 
duced/oxidised forms are critical for refolding recombinant protein into func- 
tional products. Disruptions in nominal levels of glutathione, precursors, 
products, and other compounds linked to sulphur metabolism give some in- 
sightful aetiological clues because they are all linked by chemical equilibria.
Inclusion bodies and denatured proteins have often been identified as sites 
of oxidative stress. Various redox active metals have been associated with 
inclusions and denatured proteins. Research into Fenton or Haber-Weiss 
chemistry has shown that the reactions are often enhanced above what the 
metal ions are capable of on their own.
1.2.7 Taurine and Hypotaurine
Taurine is oxidised from hypotaurine by XAD~ dependant hypotaurine de- 
hydrogenase (EC 1.8.1.3) or from L-Cysteate3 by sulphoalanine decarboxy- 
lase (cysteine-sulphinate decarboxylase)(EC 4.1.1.29). Although there are 
two pathways, most biosynthesis in the brain is thought to proceed via hy- 
potaurine biosynthesis(96]. Taurine has been assigned several physiologi-
3MDCK/EAAT2 have been shown to produce L-Cysteate, a naturally occurring sulfonlc 
add analog of L-ghitamate.|95]
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cal properties. Taurine preserves gap junctional intercellular communication 
in liver hepatocytes subjected to a H2O2 stress that normally impairs their 
functlon[971. It can act in an uncompetitiVe manner on mitochondria for 
the uptake and sequestering of Ca2+ [98J. It has been shown to attenuate 
.UPP+toxicity[99]. It is believed that taurine is able to act as an osmoregula- 
tor by shuttling K~and Cl~as an electro neutral zwitterion[100] and research 
has shown that taurine can maintain cell volume! 101).
Hypotaurine is synthesised from 3-Sulphino-L-alanlne (same as L-Cysteinesulphinic 
acid) by Sulphoalanine decarboxylase (EC 4.1.1.29) . Hypotaurine, but not 
taurine, can function as an antioxidant by scavenging free radicals produced 
in situ by the Fenton reaction! 102]. hi addition, hypotaurine prevents the ox- 
idation, spontaneous or catalyzed, of iron(n) to iron(uT)[103]. Preventing the 
oxidation of Fe2+ to Fe3~ may be of importance because this step is critical 
for the recycling of the Fenton reaction and the generation of hydroxyl rad- 
ical (HO9). This may indicate a the biochemical branch between CDO and 
7-glutamylcysteine synthase may function in response to the nature of the 
oxidative insult.
1.2.8 Dioxygenases
Dioxygenases belong to a class of enzyme that use molecular oxygen (O2) to 
oxidise a substrate. In the case of CDO, L-cysteine would be the substrate. 
These enzymes require a transition metal cofactor, typically iron although 
copper and other atoms have been reported. The reaction also requires an 
additional dinucleotide, FAD(P)) or NADfP), cofactor to drive the reaction.
In human, at least fifteen different dioxygenases have been identified. The 
specificity of their substrates are summarised below:
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Figure 1.6: Biochemically relevant roles of L-cysteine in intracellular ho- 
moeostasis.
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CDO cysteine dioxygenase
HGD homogentisate 1,2-dioxygenase
PLOD 2-oxaloglutarate 5-dioxygenase
PLOD2 2-oxaloglutarate 5-dioxygenase
PLOD3 2-oxaloglutarate 5-dioxygenase
HPD 4-hydroxyphenyl pyruvate dioxygenase
INDO indolamine pyruvate 2,3-dioxygenase
P4HA1 2-oxaloglutarate 4-dioxygenase
P4HA2 2-oxaloglutarate 4-dioxygenase
P4HB 2-oxaloglutarate 4-dioxygenase
TDO2 tryptophan 2,3-dioxygenase
BBOX1 --oxaloglutarate dioxygenase 1
HAAO 3-hydroxyanthranilate 3,4-dioxygenase
BCDO 3-carotine dioxygenase
BCDO2 3-carotine dioxygenase
The structures and mechanisms of action of several dioxygenases have been 
solved. The mechanism of quercetin 2,3-dioxygenase and 2,3-dihydroxybiphenyl 
1,2-dioxygenase is pictured in the Appendix on pages 145 and 146, respec­ 
tively [1O4][105]. For dioxygenases with sequence homology, one could specu­ 
late that the reaction mechanisms were also similar. However, in the situation 
of cysteine dioxygenase, no such sequence homology exists. A phylogenetic
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analysis of human dioxygenases (Figure 1.7) and the following multiple align­ 
ment, for the same sequences, illustrate the uniqueness of cysteine dioxyge-
nase.
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1 
1 
1 
1 
1
IEQTE. .... .VLKPRTLADLIRILHQLFAIS. . . . .DEVN
LELK. ...... .YISGFGNECSSEDPRCPg. .SLPEGQN
ITTYSDKGAKPERGRFLHFHSVTFWVGNAKQ..A..ASFYlHAM.ENSWTISKEYHIDEEVGFALPNPQE..NLPDFYN
IIWYI..... LIIGILLPQSLAHPGFFTSI|g.-QMTDLIH
BLRRA..........LLCLAVAALVRADAPE.........
BRPLL...........LLALLGWLLLAEAKS.....DAKP
BGGCT.VKPQLLLLALVLHPWNPCLGADSEK....PSSIP
ISGCP...................FLGNNFg...... I YT
.QKAEALDGAHLMQILWYDEEE..SLYPAVW iKLWV...SALLMAWFGVLSCVQAEFFTSIg..HMTDLIY 
ITSSG.PGPRFLLLLPLLLPPAASASDRPR*....RDPVN1ERRL...............GVRAWVKENR*..SFQPPVC
IDIIF.........................5
fYRL....PVFKRYMGNTPQKKAVFGQCRELPCVAPLLT
CDO
HGD
HPD
INDO
P4HA1
P4HB
PLOD
PLOD2
TDO2
BBOX1
P4HA2
PLOD3
HAAO
BCDO
BCDO2
consensus
30 VEE..VQ.AIMEAYESDPIEWAMYA....KFDQYRY..TR
31 NPQVCPY.NLYAEQLSGSAFTCPRS...TNKRSWLYRILP
37 CSKMGFE.PLAYRGLETGSREVVSH..VIKQGKIVFVLSS
38 DWMFIAK.HLPDLIESGQLRERVEKLNMLSIDHLTDHKSQ
34 TEKDLVT.SLKDYIKAEEDKLEQIK....KWAEKLDRLTS
22 EEDHVLV.LRKSNFAEALAAHKYLL..VEFYAPWCGHCKA
25 EDNLLVL.TVATKETEGFRRFKRSA....QFFNYKIQALG
36 TDKLLVI.TVATKESDGFHRFMQSA....KYFNYTVKVLG
15 FKKLPVEGSEEDKSQTGVNRASKGGLIYGNYLHLEKVLNA
34 LRDNCPC.SDCYLDSAKARKLLVEA......LDVNIGIKG
36 AEKELVQ.SLKEYILVEEAKLSKIK....SWANKMEALTS
36 PEKLLVI.TVATAETEGYLRFLRSA....EFFNYTVRTLG
24 NKLMHQE.QLKVMFVGGPNTRKDYH..IEEGEEVFYQLEG 
	NRKEQLE.PVRAKVTGKIPAWLQGT8
37
LLRNGPGMHTVGE 
TVEEAPR.GISARVWGHFPKWLNGS..LLRIGPGKFEFGK
CDO
HGD
HPD
INDO
P4HA1
P4HB
PLOD
PLOD2
TDO2
BBOX1
P4HA2
PLOD3
HAAO
BOX)
BCDO2
consensus
61 N.LVDQGNGKFNLM.ILCWlESHGSSIH. .... . DHTNSH
67 S.VSHKPFESI. ...... . DESHVTHNW . DEVDPDPNQLR
74 A.LNPWNKEMGDHL. . . . VKHKDGV . . . . @DIAFEVEDC .
77 R . LARLVLGCITMAYVWGKlHEDVRKVLPRNIAVPYCQLS
T.ATKDPEGFVGHP- ..... .VNAFKLM.
L . APEYAKAAGKLK
69
59
60
71 Q . GEEWRGGDGINS . . . . l|
55
67
71
71
61
45
74
. . . . .
L.GEDWNVEKGTSA. . . . .1GKQKVRLL.QKVRLM .
QELQSETKGNKIHDEHLFIITHQAYELWF 
L.IFDRKKVYITWPDEH.YSEFQADWLK. 
K.SAADAEGYLAHP.......VNAYKLV.
L.GEEWRGGDVART....VlGSQKVRWL._
D.MVLRVLEQGKHRDVV.l|QKEIFLLPARVPHSPQRFAN 
S.RYNHWFDGLALLHSFTIBDSEVYYRS. [3YLRSDTYNTN 
D.KYNHWFDGMALLHQFRMBK@TVTYRS.0FLQSDTYKAN
SRLNTEWSELE 
SVDATEESDLA 5KALEKHADKE 
SEVMEHYADQD 2QILWELDSVR 2RCFSKQARAK SRLNTDWPALE 
SKEMEKYADRE
CDO 
HGD
HPD
INDO
P4HA1
P4HB
PLOD
PLOD2
TDO2
BBOX1
P4HA2
PLOD3
HAAO
BCDO
BCDO2
consensus
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93 .................CFLKMLQGNLKE.......... T CDO
97 WKPFEIPKASQKKVDFVSGLHTLCGAGDI.KSNNGLAIHI HGD
104 ..DYIVQKARERGAKIMREPWV.....EQ.DKFGKVKFAV HPD
116 .KKLELPPILVYADCVLANWKK......K.DPNKPLTYEN INDO
100 ..NLVLKDMSDGFISNLTIQRPVLSNDED.QVGAAKALLR P4HA1
92 .........QQYGVRGYPTIKFFRNGDTA.SPKEYTAGRE P4HB
93 . .DLVILFADSYDVLFASGPRELLKKFRQ.ARSQWFSAE PLOD
105 . .DLVVMFTECFDVIFAGGPEEVLKKFQK.ANHKWFAAD PLOD2
95 .........EIFQNGHVRDERNMLKVVSR..MHRVSVILK TDO2
104 LQRELFFPECQYWGSELQLPTLDFEDVLRYDEHAYKWLST BBOX1
102 ..DLVLQDSAAGFIANLSVQRQFFPTDED.EIGAAKALMR P4HA2
105 ..DMIIMFVDSYDVILAGSPTELLKKFVQ.SGSRLLFSAE PLOD3
99 ..TVGLVVERRRLETELDGLRYYVGDTMD......VLFEK HAAO
83 . . . . . .IEANRIWSEFGTMAY. . PDPCK .NIFSKAFSYL BCDO
112 ......SAKNRIVISEFGTLA..LPDPCK......NVFER BCDO2
	consensus
106 LFAWPDK..KSNEMVKKSERV...L.RENQCHYI..NDSI CDO
136 FLCNTSM..ENRCFYNSDGDF.LIV..PQKGNL..LIYTE HGD
136 LQTYGDT..THTLVEKMNYIG.QFLPGYEAPBFM.DPLLP HPD
148 MDVLFSF..RDGDCSKGFFLV.SLL..VEIA§A..SAIKV INDO
137 LQDTYNL..DTDTISKGNLPG...V...KHKSFLTAEDCF P4HA1
122 ADDIVNW......LKKRTGPA.ATT..LPDGBA..AESLV P4HB
130 ELIYPDR..RLETKYPVVSDG.KRF..LGSGBFI.-GYAP PLOD
142 GILWPDK..RLADKYPVVHIG.KRY..LNSGBFI..GYAP PLOD2
124 LLVQQFS..ILETMTALDFNDFREY.LSPASlFQSLQFRL TDO2
144 LKKVGIV..RLTGASDKPGEV.SKL..GKRMlFLYLTFYG BBOX1
139 LQDTYRL..DPGTISRGELPG.TKY.....QflMLSVDDCF P4HA2
142 SFCWPEW..GLAEQYPEVGTG.KRF..LNSG^FI..GFAT PLOD3
131 WFYCKDLGTQLAPIIQEFFSS.EQY...RTGKPI...... HAAO
114 SHTIPDF..TDNCLINIMKCG.EDF.......YA.TSETN BCDO
138 FMSRFELPGKAAAMTDDTNVNYVRY....KGDYYLCTETN BCDO2
	* consensus
138 GLHRVENISHTEPAVSLHLYSPPFDTCHAFDQRTGHKNKV CDO
169 FGKML..VQPNEI..CVIQRGMRFSIDVFEE....TRGYI HGD
172 KLPKC.SLEMIDHIVGNQPDQEMVSASEWYL.KNLQFHRF HPD
181 IPTVF...KAMQM......QERDTLLKALLEIASCLE.KA INDO
169 ELGKV.AYTEADY..YHTELWMEQALRQLDEGEISTIDKV P4HA1
151 ESSEV...AVIGF....FKDVESDSAKQFLQ.......AA P4HB
163 NLSKL..VAEWEG..QDSDSDQLFYTKIFLD.PEKREQIN PLOD
175 YVNRI..VQQWNL..QDNDDDQLFYTKVYID.PLKREAIN PLOD2
161 LENKIGVLQNMRV.........PYNRRHYRD......... TDO2
179 HTWQV..QDKIDA...NNVAYTTGKLSFHTDYPALHHPPG BBOX1
171 GMGRS.AYNEGDY..YHTVLWMEQVLKQLDAGEEATTTKS P4HA2
175 TIHQI..VRQWKY..KDDDDDQLFYTRLYLD.PGLREKLS PLOD3
161 .PDQL..LKEPPFPLSTRSIMEPMSLDAWLD....SHHRE HAAO
143 YIRKI.NPQTLET.......LEKVDYRKYVAVNLATSHPH BCDO
174 FMNKV.DIETLEK.......TEKVDWSKFIAVNGATAHPH BCDO2
	consensus
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TLC. .EFDT. . VDLSAVDVHPNVSIGVFI a 
EES. .EEKE. . EQVAEFQKQKEVLLSLFD a 
ELD. .DKGQ.VVRINFNNATRDTIFDVPVa 
TLT. .NQTE. . AELATPEGIYERPVDYLP " 
GFC. .NQDR. .RTLPGGQPPPRVFLAVFVa 
SYA.WERTQ. ......... . GSVALSVTQD
PFR . LDILK . MATAYIRRMSWASCLAFHRg 
PLK . MNLWK . I ATSKIRGKAFSDGI SWEPQ
*
IPIAWYEDRQ 
MPINEPAPGK 
GWKGNPQLSD 
LDPEHQR NG 
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FEMGHVR RN 
FENGKAR KN 
LVEAWLE TP 
LKKNNPQ FQ 
LDPSHER GG 
FDRNRVR: RN 
YGQGSSE LR 
VPEGKKQ KS 
VPPEEVD GE
*
VAWHGNYTPY 
EDIITAIRHL 
LLGIQQTAGG 
AKEKDVNKSA 
LLDFIKHNQL 
PRFWTFETGC 
PNSWTQDNGC 
EEEFIRIQAK 
QSK. . .HKII 
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201 ........................................ CDO
314 DFV..IFPPRWGVADKTFRPPYYHRNCMSEFMGLIRGHYE HGD
312 ENIDALEELK....ILVDYDEKGYLLQ...IFTKPVQDRP HPD
324 GDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPK INDO
296 EGIKMTPRRQ..................KKLFCRYHDGNR P4HA1
274 NFKTAAESFKGKILFIFIDSDHTDNQRILEFFGLKKEECP P4HB
306 QRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQ PLOD
316 DILLTLDYPKEALKLFIHNKEVYHEKDIKVFFDKAKHEIK PLOD2
281 ERRLSYRALQGALMIYFYREEPRFQVPFQLLTSLMDIDSL TDO2
316 EFVDLMNSKESKFTFKMNPGDVITFDNWRLLHGRRSYE.A BBOX1
297 EGVKLTPRRQ..................KRLFCRYHHGNR P4HA2
316 QRLLLLDYPPDRVTLFLHNNEVFHEPHIADSWPQLQDHFS PLOD3
287 ........................................ HAAO
290 RTRQPVQTKFYTGAMVVFHHVNAYEEDGCIVFDVIAYEDN BOX)
316 RTGQLLPGRYYSKPFVTFHQINAFEDQGCVIIDLCCQDNG BCDO2
	consensus
201 ........................................ CDO
352 AKQGGF..LPGGGSLHSTMTPHGPDADCFEKASKVKLAPE HGD
345 TLF..LEVIQ..RHNHQGFGAGNFNSLFKAFEEEQNLRGN HPD
364 ENK.....TS..EDPSKLEAKGTGGTDLMNFLKTVRSTTE INDO
318 NPK..F.ILA.............PAKQEDEWDKPRIIRFH P4HA1
314 AVR....LIT....LEEEMTKYKPESEELTAERITEFC.H P4HB
346 SVK....LVG....PEVRMANADARNMGADLCRQDRSCTY PLOD
356 TIK....IVG....PEENLSQAEARNMGMDFCRQDEKCDY PLOD2
321 MTKWRYNHVC.MVHRMLGSKAGTGGSSGYHYLRSTVSDRY TDO2
355 GTE ..... IS .. RHLEGAYADWDWMSRLRILRQRVENGN BBOX1
319 APQ..L.LIA.............PFKEEDEWDSPHIVRYY P4HA2
356 AVK....LVG....PEEALSPGEARDMAMDLCRQDPECEF PLOD3
287 ........................................ HAAO
330 SLYQLF.YLA...NLNQDFKE.NSRLTSVPTLRRFAVPLH BOX)
356 RTLEVY.QLQNLRKAGEGLDQ.VHNSAAKSFPRRFVLPLN BCDO2
	consensus
201 ........................................ CDO
390 RIADGTMAFMFESSLSLAVTKWGLKASRCLDENYHKCWEP HGD
381 LTNMETNGWPGM. .......................... HPD
397 KSLLKEG................................. INDO
342 DIISDAE............IEIVKDLAKPRLSR.ATVHDP P4HA1
345 RF.LEGK.IKPHLMSQELPEDWDKQPVKVLV......... P4HB
378 YFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSN PLOD
388 YFSVDADVVLTNPRTLKILIEQNRKIIAPLVTRHGKLWSN PLOD2
360 KVFVD....LFNLSTYLIPRHWIPKM.NPTI..HKFLY.. TDO2
388 ........................................ BBOX1
343 DVMSDEE............IERIKEIAKPKLAR.ATVRDP P4HA2
388 YFSLDADAVLTNLQTLRILIEENRKVIAPMLSRHGKLWSN PLOD3
287 ........................................ HAAO
365 .VDKNAEVGTNLIKVASTTATALKEEDGQVYCQPEFLYEG BCDO
394 .VSLNAPEGDNLSPLSYTSASAVKQADGTICCSHENLHQE BCDO2
	consensus
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201 ........................................ CDO
430 LKSHFTPNSRNPAEPN........................ HGD
394 ........................................ HPD
404 ........................................ INDO
369 ETGKLTTAQY.............................. P4HA1
374 ......GKNFEDVAFDEKKNVFVEFYAPW.CGHCKQLAPI P4HB
418 FWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLI PLOD
428 FWGALSPDGYYARSEDYVDIVQGNRVGVWNVPYMANVYLI PLOD2
391 .TAEYCDSSYFSSDESD. ...................... TDO2
388 ........................................ BBOX1
370 KTGVLTVASY.............................. P4HA2
428 FWGALSPDEYYARSEDYVELVQRKRVGVWNVPYISQAYVI PLOD3
287 ........................................ HAAO
404 L..ELPRVNYAHNGKQY.......RY.VFATG..VQWSPI BCDO
433 ...DLEKEGGIEFPQIYYDRFSGKKYHFF.YG.CGFRHLV BCDO2
	consensus
201 ........................................ CDO
446 ........................................ HGD
394 ........................................ HPD
404 ........................................ INDO
379 ....... .RVSKSAWLSGYENPWSRINMRIQDLTGLDVS P4HA1
407 WDKLGETYKDHENIVI.AKMDSTANEVEAVKVH.SFPTLK P4HB
458 KGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLT PLOD
468 KGKTLRSEMNERNYFVRDKLDPDMALCRNAREMGVFMYIS PLOD2
407 ........................................ TDO2
388 ........................................ BBOX1
380 ........RVSKSSWLEEDDDPVVARVNRRMQHITGLTVK P4HA2
468 RGDTLRMELPQRDVFSGSDTDPDMAFCKSFRDKGIFLHLS PLOD3
287 ........................................ HAAO
432 PTKIIKYDILTKSSLKWREDDCWPAEPLFVPAPGAKDEDD BCDO
468 GDSLIKVDVVNKTLKVWREDGFYPSEPVFVPAPGTNEEDG BCDO2
	consensus
201 ........................................ CDO
446 ........................................ HGD
394 ........................................ HPD
404 ........................................ INDO
411 TAEELQVANYGVGGQYEPHFDFARKDEPDAFKELGTGNRI P4HA1
445 .FFPASADRTVIDYNGERTLDGFKKFLESG.GQDGAGDDD P4HB
498 NRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQ PLOD
508 NRHEFGRLLSTANYNTSHYNNDLWQIFENPVDWKEKYINR PLOD2
407 ........................................ TDO2
388 ........................................ BBOX1
412 TAELLQVANYGVGGQYEPHFDFSRNDERDTFKHLGTGNRV P4HA2
508 NQHEFGRLLATSRYDTEHLHPDLWQIFDNPVDWKEQYIHE PLOD3
287 ........................................ HAAO
472 GVILSAIVSTDPQKLPFLLILDAKSFTELARASVDVDMHM BCDO
508 GVILSWITPNQNESNFLLVLDAKNFEELGRAEVPVQMPY BCDO2
	consensus
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201 ........................................ CDO
446 ........................................ HGD
394 ........................................ HPD
404 ........................................ INDO
451 ATWLFYMSDVSAGGATVFPEVGASVWPKKGTAVFWYNLFA P4HA1
483 OLE .....D.LEEAEEPDME......EDDDQKAVKDEL. . P4HB
538 NYTKALAGK.LVETPCPDVYWFPIFTEVACDELVEEMEHF PLOD
548 DYSKIFTEN.IVEQPCPDVFWFPIFSEKACDELVEEMEHY PLOD2
407 ........................................ TDO2
388 ........................................ BBOX1
452 ATFLNYMSDVEAGGATVFPDLGAAIWPKKGTAVFWYNLLR P4HA2
548 NYSRALEGEGIVEQPCPDVYWFPLLSEQMCDELVAEMEHY PLOD3
287 ........................................ HAAO
512 DLHGLFITD.........MOW.....DTKKQAASEEQRDR BCDO
548 GFHGTFIPI............................... BCDO2
	consensus
201 ........................................ CDO
446 ........................................ HGD
394 ........................................ HPD
404 ........................................ INDO
491 SGEGDYSTRHAACPVLVGNKWVSNKWLHERGQEFRRPCTL P4HA1
509 ........................................ P4HB
577 GQWSLGNNKDNRIQGGYENVPTIDIHMNQIGFEREWHKFL PLOD
587 GKWSGGKHHDSRISGGYENVPTDDIHMKQVDLENVWLDFI PLOD2
407 ........................................ TDO2
388 ........................................ BBOX1
492 SGEGDYRTRHAACPVLVGCKWVSNKWFHERGQEFLRPCGS P4HA2
588 GQWSGGRHEDSRLAGGYENVPTVDIHMKQVGYEDQWLQLL PLOD3
287 ........................................ HAAO
538 ASDCHGAPLT.............................. BCDO
557 ........................................ BCDO2
	consensus
201 ........................................ CDO
446 ........................................ HGD
394 ........................................ HPD
404 ........................................ INDO
531 SELE.................................... P4HA1
509 ........................................ P4HB
617 LEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSLMPH PLOD
627 REFIAPVTLKVFAGYYTKGFALLNFVVKYSPERQRSLRPH PLOD2
407 ........................................ TDO2
388 ........................................ BBOX1
532 TEVD.................................... P4HA2
628 RTYVGPMTESLFPGYHTKARAVMNFVVRYRPDEQPSLRPH PLOD3
287 ........................................ HAAO
548 ........................................ BCDO
557 ........................................ BCDO2
	consensus
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201 ........................................ CDO
446 ........................................ HGD
394 ........................................ HPD
404 ........................................ INDO
535 ........................................ P4HA1
509 ........................................ P4HB
657 HDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGW PLOD
667 HDASTFTINIALNNVGEDFQGGGCKFLRYNCSIESPRKGW PLOD2
407 ........................................ TDO2
388 ........................................ BBOX1
536 ........................................ P4HA2
668 HDSSTFTLNVALNHKGLDYEGGGCRFLRYDCVISSPRKGW PLOD3
287 ........................................ HAAO
548 ........................................ BCDO
557 ........................................ BCDO2
	consensus
201 ............................... CDO
446 ............................... HGD
394 ............................... HPD
404 ............................... INDO
535 ............................... P4HA1
509 ............................... P4HB
697 TLMHPGRLTHYHEGLPTTRGTRYIAVSFVDP PLOD
707 SFMHPGRLTHLHEGLPVKNGTRYIAVSFIDP PLOD2
407 ............................... TDO2
388 ............................... BBOX1
536 ............................... P4HA2
708 ALLHPGRLTHYHEGLPTTWGTRYIMVSFVDP PLOD3
287 ............................... HAAO
548 ............................... BCDO
557 ............................... BCDO2
	consensus
(X) non conserved | similar 
S conserved 
  all match
1.2.9 Cysteine Dioxygenase
Pointing out the Fenton reaction as a mechanism for the generation of ROS in 
neurodegenerative disease is like beating a dead horse. Understanding what 
dysregulates the cell environment that allows opportunistic transition metals 
to bind to misfolded proteins and carry out their unique chemistry is a topic 
of importance in the field.
Cysteine dioxygenase (EC 1.13.11.20) (CDO) catalyses the conversion of
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Figure 1.7: Phyiogenetic analysis of sequence data of human dio^Qrgenases.
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cysteine to 3-Sulphino-L-alanine (also named L-Cysteinesulphinic acid and 3- 
Sulphinoalanine), a necessary substrate for hypotaurine and taurine biosyn- 
thesis. It has 200 amino acid residues in human and rat, has a calculated 
molecular weight of 22984 Da in man, it uses Fe2+ as a cofactor, and re- 
quires NAD(P)H. CDO has been identified in homo sapiens, rattus norvegucus, 
drosophila melanogaster (fly), caenorhabditis elegans (nematode)(preliminary) 
and schistosomajaponicum (oriental blood fluke). CDO shares no sequence 
homology with other proteins (including other dioxygenases) yet there is con- 
siderable protein sequence homology amongst CDOs in vastly different or- 
ganisms (Figure 1.8). hi regions where the primary sequences are not as 
conserved, there may well be a considerable conservation in their secondary/ 
tertiary structure (Figure 5.4, page 112). Such conservation may indicate a 
similarly conserved physiological role as well. Substrates and products of 
CDO are involved in radical scavenging, oxidation and reduction homoeosta- 
sis, osmotic regulation, detoxification, and signal transduction.
It is believed that CDO is a principal regulator of intracellular cysteine 
level! 106]. Owing to the fact that glutathione levels are regulated by the avail- 
ability of cysteine, CDO is automatically suspect as a possible regulator of 
glutathione levels as well.
Additional interesting physiological parallels of a cysteine dioxygenase from 
the fungus histoplasma capsulation can be drawn. It exists in nature as a 
multicellular fungus but is a unicellular pathogenic yeast in an animal host. 
The phase change of histoplasma capsulation is dependant on a low redox 
potential, a change in intracellular cysteine levels, as well as cysteine/redox 
dependant changes in mitochondria! respiration; expression of cysteine dioxy- 
genase is believed to be the enzyme mediating the intracellular redox changes 
that lead to differentiation into the pathogenic form[107, 108. 109]. Although
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Figure 1.8: Protein sequence homology of CDO
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a different organism, CDO has been shown to regulate the redox status as 
well as influence mitochondria! respiration.
1.2.1O Summary
Cysteine dioxygenase is a rate limiting enzyme that is responsible for reg- 
ulating intracellular cysteine levels and for the biosynthesis of hypotaurine 
and taurine. Glutathione and neuromelanin[l 10] biosynthesis are dependant 
upon the availability of cysteine. Hypotaurine, taurine, neuromelanin and 
GSH/GSSG are all important compounds for maintaining homoeostasis and 
for responding to different stressors present under normal and pathological 
states. As well as being a key biosynthesis enzyme, CDO also appears to be 
able to shift the stress response of the cell depending on the nature of the 
insult.
Chapter 2
Aims
Tlie physical characterisation of CDO is the primary objective. Firstly, to ex­ 
press the protein an confirm the primary structure. Secondly, to find solution 
conditions in which the protein is stable and appears to be folded. Lastly, to 
quantify secondary and tertiary structural characteristics of the protein.
A system that provides a continuous supply of protein and chromatogra- 
phy to purify the enzyme is a prerequisite to accomplish these goals. Circular 
dichroism is a physical technique to measure the secondary structure of the 
protein. Dynamic light scattering is used to monitor the behaviour of CDO in 
solution and to design experiments around it. Nuclear magnetic resonance 
and protein crystallography are the final techniques to quantitatively analyse 
the actual structure of the protein under near physiological conditions. The 
ultimate aim is to determine the tertiary structure of the protein or to at least 
lay down the foundations to solve its structure.
Gaining detailed structural information about CDO is of more than just 
academic interest. Pharmacophores could be synthesised, based upon struc­ 
ture, specific to the protein that act as antagonists, agonists, or modulate 
the function in some other manner. Such compounds would be useful to re-
47
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searchers studying cell or animal models of diseases. If the modulation of the 
enzyme proves that it could play a pivotal role in any pathology, the struc- 
ture is of benefit pharmacologically for the development of next generation 
drugs based on structure; "rational drug design". Drugs such as Relenza™ ! 
. Amprenavir™ 2 , B.VP77873 and Entacapone™ 4 are a few examples of thera- 
peutics rationally designed from 3-D structures of proteins! 111, 112, 113].
'Relenza or Zanamivir/GG167 is a potent neuraminidase inhibitor used as an anti- 
influenza drug. Relenza was designed based on the x-ray crystallograpbJc structure of in­ 
fluenza neuraminidase.
2Amprenavir is an AIDS protease inhibitor that was designed based on the x-ray crystallo- 
graphic structure of HTV-protease . It is licensed to GalaxoWellcome/Vertex and is also known 
as Vertex VX-478. Agenerase or 141W94.
3BNP7787 is a drug rationally designed to prevent toxdsity associated with taxanes and 
dsplattn used in chemotherapy and without side-effects. It was developed by Cray Super­ 
computer and BioNumerik Pharmaceuticals.
4Entacapone is a Catechol OMethyitransferase inhibitor marketed by Orion Phanna and 
is being used to extend the effectiveness of levodopa therapy in Parkinson's Disease
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1. Expression of CDO in a bacterial system
(a) Proof of expression
i. PCR analysis of construct 
ii. SDS-PAGE of product 
iii. Sequencing of the construct insert
(b) Refine system for frequent bulk expression
2. Analysis of expressed product
(a) Concentration Determination
i. Surface Plasmon Resonance 
ii. Spectrophotometry
(b) Size determination
i. SDS-PAGE 
ii. Mass spectroscopy 
iii. Dynamic light scattering
—> Hydrodynamic Radius
—> Aggregation State
(c) Analysis of Secondary Structure 
i. Circular Dichroism
(d) Analysis of Tertiary/Quaternary Structure
i. X-ray Crystallography 
ii. Nuclear Magnetic Resonance
Figure 2.1: Representation of the aims of the study.
Chapter 3
Expression of Cysteine 
Dioxygenase
For the production of cysteine dioxygenase, a bacterial BL21(DE3) expression 
system was chosen. The vector used to induce human CDO is pET15b, an 
expression vector that co-expresses a poly-histidine fusion protein (HISx). The 
advantages of this bacterial system are that CDO can be expressed quickly, 
with minimal risk of cross contamination, and in large yields. The advantage 
of the rflSx tag is that CDO can be purified without the need for sophisticated 
chromatography equipment.
One potential drawback is that prokaryotic cells do not perform post- 
translational modifications on their expressed proteins. Endogenous CDO 
has been studied for a number of years and there has been no published ref­ 
erence of any gh/cosylation site1 . Furthermore, computational analysis indi­ 
cates that there is only one probable N-gtyeosylation site (Figure 3.1 and A.4,
1 Unpublished reports indicate that CDO is gjycosyiated. However, the degree to which CDO 
is glycosylated and the number and sequence of these sites remains unclear. It is also unclear 
if these sites are glycosylated for cell localisation, protein functionality or modulation. It has 
also not been established under which conditions and cell types CDO may be glycosylated.
50
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page 147) and one O-gtycosylation site (Figure A.5, page 148); Asparagine- 144 
and Threonine- 193 respectively. It is open to speculation whether any poten- 
tial modification affects the overall tertiary structure. Given the high degree of 
sequence homology from the nematode to man (Figure 1.8, page 45), in vastly 
different cells, makes it unlikely they share identical post-translational modi- 
fications; the prokaryotically expressed CDO is likely to retain its structure.
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Figure 3.1: Predicted N-^rcosylation of endogenous CDO using NetNGtyc 1.0.
The CDO expression system was also used with the intent of studying its 
protein product. If a gene product is post-translationaly modified, the mod- 
ifications are rarely uniform from one particle (protein) to the next. This is 
especially true if the modifications are in response to cell regulation (targeted 
destruction or feedback regulation). Using an unmodified gene product elimi- 
nates the intractable problem of puiifing each particle species of CDO.
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Figure 3.2: pET15b (Novagen, Inc.)
3.1 Aims
The aims of the expression system are firstly to confirm that the insert se- 
quence of the vector matches the sequence of the human gene. Secondly, to 
express CDO and confirm its presence by electrophoresis and western blot- 
ting. Lastly, to develop a system with increased yield and that produces a 
steady supply of protein.
3.2 Protocols
3.2.1 Expression System
A Novagen pET15b expression vector was used for all experiments (Figure 3.2 
and A.6, page 149)1114J. Human CDO cDNA was sub-cloned into the vector 
and the transfected into a BL21(DE3) cell. The cDNA was created by rtPCR 
with primers containing BamHl and Ndel and force ligated into the vector.
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Figure 3.3: Plasmid map of the pET15b-CDO construct
SOB Medium (14
20g
5g 
0.5g
SOB Plating Medium (If}
5mls
Peptone
Yeast Extract
Sodium Chloride
3M Potassium Chloride
2M Magnesium Chloride 5mls
20g
5g 
0.5g
.5=^Autoclave 
250/if 20Omg/mI Ampicillin
15g
Peptone
Yeast Extract
Sodium Chloride
3M Potassium Chloride
2M Magnesium Chloride
Bactoagar
pH=>7.5=»Autoclave 
25On£ 200mg/ml Ampicillin 
Figure 3.4: SOB growth medium and plating medium
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3.2.2 Confirmation of Expression System
Confirmation of the insert was performed by streaking colonies onto a SOB 
plate containing ampiciUin (Figure 3.4) and detecting the insert by PCR Plates 
were sealed with a strip of parafilm and incubated overnight at 37CC in hu- 
midity chamber. A pair of primers corresponding to 5* and 3* flanking T7 
promoter/terminator regions were synthesised by Alta Biosdence.
Primer
hCDO pET 5*
hCDO pET 3'
T7 Terminator
T7 Promoter
Term.-*-
PTO.+
Sequence
TCC-CCA-CGA-GCA-TAT-GGA-ACA-GA
GTT-TGG-TGC-CGG-ATC-CTT-AGT-TGT
GCT-AGT-TAT-TGC-TCA-GCG-G
TAA-TAC-GAC-TCA-CTA-TAG-GG
GTC-CGG-CGT-AGA-GGA-TC
CGG-ATA-TAG-TTC-CTC-CT
Synthesis ID
D15103DR
D15104DR
D26465CB
D26463CB
D27698CB
D27697CB
Colonies were transfered directly to PCR reaction mixtures using sterile 
pipette tips. PCR reaction mixtures consisted of: 28.8/x£ ddH2O, 1^ dNTP 
mixture (25 /iM), Ipt 5* primer (100pM), !/*£ 3* primer (100 pM),5/i£ IQx Buffer, 
Sfit 25mM MgCl?, 0.25ftf Taq Polymerase. After the mixture was inoculated 
directly with a bacterial colony, it was mixed with a vortexer and topped with 
50/il sterile mineral oil. Lysis of the cells was done by the initial melting PCR 
step. PCR reactions were done using a Perkin Elmer thermocycler using a 
step cycle. Optimal annealing temperatures were provided with the synthesis 
of the oligos. Thirty cycles were performed using a "1 min 94°" melting step, 
a "1 min 50°" annealing step and a "2 min 72°" elongation step2 . No final
2Thirty cycles were chosen based on a standard practice for amplification. The melting 
step temperatures were based upon the theoretical melting temperatures of the synthesised 
oligoneucleotldes. The elongation time was based on the product length.
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PCR Mixture
29.8/rf <MH2O
1/^dNTP 
3* Primer 
5* Primer 
10X Buffer 
25mM
PCR Cycle
(30 cycles) 
Imin at 94°C 
Imin at 50°C 
2min at 72°C
5OXTAE
242g 
57.1
TrisBase
Glacial 
Acetic Add
lOOmls 0.5M EDTA
Figure 3.5: PCR relevant mixtures.
extention step was used. PCR products were detected by running them on a 
1% agarose gel at 80V DC in IX TAE containing ethidium bromide. Detection 
of product was made using a UV transilluminator equipped with a digital 
camera.
For colonies with confirmed inserts of appropriate size, sequencing was 
performed. Two pairs of primers were synthesised corresponding to a pro­ 
moter/terminator (p/t) sequence and a region outside the promoter (p+/t+). 
The sequences were synthesised by Alta Bioscience. The primers were se­ 
lected by their specificity to the CDO construct and their annealing tempera­ 
tures.
Primer
promoter sequence
terminator sequence
upstream prom. seq.
downstream term, seq
Abbreviation
P
t
P+
t+
Sequence
TAA-TAC-GAC-TCA-CTA-TAG-GG
GCT-AGT-TAT-TGC-TCA-GCG-G
CGG-ATA-TAG-TTC-CTC-CT
GTC-CGG-CGT-AGA-GGA-TC
3.2.3 Expression of CDO
Induction of CDO was done by adding isopropyl 3-D-thiogalactopyranoside 
(TPTG). This compound in not endogenousry expressed in BL21(DE3) and is
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effective stimulating an otherwise silent transgenic vector gene. The Lac op- 
erator for the IPTG is also not expressed in BL21(DE3) cells making IPTG a 
very gene specific inducer. Cell cultures grown in 250ml volumes in If baffled 
flasks. They were incubated at 37°C on a rotary shaker. Growth curves were 
establised by taking aliquots of the sample a different times and measuring 
the absorbance at A=60Onm. Induction of CDO with IPTG was done by adding 
250^ 1M IPTG to each 250ml culture at or near ODA=60ofim=O.60 for SOB 
mediumll 15]. Induction was allowed to proceed for 6 to 8 hours. Cells were 
harvested by adding 5OOj*£ 2OOmg/ml phenylmethylsulfonyl fluoride (PMSF) 
and pelleting them by centrifugation. The pellet was resuspended in approx- 
imately 2Omls IX binding buffer (lOmM sodium phosphate, SOOmM sodium 
chloride, 5mM Imidazole). The pellet was lysed using a french press. Cellular 
debris was removed by ultracentrifugation. Post-centrifugation supernatant 
was removed and passed through a 0.22pm filter to prevent clogging of the 
affinity column.
3.2.4 Expression of Isotopically Labelled CDO
Another advantage of using the bacterial system is that it is relatively easy to 
incorporate specific isotopes into the protein. In the absence of amino acids 
in the growth medium, prokaryotes are able to de novo synthesise their own 
amino acids from a ammonium salts and glucose.
For experiments that required isotopically labelled protein, Ammonium- 
15 .V Chloride (98% 15 .V, GOSS Scientific Instruments, NLM-467) was used as 
a nitrogen source to label nitrogen. D-Glucose-U- 13C6 (99% 13C, Cambridge 
Isotope Laboratories, CLM-1396) was used as a carbon source to label carbon. 
The cultures were grown in 25Omls as previously described but in minimal
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media:
Media (If) 1OOOX Micronutrients
6g
3g
5g
Ig
lOmls
1ml
lOmls
2.6mls
1ml
1ml
Na2HPO4
KH2PO4
NaCl
(NHJC1
Vitamin Solution
10OOX Micronutrients
20% Glucose
154mg/mJ Ampicillin
fresh FeSO4
1M CaCl2
1M MgCl2
4.9g Boric Acid
1.42g Cobalt Chloride
O.56g Copper Sulphate
3.17g Manganese Chloride
0.57g Zinc Sulphate
filter sterilise 
3.2.5 Purification of CDO
An Amersham Pharmacia Biotech C 16/2O column (19-5101-O1) with an 
AC 16 adaptor (19-5109-01) was packed with Chelating Sepharose Fast Flow 
to a bed volume of 12cm. The column was packed by attaching a peristaltic 
pump to the base and filling the column with SOmls of Sepharose solution, 
the pump was run at about 3mls/min while the sepharose packed. The buffer 
draining the column for this procedure was recycled to the top of the column. 
The resulting bed volume was 12cm and the dead space above was minimised 
using the AC 16 adaptor. All solutions used in the affinity purification were 
filter sterilised using a 0.22 pm syringe filter and degassed.
CHAPTER 3. EXPRESSION OF CYSTEINE DIOXYGENASE 58
The column was first charged with 400mM NiSO4 . When the the colour of 
the column changed to blue, the free nickel was washed away with lOOmls 
Ix Binding Buffer (lOmM sodium phosphate, 5OOmM sodium chloride, 5mM 
Imidazole). The filter sterile CDO in IX binding buffer was passed through 
the column. The column was washed with an addition lOOmls fresh binding 
buffer. Non-specific binding of BL21(DE3) protein were removed by washing 
the column with 200mls IX Primary Wash Solution(6OmM Imidazole, lOmM 
sodium phosphate, SOOmM sodium chloride). The bound protein was washed 
with an additional lOOmls IX Secondary Wash Solution (4OOmM sodium fluo- 
ride, 20mM Glycine, lOmM sodium phosphate)3. The purified CDO was eluted 
in IX Elution Buffer (4OOmM sodium fluoride, 2OmM Glycine, lOmM sodium 
phosphate, 2OOmM EDTA) and collected with a fraction collector.
3.2.6 Confirmation of Expressed Protein I
This is a modification of method previously described! 116]. A Bio Rad Power 
Pac 300 and Mini Protean n Cell was used for all protein electrophoresis.
The acrylamide running gel (Laemmli, 1970) (Appendix pA) was prepared 
by mixing 6mls 1.5 M Tris/0.4% SDS, 8mls Ultrapure acrylamide (30% acry- 
lamide : 0.8% bis-acrylamide), 80/xl 10% ammonium persulphate (APS) and 
80/*£ N.N.N'.N'-tetramethyl-ethelenediamine fTEMED). The mixture was poured 
between the glass plates of a BioRad gel caster leaving 1.5 cm clearance from 
the top of the plate. Water saturated butanol was layered above to prevent 
dehydration and warping at the acrylamide interface. After the gel had poly- 
merised, the butanol was washed away with water and aspirated. A stacking 
gel was prepared by mixing 3mls 0.5M Tris/0.4% SDS, 1.5 mis Ultrapure
3The purpose of the secondary wash step will be thoroughly discussed in the next chapter 
under dynamic light scattering
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acrylamide, 7.5mls ddH2O, G/Q^i APS and 60^ TEMED. The mixture was lay­ 
ered carefully above the running gel, an appropriate comb was inserted, and 
allowed to polymerise.
Electrophoresis was done in a Ix running buffer (192mM Gtycine/25mM 
Tris/0.1% SDS)(1151, made from a IQx concentrate. Protein samples were 
placed in loading buffer (1:1) consisting of 4% SDS, 20% gfycerol, 10% p- 
mercaptoethanol, 125mM tris pH 6.8 and 0.1% bromphenol blue. Just prior 
to loading, the samples were denatured for 5 minutes in a water bath at 1O00C" 
and then centrifuged to collect condensate. Once loaded, gels were run for 1 
to 1^ hours at 4OmA and with constant current.
Gels were usually run in pairs. After electrophoresis, one gel was stained 
by incubating the gel in a plate with a Coomassie Blue solution (0.26g Coomassie 
Brilliant Blue R250 in 9Omls methanol:ff2O (1:1 v/v) + lOmls glacial acetic 
add). After a one hour incubation on a rotary shaker, gels were de-stained 
overnight in the same solvent without the dye. The second gel was left un­ 
stained and used for western blotting.
3.2.7 Confirmation of Expressed Protein n
It was necessary to have a supply of epitope specific antibodies to detect the 
presence of CDO in western blots and dot blots. The epitope was chosen from 
a predicted hydrophilic region of the swiss-prot entry for human CDO|1 16]. 
The peptide sequence was synthesised on controlled pore glass (CPG) (Al- 
taBioscience, Birmingham. England) and used as packing material for affin­ 
ity purification of IgG's from sera. Sheep sera (The Binding Site, Birmingham, 
England) from animals sensitised to the same epitope was then used as the 
source of epitope-spedfic immunoglobulins.
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Figure 3.6: GCG representation of predicted hydrophiliclty of the SwissProt 
sequence entry of human cysteine dioxygenase.
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Figure 3.7: A local alignment showing the location of the synthesised cysteine 
dioxygenase epitope with the human cysteine dioxygenase gene product.
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The column was equilibrated with PBS pH 7.0 using a peristaltic pump 
with a flow rate of about 2 mi/nan.. Normal sheep sera was niter sterilised 
through a .22pm Milllpore syringe top filter and then recycled through the 
equilibrated column for 3O min at the same flow rate. Bound immunoglob- 
ulins were thoroughly washed with fresh PBS 7.0 for 30 min. To elute the 
antibodies, the CPG was completely drained, then eluted with two separate 1 
ml fractions of lOOmM Gtycine pH 2.3. The pH of the elute was adjusted to 
8.0 using NaOH.
For western blotting analysis, the second gel was placed on a nitrocellu- 
lose membrane (0.45/*m Bio Rad Transblot Transfer Medium 162-0115) cut 
to the same dimensions of the gel. Two pieces of damp electrode paper were 
placed on either side of the gel/membrane to add a little integrity to the gel. 
Two coarse sponge separators were then placed on either side of the sand- 
wich, the stack was fastened into a transfer clasp and placed in a semi-dry 
tank. The transfer tank was filled with Ix running buffer containing 20% 
methanol. Electrophoresis was done a 200 mA for one hour. Upon comple- 
tion, the membrane was blocked for Ih at TR in 10% powdered milk in PBS 
7.0 on a rotary shaker. Using affinity purified aCDO IgG's in a concentration 
of 1:10 to 1:100 in PBS 7.O, the membranes were incubated at T4oC on a rotary 
shaker overnight. Membranes were washed three times in a fresh PBS solu- 
tion. lOmls of 1:500 dilution of donkey a sheep-peroxidase conjugated anti- 
bodies in PBS were incubated for Ihr at TR on a rotary shaker. Membranes 
were then washed three times in a fresh PBS solution for lOmin. A developing 
solution was made by dissolving 1 tablet of Sigma 4-chloro napthol dissolved 
in lOmls of MeOH and then adding 5Omls of triethanolamine buffered saline 
(5.5g NaCl + 2.8mls triethanolamine +17mls 1M HC1 per litre and pH 7.5) 
and 30/i 3O% H^O^ The solution was then applied to the membrane until the
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Figure 3.8: Promoter to terminator product from colony PCR of pETl 5b-hCDO 
(colonies 1,3,5 respectively) in BL21(DE3)
desired level of development was reached. The reaction was terminated by 
rinsing the membrane in water.
This same protocol was was used for dot blots where a small aliquot (5nQ 
of each fraction of purified CDO was placed on a nitrocellulose membrane. 
The membrane was then blocked and probed for CDO as previously described 
to determine which factions contained the eluted protein.
3.3 Results and Discussion
Three separate colonies of sub-cloned CDO were identified. Each separate cul­ 
ture was streaked on a SOB plate and after incubation, an individual colony 
from each was transfered to a PCR mixture specific for the construct pro­ 
moter and terminator. After amplification, the PCR product was run on an 
1% agarose gel. Figure 3.8 illustrates the results of the amplification. Each of 
the three colonies contained an insert that approximated the expected size of
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the human CDO gene.
Starting with colony one, the PCR product was submitted to Alta Bio- 
science for sequencing with the same promoter/terminator primers as well as 
a second outlying set The initial sequencing runs are listed in the appendix 
on pages 168 through 173. Without performing any manual base-calling, 
the sequence data were aligned together and the consensus sequence from 
the sequencing runs matched the predicted sequence of the CDO insert. The 
are listed in figures A. 14 through A. 16 on pages 174 to 176.
To detect the presence of the gene product, it was necessary to first pro­ 
duce an epitope specific antibody for CDO. Neat sheep sera was affinity pu­ 
rified against a column containing the target peptide. To test its affinity, an 
SDS-PAGE was run on human liver homogenate. After electrophoresis, the 
proteins from human liver were transfered to a nitrocellulose membrane. The 
membrane was blocked and probed for cysteine dioxygenase. F1gure3.9 illus­ 
trates the results. Normal human, horse and sheep sera were also run as 
positive controls for the secondary anti-sheep antibody. Dot blots of recom- 
binantly expressed CDO where then probed with the same immunoglobulin. 
Since recombinant CDO was detected, it also indicates that there no fame 
shifts occurred during the ligation of the insert CDO gene into the pET15b 
vector.
With an an epitope specific antibody for human CDO, the recombinant 
CDO was run on SDS-PAGE and western blotted. Figure 3.10 illustrates 
the results. Human liver homogenate were used as a positive controls and 
the chromatography flow-through of induced BL21(DE3) lysate were used 
to gauge protein binding. Since the concentration of purified CDO was far 
greater than the amount present in liver homogenate, the endogenous CDO 
band appears very faint by comparison. Also present in the wester blot and
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Figure 3.9: (a) Western blot of CDO (2) with normal hum an (3), horse(4), and 
sheep jsera(5) as controls, (b) Dot blots to CDO detected immuno-chemically. 
(Size standards are listed in the Appendix on page 178)
the gel is a smearing of the band from 25kDa downwards indicating pro- 
teotysis (Figure 3.10). The protease inhibitor phenylmethylsulfonyl fluoride 
(PMSF) was later added at all stages of purification and the experiment was 
repeated. Figure 3.11 Illustrates the dot blot used to detect which fraction 
contained CDO during purification and a pure protein using protease in­ 
hibitors. Trypsinogen was also loaded as a more accurate size marker. The gel 
was overloaded on one lane to detect the presence of contaminating proteins. 
The trypsinogen purchased from Sigma shows some contamination at higher 
molecular weights and the CDO does not indicating the the affinity purified 
CDO is more pure than a purified commercial product.
CDO is a protein not easily reduced by /?-mercaptoethanol during elec- 
trophoresis. It generally appears to run as two bands. This property is more 
evident when run on a higher percentage acrylamide gel. Figure 3.12 illus­ 
trates that CDO runs as a single band when ^-mercaptoethanol is left out of
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(a) SDS PAGE (b) Western Blot
Figure 3.1O: (a)SDS-PAGE and (b)Western blot analysis of human liver ho­ 
mogenate; flow through of homogenate of induced BL21(DE3); and affinity 
purified CDO without using protease inhibitors. (Size standards are listed 
in the Appendix on page 178). Four lanes are indicated in both gel and blot; 
starting with the size marker on the left.
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Time (min.)
0
127
20O
222
245
290
330
ODX=280
0.00
0.15
0.30
0.43
0.60 (IFTG added)
0.90
1.11
Table 3.1: Growth rate for BL21(DE3) transfected with pET15b-hCDO in SOB 
media at r37°.
the gel loading buffer. The second band is not a dimer as it runs as a com­ 
parable molecular weight to CDO. The differences are likely due to changes 
in the protein's hydrodynamic radius and not due to degradation. Since CDO 
runs as a single band in the absence of 3-mercaptoethanol, the change is 
likely due to disulfide bond stabilisation of the protein. A single band never 
seems to be present with #-mercaptoethanol regardless incubation time and 
heating, ,3-mercaptoethanol has been suggested to be a substrate for CDO. 
This indicates that at least two of the four cysteine residues in the protein are 
involved in disulfide bridge formation.
It was also desirable to get an approximate growth curve for CDO in SOB 
media, hi a 25Oml inoculated flask. The absorbance of the medium (ODA=28o) 
was taken at different time intervals while it was incubating at 37° C on a 
rotary shaker fTable 3.1). The data were then plotted (Figure 3.13) and fit­ 
ted by a second order polynomial (Equation 3.1). This equation was used to 
approximate the time when the BL21(DE3) cell line reached the cell cycle for 
induction.
ABS = 5.997544 • 1(T3 - 8.176101 • KT4* + 1.284495 • KT5*2 (3.1)
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(a) dot blot western of CDO (b) Overload of CDO on SDS- 
PAGE
Figure 3.11: Dot blot of CDO eluted from a nickel column. Gel overload 
of trypsinogen, CDO, and a lower concentration of CDO(Size standards are 
listed in the Appendix on page 178)
u. '?
(a) Dot blot of dute at pH 6.5 and (b) CDO. CDOr6.5. CDOr7.5. 
7.5 Lysate. CDOr++
Figure 3.12: Dot blot of elute at pH 6.5 and pH 7.5. A 15% SDS-PAGE of CDO 
without /?-mercaptoethanol (6.5), CDO with /?-mercaptoethanol, flow-through 
firom the column, and concentrated CDO 1 week with /?-mercaptoethanol.(Size 
standards are listed in the Appendix on page 178)
CHAPTER 3. EXPRESSION OF CYSTEINE DIOXYGENASE 68
STATIST: Prtynonial Regression o» Outer 2
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(a) A) time(min.) B) Absorbance (28Onm)
Figure 3.13: Growth curve for BL21(DE3) in SOB media
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Growth curves were not done for CDO in minimal media. Growth rates 
for minimal media were greatly depressed. All cultures for expression were 
started with an overnight inoculum. The growth cycle of this initial inoculum 
was not easily controlled in minimal media. Owing to this problem, growth 
curves in minimal media showed too much variation to be useful for expres­ 
sion experiments.
Chapter 4
Physical Characterisation of CDO
Once a system was developed that produced a steady supply of CDO , at­ 
tempts were made to characterise the protein structurally. Computational 
analysis of CDO (see Appendix A. page 149 to 165) had given a theoretical 
model. Experimental techniques were necessary to test whether CDO fit the 
predicted model.
4.1 Aims
To measure the mass of the recombinant protein using mass spectroscopy. 
Explore the use of surface plasmon resonance to accurately determine the 
concentration of CDO in a non-destructive manner. Perform an amino acid 
decomposition of CDO as a crude method of confirming its sequence and 
as a second method of protein concentration determination. To analyse the 
secondary structure of CDO using circular dichroism and measure the overall 
stability of the protein using dynamic light scattering (DLS).
70
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4.2 Methods
4.2.1 Mass Spectroscopy
Matrix assisted laser desorption time of flight mass spectroscopy (MALDI- 
TOF MS, MALDI) is a technique that allows the precise mass of a protein 
to be measured. Other mass spectroscopic techniques are either unable to 
fully ionise a protein or are too destructive to measure the entire protein. It 
works by suspending a protein in some matrix, ionising the protein with a 
laser, and measuring the time it takes for the protein to reach a detector. 
Inertia! differences between proteins are resolved by the time-of-flight to the 
detector; this allows the masses to be measured extremely accurately.
Protocol
Affinity purified CDO was de-salted using Millipore ZipTipc\, a small scale C4 
reverse phase packing material in a pipette tip. The protocol for desalting was 
taken directly from the Millipore ZipTipc\ guidelines.
Affinity purified CDO was flash frozen with liquid nitrogen in a Pyrex tube 
and tyophilised overnight. The freeze dried protein was partially resuspended 
in 1.6M GuHCl/0.5%TFA made from a 5x stock solution. The ZipTipC4 was 
equilibrated with 10//€ of 70% acetonitrile (chromatography grade) and then 
re-equilibrated with two 10/t£ volumes of 0.1% TFA (mass spectroscopy grade). 
CDO was bound to the C4 packing material with 10 repeated aspirations 
from a protein suspension in 1.6M GuHCl/0.5%TFA. The bound CDO sample 
was de-salted with 10 x 10/i£ repeated aspirations of 5%MeOH/0.1%TFA. The 
protein was eluted from the C4 matrix by recycling the same 4/^ solution 
of 75% acetonitrile/0.1% TFA for 10 cycles. The 4/*£ sample was submitted
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Figure 4.1: Practical theory of SPR
to the University of Birmingham chemistiy department for molecular mass 
determination by MALDI-TOF.
4.2.2 Surface Plasmon Resonance
Surface plasmon resonance (SPR) is a technique to measure the resonance 
of surface plasmons and this was used to determine protein concentration 
quickly, accurately, and without wasting/changing the sample. Plasmons 
are waves that describe charge densities fluctuations of a metal at some fre­ 
quency. Detecting these resonant frequencies can be done by directing a 
beam of light at some angle toward a metal surface, a thin gold film in these 
experiments, and then detecting a change in intensity of the reflected light. 
Plasmons are created on the opposite surface of the gold film; the surface in 
contact with a protein solution. Resonance of this surface occurs when vec­ 
tor components of the incident wave match that of the plasmon. When this 
occurs, there is a decrease in the reflected intensity on the opposite surface. 
These resonances vary with changes in the solution at the interface and are 
very sensitive to changes in the refractive index! 117). Taking advantage of 
this phenomenon, SPR was used to determine protein concentration.
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Protocol
A Biacore 3000 instrument was used for all SPR measurements. A Pioneer 
Sensor Chip Jl was used for all measurements of refractive index (Biacore 
AB, Uppsala, Sweden). This system is normally set up to measure binding of 
small molecules. In these experiments, an unmodified gold surface (Pioneer 
Jl chip) was used with the assumption that it would be chemically inert. The 
output data for the Biacore unit is in terms of resonance units (RU). However, 
there is a linear (one-to-one) relationship between the refractive index (n) and 
the surface plasmon resonance. Salt and protein standard gradients were first 
tested both to establish the linearity between SPR and n; to test how prone a 
gold surface is to protein adsorbtion; and to develop a precise value for the 
change in concentration of CDO with a change in RU (^fr). With a known 
value of the change in refractive index with concentration ( ^.) it is possible 
to calculate a protein concentration.
n = k-c-l — } (4.1) 
n
A more detailed description of the method with results can be found in a 
paper submitted for publication (Appendix page 182)
4.2.3 Amino Acid Decomposition
An amino acid decomposition is a qualitative way to access the relative ratios 
of individual amino add residues in a protein. With the advent of protein 
sequencing, this method is not commonly used any more to characterise pri-
CHAPTER 4. PHYSICAL CHARACTERISATION OF CDO 74
mary sequence. The method is however the most effective way to determine 
a protein concentration. The results of experiment are in terms of concentra­ 
tion. For a protein of known primary sequence, it is a trivial task to convert 
from the residue concentration to the overall protein concentration.
hi the case of cysteine dioxygenase, it became apparent that it was not 
easy to reproducibly measure the CDO concentration due to irreversible ag­ 
gregation. The predicted molar extinction coefficient was also different than 
the actual molar extinction coefficient. The amino acid decomposition is nec­ 
essary to get a starting concentration with which to base an actual extinction 
coefficient. One drawback is that Asn and Gin are converted to Asp and Glu; 
and Thr and Ser have 5% and 10% losses in the hydrolysis process, hi these 
experiments, this is not a concern since the other amino acids can be ref­ 
erenced and an accurate %g. 2jj- , and molar extinction coefficient could be 
developed.
Protocol
Amino acid decomposition involves the complete hydrolysis of the protein into 
its individual amino acids by boiling it in HC1. The resultant mixture is then 
passed through a reverse phase HPLC system. The resultant peaks from 
the separation of hydrolysed product are then integrated to give a percentage 
breakdown of each amino acid. It is also the most accurate way available 
to biologists to determine a proteins concentration. Other methods require 
a standard, such as lysozyme or BSA, which may not accurately reflect the 
protein of interest or it may consume too much precious sample.
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4.2.4 Dynamic Light Scattering
It is absolutely critical for structural studies, in X-ray crystallography and 
NMR, to have a mono-disperse protein sample. Dynamic light scattering is by 
far the most versatile technique to access the dispersity of a protein. It is a 
way of measuring the brownian motion of a particle (CDO) in solution. There 
is an empirical relationship between the diffusion coefficient of a particle and 
its hydrodynamic radius. This technique allows one to deduce the volume of 
a particle. If a protein is aggregating, one would expect to see an increase in 
its volume with time.
DLS measures the diffusion coefficient (D) of a particle. The diffusion coef­ 
ficient is related to the temperature (T) and the frictional coefficient (f) where 
k is the Boltzmann constant. The frictional coefficient is related to viscosity 
(;/) and the radius (R). The entire relation is explained by the Stokes-Einstein 
equation (Equation 4.3)
kT 
D = J- (4.3)
kT
No special care need to be taken to present a sample to the instrument 
save filtering it It works over a wide range of concentrations and is sensitive 
to particles as small as Inm to several microns. A single measurement can 
be done in less then a half hour which makes this an unparalled technique to 
screen conditions that may be amenable to a protein. The only drawback is 
that it is more sensitive to larger particles in solution at the exclusion of de­ 
tecting the smaller monomeric protein polymers. Thus, this technique should
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be used more qualitatively than to infer real physical data about the sample.
Protocol
Dynamic light scattering (also known as quasi-elastic light scattering of pho­ 
ton correlation spectroscopy) is a spectroscopic means of measuring the dif­ 
fusion coefficient of a particle (CDO). The radius of the protein can then be 
approximated via the Stokes-Einstein equation (Equation 4.3). In a typical 
experiment, a laser beam passes through a sample and some incident light is 
scattered by the proteins in suspension (elastic scattering). The scattered light 
is detected by a photomultiplier tube (PMT) at some angle relative to the in­ 
cident beam (90° in these experiments). The photon counting PMT measures 
changes in the intensity of the reflected photons to establish a correlation 
curve. This is an automated process and in simplified terms, the the cor­ 
relation curve determines the brownian motion of the proteins/particles and 
references a diffusion coefficient to each species of particle in solution.
kT
67TT/D
With a measured value for the diffusion coefficient (D) and solving equation 
4.3 for R yields a value for the radius of a particle. This equation is only con­ 
cerned with the radius of a perfect sphere though. For asymmetrical particles 
like proteins, the apparent radius can be much larger (Figure 4.2) and require 
a perin factor take the asymmetry into consideration.
Cysteine dioxygenase measurements were largely qualitative to determine 
stability of the protein under different buffer conditions. It is also very effective 
in quantitating a degree of aggregation in solution for establishing limits on 
salinity and protein concentration.
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Lysozyme
MW = 14,700 Da
Vp =0.73mL/g
= 22.5/13 = 1.731
F= 1.022
Figure 4.2: Lysozyme. (Image taken from Protein Solutions, Inc.)
A Zetasizer 3000HS (Malvern Instruments, Ltd.) was used for all DLS ex­ 
periments. This was equipped with a 532 nm laser that brought the sensitivity 
of the instrument to at least 2 nm particle size.
4.2.5 Rheology
Rheology is the study of viscosity and was used to make some of the DLS mea­ 
surements more quantitative. A digital plate viscometer was used to quanti- 
tate the viscosity of samples. There are several empirical relationships be­ 
tween viscosity and the physical state of a compound. In the instance of a 
protein, viscosity in itself yields little useful information. However, it is a nec­ 
essary variable to refine to describe more accurately other physical quantities. 
Because of fluctuations in the measured viscosity with temperature and 
instrument, relative viscosities (t/r) were measured (where 17 is the measured 
quantity and ij0 is the viscosity of water under the same conditions used to 
measure a buffer):
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The relative viscosity r^. provides a more accurate measurement of the ac­ 
tual quantity when other variables, as temperature, are not easily controlled. 
Often it is the viscosity of the protein that is of interest. Because a plate vis- 
cometer can induce shear and cold deform a biopolymer in solution. Specific 
and characteristic viscosities had to be quantitated indirectly via the Stokes- 
Einstein Equation (Equation: 4.6) where the diffusion coefficient, D, was mea­ 
sured from light scattering experiments.
P •
(4.4)
(4.5)
= — = ^^ (46) 
/ tor;/?
The viscosity measurements provide some preliminary background param­ 
eter for dynamic light scattering. For 77, and r^., and accurate protein viscosity, 
r/, is acquired by measuring a diffusion coefficient of a latex microsphere of 
known radius, R in a protein solution. Solving the Stokes-Einstein equation 
for rj will yield an accurate measurement of the viscosity of CDO without in­ 
ducing shear. It is usually not possible to directly measure the viscosity of 
polymers (and biopolymers) because the measuring process induces shear, 
alters their structure, and hence alters their r/c under ambient conditions.
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4.3 Results and Discussion
4.3.1 Spectroscopic Determination of CDO Produced by the 
Bacterial Expression System
An initial sample of CDO in standard buffer failed to ionise when it was sub­ 
mitted for electrospray mass spectroscopy. Instead, a CDO sample was puri­ 
fied as previously explained and prepared in acetonitrile using a ZipTiprv/ . The 
sample was submitted to the mass spectroscopy facility at the Chemistry De­ 
partment at the University of Birmingham for MALDI-TOF. The spectrograph 
of the sample (Figure 4.3) indicated two masses, a singly and doubly charged 
species of CDO. Actual and measured masses for both the monoisotopic and 
distributed isotopic averages are listed in table 4.1.
There was a difference in mass of 147 Da between the measured mass 
and the predicted mass of CDO for the singly charged species. Although this 
difference could be explained by the addition of an amino acid residue into the 
protein. DMA sequence analysis indicated otherwise. Furthermore, a change 
of 147 Da for a protein of this size is within the margin of error for MALDI- 
TOF. The likely explanation is that there was a slight calibration error of the 
instrument.
Monoisotopic (m+ + H)
Average(m+ + H )
Monoisotopic(m2+ + 2H)
Average(mz+ + 2H)
Expected
25, 132.2298 Da
25, 148.38 Da
12,566.6188 Da
12,574.69 Da
Measured
n/a
25,295 Da
n/a
12,576 Da
Am
n/a
~ 147 Da
n/a
~1 Da
Table 4.1: Calculated and measured MALDI masses for recombinant CDO 
with both singly and doubly charged species.
When a phenylalanine is inserted into the presumed CDO sequence, the
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Figure 4.3: MALDI-TOF of CDO
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mass is recalculated to be 25,295.56 Da. This is nearly the precise mass mea­ 
sured for the recombinant CDO. The likely location of the additional amino 
acid is in the fusion protein.
4.3.2 Concentration Determination of CDO using SPR
The interpretation of the data for some experiments was dependant upon hav­ 
ing an accurate value for the concentration of the protein. It was also desir­ 
able to fulfil this requirement in a non-destructive manner. It was known that 
this could be done by measuring the refractive index of the sample. However, 
refractometry is not very responsive to changes in protein concentration and 
is thus very prone to error. Surface plasmon resonance (SPR) was tested to 
evaluate the concentration of CDO.
The theory first had to be tested on a salt gradient to confirm the relation­ 
ship of SPR with refractive index. In order to calibrate the Biacore instrument, 
a sodium chloride standard was used (Figure: 4.6). Sodium chloride has an 
established index of refraction (n) at different concentrations (c) and has a %g 
of 1 .854E-3^ . Aqueous sodium chloride was measured with SPR (in Reso-«*9
nance units, RU) and the value was compared with known refractive indices. 
The calculated was measured to be 1,617,586 *.
. dn DTT dRU n = &„ • c • — — > RU = kni-- c • -5— 
oc oc
RU c —
dc
This procedure was then repeated with two protein gradients, bovine serum 
albumin (BSA) and rysozyme (Figures 4.7 & 4.8). This procedure was done in
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Figure 4.4: Acquired SPR data. (Tabulated data listed on following pages)
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order to test the validity of SPR theory with respect to protein concentration 
determination. The calculated ^
w
the ^ for lysozyme was found to be 421.632 ^.
for BSA was found to be 2676.298 ^ andmg
NaCl
BSA
Lysozyme
CDO
^(ml/mg)
1,617,586
2,676.298
421.632
3C
Table 4.2: Calculated values of ^ for standard gradients and CDO.
A gradient of affinity purified CDO was then run on the SPR apparatus. 
Unlike the NaCl, BSA and lysozyme gradients, the CDO gradient did not give 
a step-wise response in resonance (Figure 4.5). This was due to adsorbtion of 
the protein to the gold surface of the sensor chip. Addition of L-cysteine to the 
intermediate washing steps was not effective in returning resonance changes 
to baseline indicating the nature of binding is not via a sulfhydryl group. It is 
not clear whether this affinity is from the fusion protein or CDO itself. Since 
CDO binds iron and other metals, it may indicate the recombinant protein 
retains it ability to chelate metal. It may also indicate that CDO has an affinity 
for the adsorbed L-Cysteine on the gold surface. This was an unexpected 
result and made the method inappropriate for concentration determination of 
CDO.
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Figure 4.5: Acquired SPR data. (Tabulated data listed on following pages)
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Figure 4.6: SPR of NaCl Standard Gradient
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Figure 4.7: BSA standard gradient
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Figure 4.8: Lysozyme standard gradient
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4.3.3 Determination of Amino Acid Composition of CDO 
produced in Bacterial System
The alternative technique to measure the concentration of CDO was spectro- 
scopically. To develop a molar extinction coefficient, an amino add decompo­ 
sition was performed. The results are tabulated in Figure 4.3 along with the 
actual and expected composition of CDO. The composition of CDO is consis­ 
tent with what was expected based on its sequence. Differences between the 
actual composition and expected concentration are due to the conversion of 
Asn and Gin to Asp and Glu respectively during the hydrolysis process; Thr 
and Ser also have 5% and 10% losses respectively in the hydrolysis process.
Amino Acid
Aspartic Acid
Threonine
Serine
Glutamic Acid
Proline
Glycine
Alanine
Cysteine
Valine
Methionine
Isoleucine
Leucine
Tyrosine
Phenylalanine
Histidine
Lysine
Arginine
Glutamine
Asparagine
Tryptophan
Cone, (nmol/ml)
2000
1OOO
14OO
2000
780
1400
15OO
n/a
1100
380
750
1700
350
710
1300
980
980
0
0
0
Composition
10.9%
5.5%
7.6%
10.9%
4.3%
7.6%
8.2%
n/a
6.0%
2.1%
4.1%
9.3%
1.9%
3.9%
7.1%
5.3%
5.3%
0%
0%
0%
Act. Comp.
4.545%
5.455%
8.182%
7.273%
3.636%
6.364%
5%
1.818%
5%
3.636%
4.545%
8.182%
2.727%
4.091%
8.182%
5.455%
4.545%
3.636%
6.364%
1.364%
Exp.Comp.
10.909%
4.91O%
7.369%
10.873%
4.3%
7.6%
8.2%
0%
6%
2.1%
4.1%
9.3%
1.9%
3.9%
7.1%
5.3%
5.2%
0%
0%
0%
Table 4.3: Initial amino acid decomposition of CDO by Alta Bioscience. (Alta 
code A4768, CDO B3) with measured composition, actual composition, and 
expected measured composition.
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An extinction coefficient was developed based upon the data from the de­ 
composition. It was later discovered that spectroscopic concentration mea­ 
surements using the calculated extinction coefficient did not appear to be 
consistent. Soon afterward it was discovered that CDO aggregated under 
most conditions and may explain the lack of consistency. It was not logis- 
tically possible to perform an amino add decomposition for each sample to 
accurately determine protein concentration. Since the decomposition is a 
long and expensive procedure, concentrations were approximated using the 
theoretical molar extinction coefficient based solely upon its sequence under 
mono-disperse conditions (Explained under Dynamic Light Scattering).
4.3.4 Aggregation State of Bacterially Produced CDO using 
Dynamic Light Scattering
Dynamic light scattering (DLS) was used to measure the aggregation state 
of CDO. A freshly purified sample eluted with high imidazole and salt was 
measured. A measurement was taken every two hours. Figure 4.9 illustrates 
the results of each measurement. Each coloured plot represents a measure­ 
ment at a different time. The figure clearly shows a progression in the size of 
the protein from about 4-5nm to 10/mi over a 24 hour time period at room 
temperature.
The mass of CDO from the MALDI data indicated it was 25,295 Da. The 
predicted size of a perfect sphere of mass 25.295 Da is 2.4381 nm (based on 
prediction from Protein Solutions molecular weight calculator). The masses 
measured in figure 4.9 and in all DLS experiments are based upon the dif­ 
fusion coefficient (D). Calculation of the hydrodynamic radius is based upon 
temperature (T) and viscosity (77) where k and TT are constants.
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Figure 4.9: Measurement of time dependant aggregation of CDO using dy­ 
namic light scattering.
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Most proteins are asymmetrical so the perfect sphere model is not accu­ 
rate. They also contain a layer of hydration. Both these characteristics will 
increase its hydrodynamic radius above that of a perfect sphere. A second 
constant could have been added to the above equation take symmetry into 
consideration but, since it was not possible to regulate T and to measure 
precisely 77, it was not practical. The results are more qualitative but clearly 
illustrate aggregation and is strongly suggestive that CDO is mono-disperse at 
the time of purification. Since many recombinanuy expressed proteins form 
inclusion bodies, showing that the sample is monodisperse at the time of pu­ 
rification is important; studying its structure is not an intractable problem.
The fidelity of all experimental data was contingent upon finding a buffer 
that was appropriate for CDO that prevented aggregation. The protein was 
not stable in any number of standard buffers so DLS experiments were set 
up, albeit qualitatively, to assay various additives on CDO. It soon became 
apparent that CDO has a tendency to aggregate (at almost any concentration) 
over a period of hours to days.
Another important consideration in DLS is that larger particles scatter 
much more strongly than smaller particles. To compensate for this, Malvern 
software is able to plot DLS data according to intensity as well as by number. 
Figure 4. 1 1 illustrates the same measurement of CDO according to number 
and intensity. This is a monodisperse sample but the presence of a very few 
larger species skewed the result when viewed by intensity. At some point, if 
too many larger species are present, detection of the monomer becomes im­ 
possible. For all experiments, it was necessary to re-suspend samples in a
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starting buffer before aggregation has progressed to this point. The samples 
were then aliquotted and frozen until they were ready to be assayed.
An experiment was set up where freshly purified CDO was dialysed and 
concentrated for half a day. The solution was then aliquotted and flash frozen. 
A matrix of additives described in the literature were added in turn to each 
aliquot and the aggregation state of CDO with time was monitored. Figure 
4.10 illustrates the most striking result. It is important to note that the pro­ 
tein had already started to aggregate the moment it was eluted off the col­ 
umn and that at least 12 hours had transpired when the measurements were 
taken. It is also important to note that the scale for this data on the x-axis 
is logarithmic, not linear. Everything taken into consideration, there is no 
question that glycine has a profound beneficial effect on the dispersity of the 
protein.
It was also found that sodium fluoride (NaF) was more beneficial than 
sodium chloride in preventing the aggregation of CDO. Imidazole seemed to 
accelerate aggregation under some of the conditions tested and EDTA was 
chosen as an alternative in the elution step during affinity purification. A 
suitable buffer with a pH lower than 7.8 was not found. It was not logistically 
possible to measure the viscosity of every buffer or combination of buffers. 
As a result, interpretation of DLS experiments were based upon changes in 
apparent hydrodynamic radii of samples rather than absolute values. Addi­ 
tion of glycerol to a monodisperse sample illustrates the impact viscosity can 
have on the apparent size of CDO (Figure 4.12). Subtle changes in a buffers 
pH, ionic strength, ion type, etc. can have an impact on the buffers viscosity. 
Table 4.4 are a few measured viscosities. Since particle sizes are calculated 
from Rm = g^. Any miscalculation of viscosity will be exaggerated 6?rD times 
in the size calculation.
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Buffer
lOOrnM NaF, 20mM Gty, lOmM PO4 pH 8
lOOmM NaF, 20mM Gty, lOmM PO4 pH 7.4
lOOmM NaF, 20mM Gty, lOmM PO4 pH 7.0
lOOmM NaF, 20mM Gty, lOmM PO4 pH 6.5
200mM NaF, 25mM Gty
200mM NaF, 50mM Gty, 5% Gtycerol
200mM NaCl, ImM Gty.lOOmM PO4 , pH 7.5
above t + 1/*M FeSO4
JL
10
1
1
.9950
.9847
1.0827
1.2052
1.0205
1.0205
i)
.89O4
.8904
.8859
.8768
0.9900
1.0731
.9087
.9087
Table 4.4: Measured viscosities for some buffers used for DLS experiments
To test the results more quantitatively, gtycine was added to every solu­ 
tion (ImM) during and following the purification step. Figure 4.11 shows the 
result. The discovery that gtycine prevents aggregation was very fortuitous. 
Finding conditions that keep a protein memo-disperse is usually the rate limit­ 
ing step to determining the tertiary structure by NMR and in growing protein 
crystals. The final preparatory step necessary for structural characterisa­ 
tion is to reproducibly concentrate the protein without aggregation and to 
determine the point of maximal concentration while preserving the disper- 
sity. The most appropriate method to concentrate the sample was to elute 
CDO at high concentration EDTA, in a well packed column, and to use the 
most concentrated fraction. 4OOmM Sodium fluoride with lOmM Gtycine and 
lOmM Na2HPO4 at a pH of 7.8 to 8.0 were the most stable buffers found. 
Dialysis against potyethelenegtycol to concentrate CDO did not seem to pre­ 
serve the dispersity of the sample. Dialysis against desicants like sephadex 
were equally un-beneficial. Centrifugal concentrators were not used for fear 
of aggregation at the membrane interface.
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(a) PBS
(b)BME
(c) SDS
(d) Gfycine
Figure 4.10: Time dependant measurements: (a) CDO in PBS (b) CDO in PBS 
with 0.01% £-mercaptoethanol (c) CDO in PBS with 0.01% SDS (d) CDO in 
PBS with ImM Glycine
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Figure 4.11: Cysteine Dioxygenase suspended in 25mM Glycine/200mM NaF
Figure 4.12: Influence of viscosity on particle size. Monodisperse CDO in NaF 
without (Red) and with 10% glycerol (Green)
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Figure 4.13: Cysteine Dioxygenase in ImM Gtycine/lM NaCl/lOmM Phos­ 
phate pH 6
Figure 4.14: Cysteine Dioxygenase in ImM Gtycine/lM NaCl/lOmM Phos­ 
phate/excess iodoacetic acid pH 6
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Figure 4.15: Cysteine Dioxygenase in lOOmM POJ ImM Gty/200mM NaCl pH 7.5, 
lOmM P04/20mM Gly/lOOmM NaF pH 8.0, 
lOmM PO4/20mM Gly/lOOmM NaF pH 7.4
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(a) NaCl pH 6.0
** I U
(b) NaF pH 6.0
Figure 4.16: Effect of pH on CDO aggregation
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(a) NaF pH 7.4
(b) NaF pH 7.8
Figure 4.17: Effect of pH on CDO aggregation
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(a) Gtycine (b) Imadazole
(c) Triton-X (d)Urea
(e) Urea+Performic (f) lodoacetic Add 
Add
Figure 4.18: Photon correlation spectroscopy results of affinity purified CDO.
Chapter 5
Structural Analysis
The structure of CDO has not been characterised before. An understand­ 
ing of its three dimensional shape will eventually lead to an understanding 
of how the protein functions. Knowledge of its active sites and any regula­ 
tory domains may eventually lead to the development of pharmacophores of 
therapeutic value.
Recombinant CDO is not a perfect model of the endogenous protein and 
may not represent the actual structure. Regardless of possible discrepancies 
between the two proteins, it has a unique protein sequence with no known 
structures for any domain. For this reason, structural information is valuable 
for computational modellers. If in the future the structure of endogenous CDO 
becomes available, the structural information of the unmodified protein may 
prove to be important model for comparison.
5.1 Aims
The objective of the following sets of experiments gain as much information 
about the structure of CDO. Circular dichroism will be used to measure the
101
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secondaiy structure of the protein and compare it to sequence predictions. 
Crystallography assays are set up to grow protein crystals that can be used in 
x-ray detraction studies. Nuclear magnetic resonance (NMR) were designed for 
functionality tests of the recombinant protein by analysis of the structure of 
its substrate and product. Two and three dimensional NMR experiments were 
also set up as an alternative method for solving the overall tertiary structure 
ofCDO.
5.2 Methods
5.2.1 Circular Dichroism
Circular dichroism (CD) is a spectroscopic technique that can measure the 
secondary structure of a protein. Generally, this secondary structure is bro­ 
ken down into three different categories: a-helix, /?-sheet, and random coil, 
a-helical elements are generally stretches of the protein backbone that form 
straight helical elements. Regions forming /8-sheets are regions that are able 
to pair up with adjacent stretches of the amide backbone and may be parallel 
or anti-parallel. The random coil are stretches that have no apparent defined 
structure. These secondary structures ultimately contribute to the overall 
tertiary structure of the protein.
Circular dichroism refers to technique that characterises the optical char­ 
acteristics of an asymmetric molecule, CDO in this instance. The results are 
independent of the known sequence. This information can be used to qual­ 
itatively determine secondary structure information about a peptide. Theo­ 
retically, it could also be used to determine quaternary structure informa­ 
tion (such as monomer and dimer). It was initially discovered that peptides
CHAPTERS. STRUCTURAL ANALYSIS 103
of known secondary structures exhibited very different CD spectra and that 
a linear combination of these spectra can give a representative distribution 
of these secondary structures in a protein! 1181. Today, with the growing 
databases of known protein structures, this technique has been refined in 
complex computer algorithms to semi-empirically determine a proteins sec­ 
ondary structure.
160 210 230 260
Figure 5.1: Standard curves for pure peptide solutions containing 100% a- 
helix, 5-sheet, and random coil. Image taken from Protein Solutions, Inc.
In a CD measurement, plane polarised light (with an initial angle, 90) passes 
through a sample (of path length t) and the transmitted light is analysed to 
determine to what degree the sample rotated the incident beam (ellipticity, 
0) and to what extent the sample absorbed at a particular wavelength (A). 
Typical measurements are between Aigo^m and A>3oontn- The ellipticity at a given 
wavelength and the optical rotation (o) are measured in terms of degrees! 119).
. 180 - 1 • (nL - nR)
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Deconvolution of CD spectra to attribute percentages of secondary struc­ 
ture were done predominantly with the K2D programme. Variables required 
by this programme are wavelength, ellipticity, path length, and protein con­ 
centration.
5.2.2 Protein Crystallography
Protein crystallography is a technique that seeks to solve a proteins structure 
by crystallising a protein. Proteins, just as salts or pure compounds, can join 
together in a highly ordered lattice. The resultant crystals are not dissimilar 
in appearance to a crystal of salts, sugars, gems, etc. Protein crystals contain 
a high percentage of water and are generally very fragile.
The resultant protein crystal is analysed by an intense x-ray beam. An 
intense and highly columnated beam is passed through the crystal and anal­ 
ysed by a detector. Because crystals are periodic lattices by definition, the 
x-rays reflect between and detract between and within each unit protein. The 
detraction pattern eventually leads to an electron density map of an individ­ 
ual protein. It is possible to then "fit" the peptide sequence into this map and 
yield the overall structure of the protein.
A protein sample must be monodisperse to crystallise. During crystallisa­ 
tion. as opposed to aggregation, the protein comes together and interlocks in 
a periodic manner. This is achieved during a process of concentration near 
its solubility limit. A protein must be concentrated very slowly in order to 
crystallise.
Several procedures have been developed to crystallise a protein but the
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"hanging drop" method is the most basic. A schematic of this method is 
detailed in figure 5.2. A protein sample is mixed with a 50% mixture of a
Coverslip 
Hanging Drop
XRL Plate Well 
Mother Liquor
Figure 5.2: Schematic of the hanging drop method
crystallisation solution, the mother liquor. A volume small enough to be sus­ 
pended as a drop is placed on a glass coverslip and inverted. The coverslip is 
sealed above a well containing mother liquor. The mother liquor can contain 
any number of buffers that may be conducive to crystallisation; it also con­ 
tains hygroscopic compounds such as polyetheleneglycol (PEG). Over time, 
water vapour from the suspended sample diffuses into the mother liquor be­ 
low. The hanging drop method relies on this vapour diffusion to slowly con­ 
centrate CDO.
There is no prescribed mother liquor solution that will crystallise all pro­ 
teins so a matrix of solutions need to be tested. Proteins often crystallise near 
their isoelectric points 1 but this variable needs to be assayed as well. The rate 
of crystallisation is dependant upon the temperature and PEG concentrations 
and need to be tested in turn.
'The predicted isoelectric point for CDO is listed in Fig. 5.8 on page 118.
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300 mM Sodium Acetate / 25% PEG 2000 MME
2OO mM U2SO4/ 25% PEG 2OOO MME
2OO mM MgCl2 / 25% PEG 20OO MME
200 mM KBr / 25% PEG 2000 MME
200 mM KSCN / 25% PEG 2OOO MME
8OO mM Sodium Formate / 25% PEG 20OO MME
3OO mM Sodium Acetate / 15% PEG 4000
2OO mM U2SO4 / 15% PEG 4OOO
200 mM MgCl2/ 15% PEG 4OOO
200 mM KBr / 15% PEG 4000
2OO mM KSCN / 15% PEG 4000
800 mM Sodium Formate / 15% PEG 4000
300 mM Sodium Acetate / 10% PEG 8k+ / 1O% PEG Ik
2OO mM Li2SO4 / 1O% PEG 8k+ / 1O% PEG Ik
2OO mM MgCl2 / 1O% PEG 8k+ / 1O% PEG Ik
200 mM KBr / 10% PEG 8k+ / 10% PEG Ik
2OO mM KSCN / 10% PEG 8k+ / 1O% PEG Ik
8OO mM Na Formate / 1O% PEG 8k+ / 1O% PEG Ik
300 mM Na Acetate / 8% PEG 20k+ / 8% PEG 550 MME
2OO mM Li2SO4 / 8% PEG 20k+ / 8% PEG 550 MME
2OO mM MgCl2 / 8% PEG 20k+ / 8% PEG 550 MME
2OO mM KBr / 8% PEG 20k+ / 8% PEG 550 MME
2OO mM KSCN / 8% PEG 20k+ / 8% PEG 550 MME
800 mM Na Formate / 8% PEG 20k+ / 8% PEG 550 MME
Sodium Acetate pH 4.5
Sodium Acetate pH 5.5
Sodium Cacodylate pH 6.5
TRIS pH 7.5
TRIS pH 8.5
Table 5.1: Clear Strategy 1 crystallisation matrix solutions.
Protocol
Coverslips and XRL plates were purchased from Molecular Dimensions, Ltd. 
A matrix of buffers were supplied in with a Clear Strategy 1 protein crystalli­ 
sation kit (Molecular Dimensions) (Figure 5.1). Coverslips were siliconised 
making them more hydrophobic. Coverslips were sealed to the XRL plates 
with vacuum grease (DuPont).
Purified CDO was mixed with a 50% mixture of each solution. The pH of 
each solution was adjusted beforehand with each of the 5 supplied buffers.
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Approximately 50ji£ to 100/*£ were placed at the centre of the coverslip. A 1ml 
volume of mother liquor was used at the bottom of the 24 well XRL plate. 
The samples were left to incubate at room temperature for a period of days to 
weeks. Samples were the evaluated to see whether the drops remained clear, 
showed precipitation, or contained crystalline material. Evaluation was done 
with a light microscope equipped with a digital camera.
If a sample remained clear at a given condition, the procedure was then 
repeated at a higher starting concentration of CDO. For samples that showed 
precipitation, the procedure was repeated at a lower starting concentration of 
CDO.
5.2.3 Nuclear Magnetic Resonance
Nuclear magnetic resonance (NMR) is a technique that involves subjecting a 
sample to intense modulated magnetic fields. This method can gather infor­ 
mation about the primary, secondary, tertiary, and quaternary structure and 
even the dynamics of a protein. The same technique may be referred to a mag­ 
netic resonance imaging (MRI) in medicine when it is applied to macroscopic 
structures, as organs. A detailed understanding of the physics behind the 
technique is not necessary; as long as a qualitative understanding of the the­ 
ory is understood together with the methodology required to interpret spectra. 
NMR is concerned with resonances induced in chemical bonds by a magnetic 
field.
Different atoms respond differently to intense magnetic fields by virtue of 
whether they are magnetically polar or not and the symmetry of their polarity. 
The polarity and symmetry thereof is dictated by the laws of quantum physics 
and is of no concern to the molecular biologist. Typically, a biologist is only
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concerned with hydrogen, nitrogen, and carbon as these elements are the 
most abundant in a protein and are the centre of interest in determining 
protein structure.
Hydrogen, as opposed to deuterium (*H) and tritium 1?H), is magnetically 
polar and is the most commonly practised NMR, 1 H NMR. Deuterium is apolar 
so it is a common practice to use deuterated solvents (ie: D2O vs. H^O) with a 
buffer to render them invisible, if one is interested in only the protein or sub­ 
strate/product. Most naturally occurring carbon ( 12Q and nitrogen (14 .Y) are 
either apolar or not sufficiently symmetrical enough making them effectively 
apolar for all intents and purposes. Completely incorporating 13C and 15N, 
which are polar non-radioactive isotopes, into a protein makes them "visible" 
to an NMR spectra and yields structural information.
As a general rule, NMR requires a concentrated, mono-disperse, homoge­ 
neous protein sample. Presently, it is limited to proteins roughly SOkDa or 
smaller in size. The single greatest limitation of NMR is the expense of 13C 
products. It has been used in these experiments to probe the functionality 
of CDO by testing substrate/product conversion (functionality) as well as two 
and three dimensional NMR of the CDO protein itself.
5.2.4 Protocol
For the functionality tests, NMR spectra were first obtained of CDO sub­ 
strates, products and co-factors both with and without enzyme. Samples were 
dissolved in an appropriate aqueous buffer which was quickly frozen. Frozen 
samples were then lyophilised to remove H?O and were resuspended in D2O 
(99.9% purity, Sigma). Spectra for all functionality tests were performed on 
either Brucker AP300S 300MHz or on an AV300 300MHz.
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Substrates and product standards for NMR functionality tests of CDO were 
dissolved in PBS, frozen, lyophilised overnight, and resuspended in 99% D2O: 
5-nicotinamide adenine dinucleotide, reduced form (Sigma, N-6005), 3-nicotinamide 
adenine dinucleotide (Sigma, N-O632), L-cysteinesulfinic acid (Sigma, C-4418), 
L-cysteine (Sigma, C-8152). A cystine standard was not performed because 
NMR spectra because its spectra is nearly indistinguishable from L-Cysteine. 
Furthermore, deuterated additives that prevent L-Cysteine/cystine intercon- 
version are cost prohibitive.
For experiments involving direct structural studies of CDO, spin labels 
were incorporated into the protein by growth and induction in minimal me­ 
dia supplemented with the label of choice: Ammonium- 15.V Chloride (98% 
15A•, GOSS Scientific Instruments, NLM-467) and D-Glucose-U- 13C6 (99% 13C, 
Cambridge Isotope Laboratories. CLM-1396). Protein samples were supple­ 
mented with 1O% Deuterium Oxide (99.9% D, Aldrich, 26,979-4) and analysed 
on either a Brucker 500MHz or a Varian 6OOMHz magnet.
5.3 Results and Discussion
5.3.1 Secondary Structure Determined Using 
Circular Dichroism
Since a bacterial system was used to express CDO, concerns were raised that 
the protein may not fold property because the bacterial environment is much 
more reducing that its eukaryotic partner. CD was then used to determine 
if the recombinant CDO had comparable secondary structure as would be 
expected from its primary sequence.
Secondary structures are formed by the chemical nature of the arnino acid
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Figure 5.3: Predicted secondary structure of cysteine dioxygenase aligned 
with its primary sequence.
ligands (hydrophilic/hydrophobic, aromatic/aliphatic, etc.). There are several 
computer programs that take a primary amlno acid sequence a predict what 
percentage of the protein should be helical, sheet, and coil. The sequence of 
cysteine dioxygenase was submitted to one of these programmes (PHDsec). 
The results of this analysis are listed in in the appendix on page 149 to 165. 
To present this data in a more useful format, the results were aligned with 
the CDO sequence using T^Xshade (Figure 5.3). It is useful to compare these 
predictions with the experimentally measured distributions from CD. The data 
for secondary structure prediction are listed in the Appendix on pages A to A. 
An initial CDO sample was dialysed into 200mM Ya2#PO4 pH 7.0 to avoid
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absorbance problems associated with chloride ion. Because the sample was 
dilute, A 0.2mm path length quartz cuvette (Hellma, Uk) was used. The sam­ 
ple was scanned at lOOnm/min, with a 1 second response time, a Inm band­ 
width, and the approximate concentration was 3mg/ml (Figure 5.9). The ini­ 
tial spectrum was then submitted to the K2D deconvolution program for de- 
convolution. The results then indicated that CDO was 4O% alpha-helix, 8% 
beta-sheet and 52% random coil. The CD spectroscopic results do not vary 
much from what was predicted by the GCG programme based on the CDO 
primary sequence alone.
Method
CD Results
GCG Predicted
a — helix
40%
«35%
ft— sheet
8%
«4.5%
random coil
52%
«60.5%
Table 5.2: Tabulation of predicted secondary structure of CDO based on 
CD spectroscopic results and theoretical predictions based on computational 
analysis of primary sequence.
It is important to note that the the critical deconvolution was performed 
within the range of 200nm and 24Onm and the absorbance problems below 
2OOnm were minimised or eliminated. This was an encouraging result be­ 
cause it indicated that the protein maintained secondary structure. Because 
the result was so similar to what would have been expected based on CDO's 
primary sequence, it also indicates the actual secondary structures of CDO 
in other organisms (because of the strong sequence homology) may also be 
homologous in their secondary and presumably tertiary structures as well 
(Figure 5.4).
Pursuant to the initial folding of recombinant CDO, it was discovered that 
the protein has a tendency to aggregate, particularly at higher concentrations 
(See section: Dynamic light scattering). Further CD studies were carried out
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Figure 5.4: Predicted secondary structural homology of CDO
on CDO in buffers that prevent aggregation and are at concentrations neces­ 
sary to be detected by NMR to ensure the protein was not being denatured in 
the process of preventing its aggregation.
Subsequent results had to be performed at higher concentrations. They 
also had to be performed in buffers that are either chiral fTris)2 or highly 
absorbing in the far-UV range (Gfycine). To surmount this problem, a spe­ 
cial cuvette, 0.10 mm in path length, had to be used. The symmetry of the 
spectra do not vary appreciably from the initial results indicating that CDO is 
a stable protein structurally. Moving to a 0.01 mm path length cuvette was 
not possible because the protein CD spectra was lost. Thoroughly testing the
2Chirality is a property where the mirror image of a chemical results in a chemically distinct 
different compound. There is a requirement of a certain number of mirror planes to meet 
achieve this property. Chiral compounds, such as L-Cysteine and D-Cysteine (Levorotary and 
Dextrorotary), rotate light in opposite directions. Chiral buffers, such as Tris. will influence 
spectra taken from protein samples.
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CD spectra below the isoelectric point (Figure 5.8) was not feasible because 
the conditions found to keep the protein mono-disperse were only appropriate 
above the isoelectric point.
Samples of affinity purified CDO were diarysed against lOOmM NaF, 2OmM Glycine, 
lOmM PO4. The concentrations of the samples were estimated by taking the 
absorbance at A=28O nm and using the extinction coefficient for the recom- 
binant CDO sequence. All samples were of the same concentration of about 
1.24mg/ml but varied in pH.
rCDO —
(1 cm path length)
= 4.93£-5.A/
mm
= 1.24 ml
These results (Figure 5.5) indicate that there is a shift in the secondary 
structure of the recombinant protein as a function of pH. The change oc­ 
curred in buffers slightly more acidic than pH 7.4. There was no detectable 
structural change between the range of 7.4-8.0. All these measurements were 
performed at nearly identical ionic strengths. The near identical absorbance 
of these samples indicate that there was virtually no change in protein con­ 
centration during the dialysis of the samples. The conformational changes 
appear to be real structural changes and not an artifact; As a control, a CD 
spectrum of CDO, pH 7.4, was run under identical conditions as the previ­ 
ous save the addition of 250 nM FeSO4 (Figure 5.6). Iron sulphate has bee
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Figure 5.5: Recombinant cysteine dioxygenase pH dependant changes in the 
optical rotation of light in lOOmM NaF,2OmM Gry, lOmM PO4. (pH 8-blue, pH 
7.4-green, red-pH7.0, and pH 5-yeUow
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shown in dynamic light scattering experiments to cause flocculation under 
these conditions. The resultant spectra yielded no secondary structural in­ 
formation.
CDlmdeql
HT[V|
190 200 250 
Wavelength[nm|
30(
Figure 5.6: Total loss of secondary structural information under conditions 
of protein aggregation of the recombinant CDO. (1.24mg/ml, lOOmM NaF, 
20mM Gfy, 250nm FeSO4 pH 7.4)
Data acquired from the CD spectra were saved as text files and were im­ 
ported into MS Excel. Data points corresponding to wavelengths 2OOnm to 240nm 
were saved as a separate text file for analysis by the K2D programme, a CD 
deconvolution programme developed at EMBL Heibelberg. The source code, 
written in C for Solaris, was compiled under Linux using g++. Interpretation of 
the spectra led to the tabulated percentages of random coil listed in table 5.3.
A more detailed analysis of the spectra using the CDNN 2.1, a programme 
that tries to draw more secondary structural information from a spectra. The
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PH
8.0
7.4
7.0
5.0
% Random Coil
49
48
48
45
Table 5.3: Deconvolution of CD spectra for CDO in lOOmM NaF, 2OmM Gfy, 
lOmM Phosphate at varying pH
concentration of the sample was defined as 1.25mg/ml, 25kD, 22Oaa residues 
long, and with a path length of 0.01cm. Figure 5.7 tabulates the results. 
There is a linear relation between a change in secondary structure with the 
pH and the most dramatic change occurs between pH 7.4 and 7.0. This is also 
a change around the predicted isoelectric point, pH 7.02, for CDO (Figure 5.8). 
Sums of secondary characteristics exceeding 1OO% may be viewed as a win­ 
dow of error in interpreting the accuracy of the defined secondary structures. 
Contributions to this error include changes in concentration, variability of the 
cuvette pathlength or position, as well as possible structural characteristics 
that share similarity to one or more of the defined categories. However, vi­ 
sual inspection of the plotted data indicate that there is some decrease in 
the apparent secondary structure of the protein that is very pH dependant 
(Figure 5.5).
Overview of Results
CD spectra of CDO in 2OOmM Phosphate buffer alone indicated a defined 
secondary structure of 40% a-helix, 8% 3-sheet, and 52% random coil, hi 
the absence of chloride ions (from NaCl), there was a dramatic decrease in 
the associated fluorescence which allowed higher concentrations of protein 
to be used with less noise. Addition of NaF as a less fluorescent alternative
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to NaCl and addition of glydne introduced noise. DLS experiments indicated 
these were favourable conditions for CDO stability. In these buffers, samples 
had to be integrated ten or more times and at slower scan rates to obtain 
continuous curves. However, the sample stability with time, acquisition times 
and instrument availability were considerations that had to be balanced. The 
results were not far different from the standard CDO spectra in phosphate 
alone.
Because of the variability involved in deconvolution from one software 
package to the next, many groups will argue that it is not a reliable technique 
to assign secondary structures. The main purpose of these experiments was 
to at least show that the protein did not conform to an molten globule with no 
secondary structure. In establishing that that the protein is at most 50% ran­ 
dom coil, a statement can be made that the remaining 50% of the rCDO con­ 
forms to some ordered structure. Some of the variability could be attributed 
to the poly-histidine fusion protein. While it would have been desirable to 
remove it with thrombin, chromatographic equipment needed to fractionate 
thrombin, CDO and the fusion protein apart was not available. Attempts to 
remove the fusion protein with thrombin-agarose were not successful. Con­ 
taminants such as agarose (even after centrifugation), glycerol, and possibly 
albumin prevented ionisation of the sample for MALDI and prevented mea­ 
surement with DLS.
PH
5.0
7.0
7.4
8.0
aH.
13.3%
14.3%
16.4%
16.9%
Anti-Parallel
18.5%
17.5%
15.7%
15.3%
Parallel
17.1%
16.3%
14.9%
14.6%
jSTurn
22.2%
21.8%
21.0%
20.8%
R.C.
52.3%
50.9%
48.1%
47.5%
Sum
123.4%
120.7%
116.1%
115.1%
Figure 5.7: CDNN 2.1 interpretation of CD spectra using the 210nm-260nm 
method.
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Figure 5.8: Predicted isoelectric point of CDO calculated using GCG Predic­ 
tions based on primary sequence of the 220aa recombinant CDO.
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Figure 5.11: f3f4
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Figure 5.12: f5fB
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NH2 
L-cysteinesutfinic acid
Figure 5.14: Conversion of L-Cysteine to L-cysteinesulfinic acid 
5.3.2 Functionality Assay Using NMR
The NMR functionality assay of CDO was dependant on the very different 
chemical differences between L-cysteine and L-cysteinesulfinic acid. The *H 
NMR experiment was performed in D2O so only the hydrogens attached to 
aliphatic carbons3 appear in the spectra. The greatest expected proton shift 
for substrate conversion was that for the carbon adjacent to the sulfhydryl 
group.
Sulphur, oxygen, carbon, and hydrogen have electronegativities of 2.4, 3.5, 
2.5 and 2.2 respectively. Depending in the difference in magnitude of these 
values, a dipole moment will exist between two bound atoms. When the proton 
of the sulfhydryl group is replaced with three oxygen bonds, the electronega- 
uvity of the sulphur is increased due to the electron withdrawing effect of the 
oxygens. Do to the greater electronegauvity of the sulfinic acid group, a NMR 
resonance shift is expected for the adjacent carbon.
As standards, NMR spectra were taken for L-cysteine, L-cysteinesulfinic 
acid, NAD+ and NADH individually (Figure 5.15 and 5.16). There was an eas­ 
ily detectable shift between L-cysteine and L-cysteinesulfinic add. The scales 
between the substrate and product do not match because the resonances are 
affected by concentration and pH. It is the relative shifts that are important.
3Aromatic protons are detected in NAD+/NADH *H NMR spectra as well
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Figure 5.15: 1-D NMR of (a) cysteine and (b) cysteinesulfinic acid
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Figure 5.16: 1-D NMR spectra of NAD+
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Compounds that prevent the oxidation of L-cysteine to cystine were not added 
because they would complicate the NMR spectra. Differences in spectra be­ 
tween L-cysteine and cystine were not expected to vary appreciable due to the 
similar electronegatrvities. The singlet resonance that appears at resonances 
0.48 ppm and 0.28 ppm represents trace hydrogen deuterium oxide (HDO) 
for L-cysteine and L-cysteinesulfinic respectively. The carbonyl carbon is not 
protonated and does not appear.
The cysteine used was stored under ambient conditions and likely con­ 
tained some oxidative product from exposure to the oxygen in the air. The 
relative molar concentrations were thought to be insignificant. Although not 
visible on the reproduced plot, there are faintly detectable peaks between -0.8 
and -1.0 ppm in the spectra of L-cysteine. This may be due to a cysteine- 
sulfinic/sulfonic acid group on the a-carbon.
Spectra were taken of the substrates in combination with and without the 
presence of enzyme (5.17). Most of the spectra of L-cysteine is masked by the 
resonances from the cofactors. However, the resonances just above 3.0 ppm 
corresponding to protons on the a-carbon are clearly visible. There was no 
detectable decrease in these resonances with the addition of CDO. Also, there 
were no detectable increases in resonances between 3.1 and 3.5 ppm above 
baseline with CDO. The data indicates that CDO is not functional.
The single resonance at 3.2 ppm that disappears with the addition of CDO 
is likely a methanol or acetone contaminant. Neither of these compounds were 
used at any stage in the experiment and it is not clear how it appeared in one 
sample. The Wilmad NMR tubes used for the one experiment were likely not 
dried thoroughly.
Although these data indicate the recombinant CDO to be non-functional, 
the assays were by no means exhaustive; Buffers optimal for the stability of
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Figure 5.17: 1-D NMR spectra of (a) cysteine, NAD+ and fb) cysteine, NAD+, 
and cysteine dioxygenase
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the protein were not ideal for for its catalytic activity. Organic buffers had to 
be avoided to prevent contaminating signals. Literature indicates that CDO 
is more functional in a slightly basic environment and DLS experiments have 
shown that this protein will aggregate under these conditions. Iron is a re­ 
quired co-factor of CDO. The presence of FeSO4 has also been shown to in­ 
duce aggregation in DLS experiments4 . All previous studies of endogenous 
CDO have been from HPLC/FPLC purified cell extracts. These may have in­ 
cluded an associated protein that affects the activity of CDO. Indeed, some 
groups have reported an associated "protein-A". While these results were not 
what was hoped for, the apparent lack of activity may not necessarily be due 
to the choice of expression system used. It is also possible the prokaryotic 
expression system may not incorporate the required iron atom.
5.3.3 Crystallography
Several attempts were made to get CDO to crystallise. In initial purification 
schemes, to was found that crystals formed at ~4°C in elution fractions (Fig­ 
ure 5.18). Initial purification of CDO was done in 500mM-lM NaCl, 500mM 
imidazole with either Tris or phosphate buffer (pH ~7.4). These crystals were 
blue in colour. It was assumed that the colour was due to nickel from purifi­ 
cation. It was also observed that, after elution, regions of the sephadex that 
bound CDO lost its blue hue.
A crystal was washed with H2O and dissolved in 100% MeOH. The mixture 
was then blotted and probed with antibodies for CDO. The crystal tested pos­ 
itive for the protein. The crystal was not however given further consideration 
for X-ray analysis because most protein crystals are fragile and the crystals
4The data was not recorded due to the severity of the initial measurement and the limited 
availability of the instrument.
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Figure 5.18: Crystals formed in elution fractions that contained CDO.
found were dense and sturdy. It was presumed that these were salt crystals 
and no beam time was allocated.
Further crystallisation assays were performed CDO under a variety of start­ 
ing buffers using the Clear Strategy matrix. After a period of several days to 
weeks, the hanging drops were observed using a light microscope. Figure 5.19 
lists a few typical results. CDO had a tendency to precipitate out of solution 
with a variety of morphologies. In one well, there was a portion of a CDO 
sample that appeared to be semi-crystalline (Figure 5.20). The remainder of 
the sample contained a lot of protein precipitate.
Attemps were made to focus on the pH, temperature, and starting con­ 
centration of CDO for crystallography. Soon afterwards however, DLS experi­ 
ments showed that the protein aggregated under virtually any condition. This 
process might have been slowed slightly with the increased viscosity of the 
crystallisation solutions, however, it would not be possible to form a crystal 
with a non-disperse starting protein.
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Figure 5.19: Results of protein crystallisation matrix screen
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Figure 5.20: Close up of CDO in hanging drop.
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All further crystallisation work had to be put on hold until a buffer was 
found where CDO was stable. By the time a buffer was found, it was not 
possible to resume the crystallography work due to time constraints.
5.3.4 Nuclear Magnetic Resonance
A preliminary concentrated and purified sample of cysteine dioxygenase in 
200mM NaCl/lOOmM PO4 was submitted for a 1H as a feasibility test. This 
experiment was performed before conditions were found that prevented ag­ 
gregation and the entire process from expression to concentration of purified 
sample had to be performed in one day. Although no structural information 
was expected, resonant signals were detected in the 6.5 to 8.5 ppm region 
(see Figure on page 135). These are signals associated with aromatic groups, 
structures not present in the buffer and only attributed CDO aromatic groups. 
This is the second non-theoretical result that indicated that this protein can 
be sufficiently concentrated to be assigned by NMR; the first came from circu­ 
lar dichroism data that indicated that there was enough secondary structure 
to allow sufficient separation of multi-dimensional NMR data.
CDO was later expressed in minimal media containing 15NH3C1 to incorpo­ 
rate an 15N label along the entire protein backbone of the protein. The protein 
was purified under conditions shown to keep the protein mono-disperse in 
DLS experiments. The result of the heteronuclear single quantum coherence 
(HSQC) revealed a folded protein that has sufficient secondary structure to 
be considered for assignment (Figure 5.22); An unfolded/misfolded protein 
typically has all its resonant signals overlapping in one area of the spectra. 
The signal was very weak and required a 24hr integration time for the sam­ 
ple. There was only a signal representing approximately 50% of the protein
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(See Table A. 1 on page 177); this was partly due to to concentration of the 
sample and the pH. There was also a problem supplementing the sample with 
10% D2O which resulted in too swift a change in the ionic strength of the 
buffer. Stepwise changes in ionic strength and pH invariably lead to aggre­ 
gation. However, it was possible to rescue this sample early and to obtain a 
signal by filtration through a 0.22/um filter.
Detection of a !H- 15N bond is not just dependant upon protonation of the 
nitrogen; the rate of disassociation is also important. Regions of a protein 
buried within the structure are often stabilised by hydrogen bonds. The rate 
of disassociation in these regions is very slow. For amine ligands and nitro­ 
gens along the amide backbone of the protein involved in hydrogen binding, 
the HSQC resonances are large. Circular dichroism results indicated that 
5O% of the peptide has ordered structure and NMR indicated a protein with 
roughly half the protein is internalised and folded. PHDsec, a program that 
predicts secondary characteristics of a protein, was run on the CDO sequence 
and the amino add residues were shaded using Tfc-Xshade (Figure A. 17, page 
180); this was done to see if there was a correlation between amide contain­ 
ing residues (Table A.1, page 177) and probable a-helical/3-sheet regions. 
The recombinant protein was not used in the analysis because the fusion 
protein is not buried within the protein by virtue of the fact it can bind the 
NTA-sepharose and is not sterically hindered. Because the fusion protein is 
free in solution, it is also unlikely to show strong resonances in the HSQC as 
it is not internalised. Half of the amide containing residues reside within or 
adjacent to areas of predicted secondary structure.
A second HSQC spectra was performed on a 15N labelled sample and sev­ 
eral more resonances were observed (Figure 5.23). It was impossible to de­ 
termine whether these weak resonances were signals of the remaining nitro-
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gens or whether they are noise. It is also impossible to assign a structure 
without analysis of a 13C labelled protein. However, given the concentration 
of the protein, the ionic strength of the buffer and pH, months of dedicated 
NMR time would be required to gather spectral data. Several further months 
of computation and analysis would be required to perform the assignment. 
Consideration also needs to be taken to determine the stability of CDO over 
this prolonged time period.
In summary, it has been shown that recombinant CDO has an ordered 
structure. It is possible to purify a labelled protein and sufficiently concen­ 
trate it for NMR analysis. Conditions have been found to keep the protein 
disperse while preserving its structure. It is possible to consider assigning a 
structure to CDO, however the resources and time to do so are non-trivial.
Figure 5.21: A preliminary 1-D spectra of cysteine dioxygenase
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Figure 5.22: 2-D HSQC ^-"N spectra of 15N labelled cysteine dioxygenase in 
320mM NaF, ImM Glycine, lOmM PO^3, 400/iM EDTA pH 7.8
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Figure 5.23: 2-D HSQC ^-"N spectra of 15N labelled cysteine dioxygenase in 
320mM NaF, ImM Grycine, lOmM PO^3, 4OO/zM EDTA pH 7.8 at increased 
sensitivity and integration time.
Chapter 6
Conclusions
A recombinant human CDO has been successfully expressed and highly pu­ 
rified. Experimental data has indicated that conditions exist that can keep 
the protein stable. Protein instability is always an impediment for further re­ 
search and this discovery opens up new avenues for future research on the 
protein. It was not possible to fully take advantage of the light scattering 
data to get a form factor for CDO because it was not possible to precisely 
measure and regulate variables as temperature and viscosity. Small angle 
x-ray scattering (SAXS) would have been more appropriate for topographical 
measurements.
Circular dichroism experiments have show the protein to have a discrete 
secondary structure that parallels what would be expected from sequence pre­ 
dictions. Functionality tests of recombinant CDO have shown the protein to 
be non-functional. It could be argued that the prokaryotic expression system 
used does not incorporate Fe++ ; however, EDTA has been shown to quench 
the reaction with the endogenous CDO. This indicates that a disassociation 
constant exists and the iron can bind reversibly. It is also possible that buffers 
chosen for the stability of CDO were not optimal for its function. Functionality
138
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problems are more likely to be due to a regulatory issue than with misfolding 
or fusion protein addition. To expound on this issue a little further, several 
programmes exist to predict possible modifications sites on a protein. There 
are several sites on CDO that have been identified as potential glycosylation 
sites and regulatory domains. The sequence (Figure A. 18) in the appendix 
illustrates the types of domains as well as their locations .
Experimental data has shown that the secondary structures exist in the 
same percentages and it is assumed that their distributions are in the same 
locations as well. The predicted glycosylation sites are generally located more 
toward tail end of the final transcript and their predicted probability is low 
(Figure A.1, A.4. and A.5 page 144). This indicated that at least the first 
133 residues are unmodified. Potential kinase phosphorylation sites are more 
evenly distributed about the protein; sites that affect protein activity. It seems 
more probable that eukaryotic kinases were absent in the prokaryotic expres­ 
sion system.
Cysteine dioxygenases have been discovered in schistosomajaponicum and 
drosophtia melanogaster that contain an additional nine and twenty upstream 
residues respectively. Also, some of the most conserved regions of the protein 
are stretches that lie between secondary structures; random coil domains. 
There is a high probability that these domains are external regions. The less 
conserved sites are domains with predicted post-translational sites on the 
human protein. Figure 5.4 (page 112) and the following sequence illustrates 
these contentions.
l] cydx human 
cydx~rat 
cydx~gmir 
cydx~~cele
cydx~SJap
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Attempts were made to approach solving the structure quantitatively. Crys­ 
tallography and NMR attempts were hampered by the stability of the protein. 
Once a suitable buffer was developed, time constraints prevented the resump­ 
tion of crystallography experiments. The NMR assays were more successful.
Initial 1H NMR spectra suggested that the protein could be concentrated 
to the point where it could be detected. Two dimensional NMR of 15N labelled 
CDO confirmed the circular dichroism experiments that indicated a protein 
that is folded (as opposed to misfolded or aggregated). Further HSQC exper­ 
iments yielded even more data. It was not possible to fully assign the 3D 
structure of the protein. Due to the concentration, an amount of NMR time 
needed to integrate the signal was not made available. The time needed to 
achieve this could have been minimised with a larger magnet and a cryoprobe 
but both options were unavailable. The structure of this protein could likely 
be done within a few months if the resources become available.
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Figure A. 1: Predicted N-Gtycosylation of CDO
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Fig. 4. Proposed reaction mechanism for 2JQD-<nediated dioxygenation of
Compared with KMP, the natural substrate QUE possesses an 
additional hydroxyl group at the 3' position of the B-ring. Two 
conformations are therefore possible for QUE while preserving 
an extended electronic delocalization: cii-QUE, in which the 
3'-OH group is cts to the O-heteroatom of the C-ring. and 
trans-QUE, in which the 3'-OH group is on the opposite side. In 
the x-ray structure of quercetin (30), crystal contacts induce 
QUE to adopt a cis conformation. In the 23QD-QUE complex, 
QUE is instead observed in the irons conformation only (Fig. 
2A). In this geometry, the 3'OH group fills a void formed by the 
backbone atoms of Asn74 and the side chain of Ghi73. It is not 
hydrogen bonded to any atom. Unfavorable interactions be­ 
tween the 3'OH group and the side chains of Met123 and Thr53 
would exist if the cis conformation was adopted.
i of the E-S CoaplBi m* Rote of «•». A possible mech­ 
anism for 23QD-mediated dioxygenation of flavonok is shown 
in Fig, 4. It combines the information from the present and 
previous crystallographk studies (6, 29), EPR investigations 
(10), and bio-mimetic studies (12-14). The initial step of the
distorted tetrahedral (major)/distorted trigonal bipvramidal 
(minor) native copper (structures la^j and Imam in Fig, 4, 
respectively) gains structural order, changing to a square pyra­ 
midal geometry represented by structure 2. ConcomitanUy, the 
portion of the linker peptide located in front of the active site 
entrance becomes ordered and assists, via the van der Waals 
interaction between Pro164 and the substrate molecule, the 
stabilization of the loaded substrate.
The formation of the E-S complex likely entails the loss of the 
3OH flavonol proton. Although deprotonation of the 3OH group 
may result from the lowering of its pKa on its complexation to the 
copper ion or simply from exchange to water, the 1,000-fold 
decrease in activity on a Ghi73—>Gta mutation (L M. Kooter, 
personal communication) and the proper positioning of the side 
chain of Ghi73 strongly support a role for this residue in substrate 
deprotonation. The observation of a dose interaction between the 
Ghio.273 atom and the O3 atom of the flavonol (Z43 A in
in 23OOQUE) suggests inld&ion that 
Ghi73 might be bound to the copper ion retaining the 3OH proton. 
In mechanistic terms, the retention of the 3OH proton in the 
vicinity of the copper center could be advantageous for protonating 
the leaving depside product (step 5 —» 1). Additionally, a Ghi 
residue bound to the metal is an effective way to allow, if needed, 
small adjustments in coordination geometries.
Dioxyfe* Attack. The reaction catalyzed by 23QD is a spin- 
forbidden process. The triplet ground state 62 reacts with a 
singlet ground state flavonol to form singlet ground state 
products (depside and CO). Such a reaction requires some form 
of activation. Similarly to what is observed in the case of the 
Fe3*-dependent intradiol-type catechol dioxygenases, EPR (10) 
and x-ray absorption spectroscopy (15) experiments provide 
evidence that the copper center of 23QD in complex with its 
flavonol substrates retains a formal high oxidation state. Nor­ 
mally, complexes of Cu2*, even when coordinatively unsatur- 
ated, do not bind Qy (36). This result is not surprising because 
good ligands for high oxidation state metal ions are usually 
relatively strong bases, and Qz is not The spin-forbiddeness of 
the reaction can, nonetheless, be circumvented by allowing the 
existence of a flavonoxy radical-Cu* valence tautomer (2Unt), 
arising from the flow of one electron from the flavonol into the 
copper. The radical center of this complex can react with 
the diradkal Oj (route a in Fig. 4). The pyramidalizalion of the 
flavonol C2 atom, independently observed in both E-S com­ 
plexes, is consistent with the stabilization of the unpaired 
electron on this atom. Analysis of the shape of the active site 
cavity shows that room is available for a dioxygen molecule to 
directly attack the flavonol C2 atom from the copper side. Qz 
binding would then produce the peroxide 3*, which, after 
nudeophilk attack on the C4 atom, would generate the endo- 
peroxide 4. In these peroxkBc intermediates, the C2 atom is sp3 
hybridized. The pyramidalization observed in the bound sub­ 
strates indicates that, apart from likely radical stabilization, the 
protein structure also preorganizes a conformation of the E-S 
complex favorable for subsequent intermediates.
The existence of an active flavonoxy radical-Cu* complex 
2ta*t allows, in principle, also to hypothesize a reaction mech­ 
anism in which Oj is activated by coordination to the Cu* ion 
(route b) (14). An a priori prediction of whether this complex 
possesses the reducing equivalents to do so is difficult However, 
from a geometrical point of view a binding site for Oj is available 
in the E-S complex. Differently from what was generally assumed 
from the chelating behavior of flavonok, the protein matrix 
constrains the flavonol to bind to the metal with only its O3 
atom. As a consequence, the coordination position irons to His68 
might be used by the dioxygen molecule to directly bind to the 
0lygeffi^ HHf exed with kojk 
ado (29) shows that an oxygen atom can indeed occupy this sixth 
coordination position, producing a pseudooctahedral copper 
site. Owing to this result, we have tried to model the relevant 
structures along the reaction path b: 3b and 3b2. We find that, 
although formation of 3b2 from 3b is geometrically feasible, 
intramolecular nudeophilk attack of the oxygen atom, bound to 
the copper on the C4 flavonol atom required to generate the 
endoperoxide 4 from 3b2, seems more difficult. The model 
indicates that the attacking oxygen atom would be at about 
33—4.0 A from the C4 atom and not above the carbonyl plane, 
which represents the most likely direction of attack. In contrast, 
such an arrangement seems favored in 3*.
On the basis of geometrical considerations, we therefore 
conclude that the mechanism of substrate activation (route a), 
which assumes the formation of the endoperoxide 4 from 3m, is 
favored. Experiments of radical-initiated oxygenation of fla­ 
vonols support a mechanism of substrate activation (37). In the 
presence of free radicals such as TEMPO (2^,6,6-tetramethyl-
5
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Fic. 6. fiHMial »K lianJHUi of inactivation of ortradiol <Hu«> gi naat • Only thoae intermediates for which some experimental evidence 
exists are shown. The exact step at which superoxide dimoriaU-fl from the ternaiy rnmpier has not been detennmed. The Bganda in the ferric form 
of the enzyme are unknown.
3-chloroeatechol, respectively. In contrast, oxygraph assays 
yielded a partition coefficient of 11 ± 2.
DISCUSSION
DHBD is typical of extradiol-type dioxygenases in that it is 
subject to inactivation during the steady-state cleavage reac­ 
tion (35). The present analysis indicates that this inactivation 
in DHBD requires the formation of the EAOx ternary complex. 
In particular, the rates of inactivation of EA, AEA, and EP (fe, 
>«, and>5 in Fig. 2) are negligible with respect to the rate of 
inactivation during steady-state turnover. Thus, DHBD is not 
inactivated by chelation of the active site FeOD by catecholk 
substrates (19). Although free DHBD is subject to significant 
inactivation by Oj, the apparent rate constant of this inactiva­ 
tion is significantly lower than the rate constant of inactivation 
by the piefciied catecholk substrate of the enzyme, DHB. The 
current study does not rule out the possibility that the AEA and 
EP forms are unstable in the presence of Oj. However, given 
the DHBD high K^ value for O, ( L3 nm (35)), high K^ for DHB 
(3 mtt (35)), and high Kf values for HOPDA (- 3 nm), such 
inactivation seems unlikely to be aigmfi«»nt under the condi­ 
tions studied.
Further analysis of the mechanism-based inactivation of 
DHBD revealed that it is gi™ilj»r in nature to the O^-dependent 
inactivation of DHBD in the absence of catecholk substrate, 
arising principally from the fliridation of the active site FeCIl) to 
FedlD. Thus, EPR and absorption spectroscopy data demon­ 
strate the formation of FeflID in samples of inactivated enzyme, 
and anaerobic incubation of the inactivated enzyme with FedD 
and DIT restored 1_ 
upon S&ttfe of < 
DTT «areNy"jetie&fe^£8fafthe oxidized Fedll) remained 
hnmiH to the protein. Although no association constants of an 
extradiol enzyme for Fedll) and FedD have been reported, the 
apparently higher affinity of DHBD for FedD than far FedH) is 
consistent with the orystallographk data of DHBD from Pxudo-
nvmaxnjL KKS1Q2, in which a mart* mtenmt fifftrtmilt9uuty wan
observed at the active site when the iron was reduced (55). 
Moreover, the oxidation of the active site FedD of C23O by HgOg 
resulted in the Jimngrfiatg release of FedH) (57).
The present studies suggest that the mechanism-based inac­ 
tivation of DHBD does not involve covaknt modification, as 
judged by a lack of change to the molecular mass of DHBD
inactivated in a number of ways. Moreover, DHBD was readily 
reactivated in cells in the absence of protein synthesis. Thus, 
inactivation does not involve hydroxyiation of an active site 
residue as observed in the O2-dependent inactivation of an 
o-ketoghitarate-dependent oxygenase (58), which like DHBD 
has a catalytically essential mononuclear iron bound to the 
enzyme by a 2-histidine 1-carboxylate facial triad (59). These 
results also demonstrate that although 3-chlorocatechol is a 
very potent mechanism-based inactivator and that the DHBD- 
catalyzed cleavage of 3-chlorocatechol produces an acyl haUde, 
the inactivation does not involve covalent modification by the 
acyl chloride as has been proposed for C23O (20). Indeed, one 
study reported that the inactivation of C23O by 3-chlorocat­ 
echol also involves oxidation of the active site Fed!) (60).
A straightforward MpUnatinn of the mechanism-based inac­ 
tivation of DHBD involves the dissociation ofsuperoxide from 
the EA(>2 ternary complex. In a proposed catalytic mechanism, 
formation of the EAOg ternary complex is followed by succes­ 
sive electron transfer steps from the Fed!) to the bound O2 and 
from the bound catecholate to the iron. C-O bond formation at 
C-2 in the resulting semiquinone-FedD-superoiide intermedi­ 
ate yields an iron-alkylperoxo intermediate that undergoes a 
Criegee rearrangement (3). Mechanism-based inactivation 
could arise from Himmrintinn of the bound superoxide before 
electron transfer from the catecholate to the iron or before C-O 
bond formation between the bound superoxide and semiqui- 
none. Thus, catecholk: substrates that slow either step either 
through steric or electronic factors would be good mechanism- 
based inactivators. For example, electron transfer between
3-methykatechol and Fedll) due to the expected higher reduc­ 
tion potential of a catechol with an electron-withdrawing sub- 
stituent. Consistent with this hypothesis, catechols with elec­ 
tron-withdrawing substituents were not cleaved in a model 
extradiol cleavage reaction (61).
Failure to detect superoxide in the inactivation of DHBD by 
3-chlorocatechol seems to be due to the rapid reaction of super- 
oxide with the catechol, possibly before their diffusion from the 
active site rfmmwJ of the enzyme. The current studies with 
xanthine oxidase demonstrate that 3-chlorocatechol is highly 
reactive with superoxide, mmrigfaint with the known role of 
catechols as superoxide scavengers (62, 63). Moreover, ferric
APPENDIX A. SEQUENCE SPECIFIC DETAILS OF CDO 147
NetNGlyc 1.0 Prediction Results
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Figure A.4: Predicted N-gtycosyiation sites on human CDO using NetNGlyc
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NetOdyc 2.0 Prediction Results
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Figure A.5: Predicted O-gfycosylation sites on human CEXD using NetOGtyc
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Figure A.6: Novagen pET15b vector
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The following information has been received by the server:
reference predict_h!6487 (May 29, 2002 06:22:58)
reference pred_h!6487 (May 29, 2002 05:43:03)
PPhdr from: anon@pugh.bip.bham.ac.uk
PPhdr resp: HTML
PPhdr orig: HTML
PPhdr want: ASCII
PPhdr password(###)
prediction of: - default prediction of: - PHDsec PHDacc PHDhtm ProSite £
return msf format
ret store
# default: single protein sequence
MEQTEVLKPR TLADLIRILH QLFAGDEVNV EEVQAIMEAY ESDPIEWAMY
AKFDQYRYTR NLVDQGNGKF NLMILCWGEG HGSSIHDHTN SHCFLKMLQG
NLKETLFAWP DKKSNEMVKK SERVLRENQC AYINDSIGLH RVENISHTEP
AVSLHLYSPP FDTCHAFDQR TGHKNKVTMT FHSKFGIRTP NATSGSLENN
Result of PROSITE search (Amos Bairoch):
please quote: A Bairoch, P Bucher & K Hofmann: The PROSITE database, 
its status in 1997. Nucl. Acids Res., 1997, 25, 217-221.
Pattern-ID: ASN_GLYCOSYLATION PS00001 PDOC00001
Pattern-DE: N-glycosylation site
Pattern: N[ AP] [ST] [ AP]
134 NDSI
144 NISH
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191 NATS
Pattern-ID: PKC_PHOSPHO_SITE PS00005 PDOC00005
Pattern-DE: Protein kinase C phosphorylation site
Pattern: [ST] . [RK]
121 SER
Pattern-ID: CK2_PHOSPHO_SITE PS00006 PDOC00006
Pattern-DE: Casein kinase II phosphorylation site
Pattern: [ST].{2}[DE]
11 TLAD
84 SIHD
146 SHTE
Pattern-ID: MYRISTYL PS00008 PDOC00008
Pattern-DE: N-myristoylation site
Pattern: G[ AEDRKHPFYW].{2}[STAGCN][AP]
195 GSLENN
Pattern-ID: LUM_BINDING PS00693 PDOC00581
Pattern-DE: Riboflavin synthase alpha chain family signature
Pattern: [LIVMF].{5}G[STADNQ][KREQIYW]VN[LIVM]E
19 LHQLFAGDEVNVE
Result of ProDom domain search (Sonnhammer; Corpet, Gouzy, Kahn):
- please quote: ELL Sonnhammer & D Kahn, Prot. Sci., 1994, 3, 482-492
--- Results from running BLAST against PRODOM domains
--- PLEASE quote:
APPENDIX A SEQUENCE SPECIFIC DETAILS OF CDO 152
--- F Corpet, J Gouzy, D Kahn (1998). The ProDom database
--- of protein domain families. Nucleic Ac Res 26:323-326.
--- BEGIN of BLASTP output
BLASTP 1.4.7 [16-Oct-94] [Build 12:52:03 Oct 30 1994]
Reference: Altschul, Stephen F., Warren Gish, Webb Miller, Eugene W. M> 
and David J. Lipman (1990). Basic local alignment search tool. J. Mol. 
215:403-10.
Query= prot (#) ppOld, default: single protein sequence 
/home/phd/server/work/predict_h!6487 
(200 letters)
Database: prodom_00_l
174,952 sequences; 19,895,393 total letters. 
Searching..................................................done
Sine 
c
High Proh 
Sequences producing High-scoring Segment Pairs: Score P(N)
PD016803 p2000.1 (3) CYDX(2) Q20893(l) // DIOXYGENASE C... 796 1.6e 
PD094785 p2000.1 (1) O32085_BACSU // YUBC PROTEIN 58 5.9e
>PD016803 p2000.1 (3) CYDX(2) Q20893(l) // DIOXYGENASE CYSTEINE CDO 
OXIDOREDUCTASE IRON CDO-I PUTATIVE 
Length = 180
Score = 796 (366.3 bits), Expect = 1.6e-106, P = 1.6e-106 
Identities = 143/176 (81%), Positives = 154/176 (87%)
Query: 15 LIRILHQLFAGDEVNVEEVQAIMEAYESDPIEWAMYAKFDQYRYTRNLVDQGNGKFNI^
LIR LH+LF GDEVNV+EVQ IMEAYES+P EW YAKFDQYRYTRNLVDQGNGK+NLf
Sbjct: 1 LIRQLHELFQGDEVNVDEVQKIMEAYESNPNEWRRYAKFDQYRYTRNLVDQGNGKYNI^
Query: 75 LCWGEGHGSSIHDHTNSHCFLKMLQGNLKETLFAWPDKKSNEMVKKSERVLRENQCAY]
LCWG GHGSSIHDHT+SHCFLK+L GNLKET +AWPDKK N M KK R EN CAY-*
Sbj ct: 61 LCWGPGHGSSimDHTDSHCFLKILDGNLKETKYAWPDKKHNPMDKKENRTYGENGCAY>
Query: 135 DSIGLHRVENISHTEPAVSLHLYSPPFDT<ZHAFI)QRTGHKNKVTMTFHSKFGIRTP 1£
APPENDIX A SEQUENCE SPECIFIC DETAILS OF CDO 153
D IGLHR+ENISHT PAVSLHLYSPP+DTCHAFDQRTGHKNK TMTFHSK+G RTP 
Sbjct: 121 DEIGIJnmENISHTNPAVSLHLYSPPYDTCSIAFDQRTGHKNKCTMTFHSKYGKRTP 1'
>PD094785 p2000.1 (1) O32085_BACSU // YUBC PROTEIN 
Length = 161
Score = 58 (26.7 bits), Expect = 5.9e-05, Sum P{3) = 5.9e-05 
Identities = 10/23 (43%), Positives = 16/23 (69%)
Query: 148 TEPAVSLHLYSPPFDTCHAFDQR 170
+E VSLH+YSPP + F+++ 
Sbjct: 132 SERMVSLHVYSPPLEDMTVFEEQ 154
Score = 43 (19.8 bits), Expect = 5.9e-05, Sum P(3) 
Identities = 8/41 (19%), Positives = 21/41 (51%)
5.9e-05
Query: 67 NGKFNLMILCWGEGHGSSIHDHTNSHCFLKMLQGNLKETLF 107
N + ++++ +++HDH S +L+G L +++ 
Sbjct: 56 NNELEIIVINIPPNICETTvHDHGQSIGCAMVLEGKLLNSlY 96
Score = 39 (17.9 bits), Expect = 5.9e-05, Sum P(3) = 5.9e-05 
Identities = 7/14 (50%), Positives = 9/14 (64%)
Query: 54 DQYRYTRNLVDQGN 67
DQY Y RN + + N 
Sbjct: 44 DQYAYGRNAIYRNN 57
Parameters: 
E=0.001 
B=500
V=500
-ctxfactor=l.00
Query
Frame MatID Matrix name 
+0 0 BLOSUM62
----- As Used -----
Lambda K H
0.319 0.134 0.403
----- Computed 
Lambda K 
same same
Query
Frame MatID Length Eff.Length E S W T X E2 S2 
+0 0 200 200 0.0010 86 3 11 22 0.24 32
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Statistics:
Query Expected Observed HSPs HSPs 
Frame MatID High Score High Score Reportable Reported 
+0 0 62 (28.5 bits) 796 (366.3 bits) 4 4
Query Neighborhd Word Excluded Failed Successful C
Frame MatID Words Hits Hits Extensions Extensions E
+0 0 5558 8373478 1785644 6571796 16037
Database: prodom_00_l 
Release date: unknown 
Posted date: 5:56 PM EOT Jun 21, 2000
# of letters in database: 19,895,393
# of sequences in database: 174,952
# of database sequences satisfying E: 2 
No. of states in DFA: 565 (56 KB) 
Total size of DFA: 116 KB (128 KB)
Time to generate neighborhood: O.Olu O.OOs O.Olt Real: 00:00:00 
Time to search database: 11.43u 0.05s 11.48t Real: 00:00:11 
Total cpu time: 11.45U 0.07s 11.52t Real: 00:00:11 
--- END of BLASTP output
Again: these results were obtained based on the domain data­ 
base collected by Daniel Kahn and his coworkers in Toulouse.
PLEASE quote:
F Corpet, J Gouzy, D Kahn (1998). The ProDom database 
of protein domain families. Nucleic Ac Res 26:323-326.
The general WWW page is on:
http://www.toulouse.inra.fr/prodom.html
--- For WWW graphic interfaces to PRODOM, in particular for your
--- protein family, follow the following links (each line is ONE
--- single link for your protein!!):
http://www.toulouse.inra.fr/prodom/cgi-bin/ReqProdomlI.pl?id_doml=PD016£ 
http://www.toulouse.inra.fr/prodom/cgi-bin/ReqProdomlI.pi?id_dom2=PDO16£ 
http://www.toulouse.inra.fr/prodom/cgi-bin/ReqProdomll.pl?id_doml=PD094~ 
http://www.toulouse.inra.fr/prodom/cgi-bin/ReqProdomlI.pl?id_dom2=PD094~
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--- NOTE: if you want to use the link, make sure the entire line
--- is pasted as URL into your browser!
--- END of PRODOM
The alignment that has been used as input to the network is:
--- Version of database searched for alignment:
--- SWISS-PROT release 39.0 (5/00) with 85 249 proteins
--- MAXHOM multiple sequence alignment
--- MAXHOM ALIGNMENT HEADER: ABBREVIATIONS FOR SUMMARY
---ID : identifier of aligned (homologous) protein
--- STRID : PDB identifier (only for known structures)
--- IDE : percentage of pairwise sequence identity
--- WSIM : percentage of weighted similarity
--- LALI : number of residues aligned
--- NGAP : number of insertions and deletions (indels)
--- LGAP : number of residues in all indels
--- LSEQ2 : length of aligned sequence
--- ACCNUM -. SwissProt accession number
--- OMIM : OMIM (Online Mendelian Inheritance in Man) ID
--- NAME : one-line description of aligned protein
--- MAXHOM ALIGNMENT HEADER: SUMMARY
ID STRID IDE WSIM LALI NGAP LGAP LSEQ2 ACCNUM OMIM NAME
cydx_human 100 100 200 0 0 200 Q16878 603943 CYSTEINE
cydx_rat 92 95 200 0 0 200 P21816 CYSTEINE
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--- MAXHOM ALIGNMENT: IN MSF FORMAT
MSF of: /home/phd/server/work/predict_h!6487.hsspFilter from: 1 to: 
/home/phd/server/work/predict_h!6487.msfRet MSF: 200 Type: P 29-May-
Name: predict_h!640 Len: 200
Name: cydx_human Len: 200
Name: cydx_rat Len: 200
Check: 8892
Check: 8892
Check: 9388
Weight: 1.00
Weight: 1.00
Weight: 1.00
1 50
predict_h!640 MEQTEVLKPR TLADLIRILH QLFAGDEVNV EEVQAIMEAY ESDPIEWAMY 
cydx_human MEQTEVLKPR TLADLIRILH QLFAGDEVNV EEVQAIMEAY ESDPIEWAMY 
cydx_rat MERTELLKPR TLADLIRILH ELFAGDEVNV EEVQAVLEAY ESNPAEWALY
51 100
predict_h!640 AKFDQYRYTR NLVDQGNGKF NLMILCWGEG HGSSIHDHTN SHCFLKMLQG 
cydx_human AKFDQYRYTR NLVDQGNGKF NLMILCWGEG HGSSIHDHTN SHCFLKMLQG 
cydx_rat AKFDQYRYTR NLVDQGNGKF NLMILCWGEG HGSSIHDHTD SHCFLKLLQG
101 150
predict_h!640 NLKETLFAWP DKKSNEMVKK SERVLRENQC AYINDSIGLH RVENISHTEP 
cydx_human NLKETLFAWP DKKSNEMVKK SERVLRENQC AYINDSIGLH RVENISHTEP 
cydx_rat NLKETLFDWP DKKSNEMIKK SERTLRENQC AYINDSIGLH RVENVSHTEP
151 200
predict_h!640 AVSLHLYSPP FDTCHAFDQR TGHKNKVTMT FHSKFGIRTP NATSGSLENN 
cydx_human AVSLHLYSPP FDTCHAFDQR TGHKNKVTMT FHSKFGIRTP NATSGSLENN 
cydx_rat AVSLHLYSPP FDTCHAFDQR TGHKNKVTMT FHSKFGIRTP FTTSGSLENN
Result of COILS prediction (Andrei Lupas):
A Lupas: Methods in Enzymology, 1996, 266, 513-525.
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version 2.2: Rob B. Russell & Andrei N. Lupas, 1999
no coiled-coil above probability 0.5
PHD: Profile fed neural network systems from HeiDelberg
Prediction of:
secondary structure, by PHDsec 
solvent accessibility, by PHDacc 
and helical transmembrane regions, by PHDhtm
Author: 
Burkhard Rost
EMBL, 69012 Heidelberg, Germany 
Internet: Rost@EMBL-Heidelberg.DE
All rights reserved.
The network systems are described in:
PHDsec: B Rost & C Sander: JMB, 1993, 232, 584-599.
B Rost & C Sander: Proteins, 1994, 19, 55-72. 
PHDacc: B Rost & C Sander: Proteins, 1994, 20, 216-226. 
PHDhtm: B Rost et al.: Prot. Science, 1995, 4, 521-533.
The resulting network (PHD) prediction is:
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PHD: Profile fed neural network systems from HeiDelberg
Prediction of:
secondary structure, by PHDsec 
solvent accessibility, by PHDacc 
and helical transmembrane regions, by PHDhtm
Author: 
Burkhard Rost
EMBL, 69012 Heidelberg, Germany 
Internet: Rost@EMBL-Heidelberg.DE
All rights reserved.
The network systems are described in:
PHDsec: B Rost & C Sander: JMB, 1993, 232, 584-599.
B Rost & C Sander: Proteins, 1994, 19, 55-72. 
PHDacc: B Rost & C Sander: Proteins, 1994, 20, 216-226. 
PHDhtm: B Rost et al.: Prot. Science, 1995, 4, 521-533
Some statistics
Percentage of amino acids:
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AA: | P | M | Y | C | W 
% Of AA: 3.5 3.5 3.0 2.0 1-5
Percentage of secondary structure predicted
SecStr: | H | E | L 
% Predicted: 40.5 16.5 43.0
According to the following classes:
all-alpha: %H>45 and %E< 5; all-beta : %H<5 and %E>45 
alpha-beta : %H>30 and %E>20; mixed: rest,
this means that the predicted class is: mixed class
PHD output for your protein
Wed May 29 06:23:53 2002
Jury on: 10 different architectures (version 5.94_317 ). 
Note: differently trained architectures, i.e., different versions can 
result in different predictions.
About the protein
HEADER /home/phd/server/work/predict_h!6487.fas 
COMPND 
SOURCE 
AUTHOR
SEQLENGTH 200
NCHAIN 1 chain(s) in predict_h!6487 data set 
MALIGN 1 
(=number of aligned sequences in HSSP file)
WARNING
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Expected accuracy is about 72% if, and only if, the alignment contain 
sufficient information. For your sequence there was no homologue in 
the current version of Swissprot detected. This implies that the 
expected accuracy is about 6-10 percentage points lower !
Abbreviations: PHDsec
sequence:
AA : amino acid sequence 
secondary structure:
HEL: H=helix, E=extended (sheet), blank=other (loop) 
PHD: Profile network prediction HeiDelberg 
Rel: Reliability index of prediction (0-9) 
detail:
prH: 'probability' for assigning helix 
prE: 'probability' for assigning strand 
prL: 'probability' for assigning loop
note: the 'probabilites' are scaled to the interval 0-9, e.g.,
prH=5 means, that the first output node is 0.5-0.6 
subset:
SUB: a subset of the prediction, for all residues with an expected 
average accuracy > 82% (tables in header) 
note: for this subset the following symbols are used: 
L: is loop (for which above " " is used)
".": means that no prediction is made for this residue, as the 
reliability is: Rel < 5
Abbreviations: PHDacc
SS : secondary structure
HEL: H=helix, E=extended (sheet), blank=other (loop) 
solvent accessibility:
3st: relative solvent accessibility (ace) in 3 states:
b = 0-9%, i = 9-36%, e = 36-100%. 
PHD: Profile network prediction HeiDelberg 
Rel: Reliability index of prediction (0-9) 
O_3: observed relative ace. in 3 states: B, I, E
note: for convenience a blank is used intermediate (i). 
P_3: predicted relative accessibility in 3 states
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lOst:relative accessibility in 10 states:
= n corresponds to a relative ace. of n*n % 
subset:
SUB: a subset of the prediction, for all residues with an expected
average correlation > 0.69 (tables in header)
note: for this subset the following symbols are used: 
"I": is intermediate (for which above " " is used) 
".": means that no prediction is made for this residue, as the
reliability is: Rel < 4
protein: predict length 200
AA
PHD sec 
Rel sec 
detail:
prH sec 
prE sec 
prL sec
subset: SUB sec 
accessibility 
3st: P_3 ace 
lOst: PHD ace 
Rel ace 
subset: SUB ace
.........1.........2.........3.........4.........5....
IMEQTEVLKPRTLADLIRILHQLFAGDEVNVEEVQAIMEAYESDPIEWAMYAKFT 
j HHHHHHHHHHHHH HHHHHHHHHHH HHHHHHHHHHI-
J97654347514999999999971688522799999999972677999999988E
I01112100256999999999874111122799999999974217999999988 1; 
J01011231000000000000000000133100000000000000000000000C 
|977665676430000000000157886440000000000157820000000112
|LLLL. . .LL. .HHHHHHHHHHH.LLLL..HHHHHHHHHHH.LLHHHHHHHHHHI-
|eeebebbeeebbbebbbbbbbbbbeeebbbeebebbbeb eeeebebbbbbebe 
198607006760007000000000077700076060007037967060000060": 
(330031432103317809740421013204319076536020202265606233 
j......b.......bb.bbb.b.......b..b.bbb.b.......bbb.b...
AA
PHD sec 
Rel sec 
detail:
prH sec 
prE sec 
prL sec
subset: SUB sec 
accessibility
3st: 
lOst:
P_3 ace 
PHD ace
• •••fV*. •/•••«; • •••Oa •»•£•••• -7 •*•_£•»•* ^  V/ • •*£•»•• A A. • • •
| NLVT)QGNGKFNLMILCWGEGHGSSIHDHTNSHCFLKMLQGNLKETLFAWPDKK£
JHHH EEEEEEEE HHHHHHHHHHHHHHHHHHH t
|763258872568999843789765124761589999998868886753177883
|76532100100000000011001122212578998999887888776531100E 
J01110001367899886310011232100000000000000000112220000C 
j113568885210000126789866446774200000001121100112488884 
JHH..LLLL.EEEEEEE..LLLLLL...LL.HHHHHHHHHHHHHHHHH..LLLL.
|ebbeeeeeebbbbbbbbbee bbbb e beb bbbebbeeebeebbbb eeeee 
J60077977600000000079500004830605000700776077000057997-;
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Rel ace |14221310222869682341100240201020669332122242142001323C 
subset: SUB ace |.b.........bbbbb..e.....b.......bbb.......e..b........
AA
PHD sec 
Rel sec 
detail:
prH sec 
prE sec 
prL sec
subset: SUB sec 
accessibility 
3st: P_3 ace 
lOst: PHD ace 
Rel ace 
subset: SUB ace
|SERVLRENQCAYINDSIGLHRVENISHTEPAVSLHLYSPPFDTCHAFDQRTGHJ
IHHHHHHHHHHHEEE EEEEE EEEEE EE
jj 999987644411203344256413489996337741368866332312256796
|99998876654433211000001000000110000000001122321111110C 
|00000000013444132237764521000135776432000122124532000C 
I 000011233211115566522243688896531124678877555543467786 
JHHHHHHH............EE....LLLLL..EE...LLLLL.......LLLLI
|beebbeebebbbbbebbbbb bebbeee ebbbbbb bee ebb bbee eeee 
| 07600670600000700000406007775900000030673700500765976 1; 
J11215240053160024211061231101036351400010115062210021E
AA
PHD sec 
Rel sec 
detail:
prH sec 
prE sec 
prL sec
subset: SUB sec 
accessibility 
3st: P_3 ace 
lOst: PHD ace 
Rel ace 
subset: SUB ace
.........19...,....20.
|FHSKFGIRTPNATSGSLENN| 
j EE EEE | 
j 94356514357886787899 |
|00000000000011100000| 
j 86321256621000000100 j 
j 03677742368887788899 j 
|E..LLL...LLLLLLLLLLL j
|bbbebbbebeebeeeb eee|
I 00060006067067704799)
30422032112101100335
.21 .22 .23
The resulting prediction of globularity is:
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--- GLOBE: prediction of protein globularity
--- nexp = 93 (number of predicted exposed residues)
--- nfit = 90 (number of expected exposed residues
--- diff = 3.00 (difference nexp-nfit)
--- =====> your protein appears as compact, as a globular domain
--- GLOBE: further explanations preliminaryily in:
--- http://www.Columbia.edu/~rost/Papers/98globe.html
--- END of GLOBE
Result of ASP prediction(Malin Young, Kent Kirshenbaum, Stefan Highsmitt
Kirshenbaum K, Young M and Highsmith S.
Prot. Sci.(1999) 8:1806-1815.
Young M, Kirshenbaum K, Dill KA and Highsmith S.
Prot. Sci.(1999) 8:1752-1764.
Ambivalent Sequence Predictor (ASP vl.O) mmy
Parameters: 
Window size : 5 
Min mu dPr : 9 
Z-score cutoff : -1.75
Mean dPr score=13.583, Standard deviation=2.903
....,....!.. .......2.........3....... ..4.........5....
AA |MEQTEVLKPRTLADLIRILHQLFAGDEVNVEEVQAIMEAYESDPIEWAMYAKFr 
prH sec | 01112100256999999999874111122799999999974217999999988', 
prE sec j01011231000000000000000000133100000000000000000000000C
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prL sec | 97766567643000000000015788644000000000015782000000011: 
ASP sec | ......................................................
........ .7. ....... .8. ....... .9. ....... .10. ...... .11. . .
AA | NLVDQGNGKFNLMILCWGEGHGSS IHDHTNSHCFLKMLQGNLKETLFAWPDKK£ 
prH sec | 76532100100000000011001122212578998999887888776531100E 
prE sec | 01110001367899886310011232100000000000000000112220000C 
prL sec | 113568885210000126789866446774200000001121100112488884 
ASP sec j ........................ SS ............................
• •••£•••• J> .3 » • • f ••»* ^ Tx • • • f •*•» ^. ^  * • • f •*•• .i O • ••£•••• J. / * • •
AA | SERVLRENQCAYINDSIGLHRVENISHTEPAVSLHLYSPPFDTCHAFDQRTGHI'
prH sec |99998876654433211000001000000110000000001122321111110C
prE sec |00000000013444132237764521000135776432000122124532000C
prL sec j 00001123321111556652224368889653112467887755554346778E
ASP sec .......... SSSSS ............................ SSSSS ......
........ .19. ...... .20. ...... .21. ...... .22. ...... .23
AA | FHSKFGIRTPNATSGSLENN | 
prH sec j 00000000000011100000 j 
prE sec j 86321256621000000100 j 
prL sec j 03677742368887788899 | 
ASP sec I .................... I
Please note: ASP was designed to identify the location of conformationa] 
switches in amino acid sequences. It is NOT designed to predict whether 
a given sequence does or does not contain a switch. For best results, 
ASP should be used on sequences of length >150 amino acids with >10 
sequence homologues in the SWISS-PROT data bank.
ASP has been validated against a set of globular proteins and may not 
be generally applicable. Please see Young et al., Protein Science 
8(9):1852-64. 1999. for details and for how best to interpret this 
output. We consider ASP to be experimental at this time, and would 
appreciate any feedback from our users.
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- PredictProtein (PP): News 2000
- PP home:
New York http://cubic.bioc.Columbia.edu/predictprotein/
- PP mirrors:
Australia Sydney http://molmod.angis.org.au/predictprotein/
Germany EMBL http://www.embl-heidelberg.de/predictprotein/
China CBI,Peking http://www.cbi.pku.edu.cn/predictprotein/
China Inst. Microbiol. http://micronet.im.ac.cn/predictprotein/
England EBI http://www.ebi.ac.uk/~rost/predictprotein/ 
India CDFD http://www.cdfd.org.in/~www/pp/predictprotein/
India Pune http://202.41.70.33/predictprotein/
Iran Tehran http://www.ibc.ut.ac.ir/predictprotein/
Israel Beer-Sheva http://www.cs.bgu.ac.il/~dfischer/predictprote
Italy Rome http://obelix.bio.uniroma2.it/www/predictprot€
Mexico Cuernavaca UNAM http://www.ibt.unam.mx/paginas/lorenzo/predict
Netherlands CMBI http://www.cmbi.kun.nl/bioinf/predictprotein/
Russia Puschino http://mirror.protres.ru/predictprotein/
Singapore http://embl.bic.nus.edu.sg/predictprotein/
Spain CNB http://www.es.embnet.org/Services/MolBio/Pred3
Switzerland Glaxo http://www.gwer.ch/tools/predictprotein/
USA San Diego SDSC http://www.sdsc.edu/predictprotein/
- Tools to post-process PP results:
- Generate a PostScript (or GIF, or TIFF):
ESPript (New York) http://cubic.bioc.Columbia.edu/cgi/pp/nph-ESPript_ 
ESPript (Toulouse) http://www-pgml.ipbs.fr:8080/ESPript
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\feature{top}{l}{!2..22}{box:$\alpha 
\feature{top}{l}{30..40}(box:$\alpha $2}{} 
\feature{top}{l}{44..62}{box:$\alpha $3}{} 
\feature{top}{l}{70..76}{-->}{$\beta $1} 
\feature{top}{l}{91..107}{box:$\alpha $4}{} 
\feature{top}{l}{H6..127}{box:$\alpha $5J{} 
\feature{top}{l}{l40..141}{-->}{$\beta $2} 
\feature{top}{l}{!53..154}{-->}j$\beta $3} 
\feature{top}{l}{!77-.181}{-->}{$\beta $4}
Figure A.7: Predicted secondary features by TgXshade based upon PhD se­ 
quence analysis of CDO in preceding data.
I1AA_MULTIPLE_ALIGNMENT 1.0
PileUp of: @/home/pugh/anon/.seqlab-pugh/pileup_244.list
Symbol comparison table: GenRunData:blosum62.cmp CompCheck: 1102
GapWeight: 8 
GapLengthWeight: 2
pileup_244.msf MSF: 221 Type: P May 28, 2002 16:53 Check: 6608
Name: cydx_human
Name: cydx_rat
Name: cydx_gmir
Name: cydx_cele
Name: cydx_sj ap
Len: 221 Check: 9529 Weight: 1.00
Len: 221 Check: 9956 Weight: 1.00
Len: 221 Check: 6058 Weight: 1.00
Len: 221 Check: 5305 Weight: 1.00
Len: 221 Check: 5760 Weight: 1.00
50
-M EQTEVLKPRT LADLIRILHQ LFAGDEVNVE EVQAIMEAYE
-M ERTELLKPRT LADLIRILHE LFAGDEVNVE EVQAVLEAYE
-M EHTEVWPKT LDELIAILHQ IFESDNINVE EVQQIMESYE 
._ ——————MIS FVQLWQIRE IFQQKLIDVD EVMKLMASYK
cydx_human
cydx_rat ———— 
cydx_gmir ———— 
cydx_cele ———— 
cydx_sjap MSMYTHQSNN ELIPLKTVST LNDLIKTIRI IFNQKEINVN EIHKILNDFQ
cydx_human
cydx_rat
cydx_gmir
cydx_cele
cydx_sj ap
51
SDPIEWAMYA
SNPAEWALYA
SNPQDWNKFA
SNANEWRRFA
CDFTEWQKYI
KFDQYRYTRN 
KFDQYRYTRN 
KFDQYRYTRN 
IFDMNKYTRN 
YFNKTHYTRN
LVDQGNGKFN 
LVDQGNGKFN 
LVDEGNGKFN 
LVDVGNGKYN 
LIDEGNGRYN
LMILCWGEGH 
LMILCWGEGH 
LMILCWGEGH 
LMILCWGPGM 
LFLLCWSEDQ
100
GSSIHDHTNS 
GSSIHDHTDS 
GSSIHDHTDS 
ASSVHDHTDA 
GTRIHDHSGA
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	101 150 
cydx_human HCFLKMLQGN LKETLFAWPD ....KKSN.. ......EMVK KSERVLRENQ
cydx_rat HCFLKLLQGN LKETLFDWPD ....KKSN.. ......EMIK KSERTLRENQ
cydx_gmir HCFMKLLQGQ LKETLFEWPE . . . .GEQN. . .... .GEMVQ KSRDPDGKQG
cydx_cele HCFVKILDGE LTETKYAWP. ....RKRH.. .....VPLDI SENKTYGMNG
cydx_sjap HCFVKLIKGC IKETIFEWPK YFTVEKSNYS INQIDLPLTV KSVSEMRPGD
	151 200
cydx_human CAYINDSIGL HRVENISHTE PAVSLHLYSP PFDTCHAFDQ RTGHKNKVTM
cydx_rat CAYINDSIGL HRVENVSHTE PAVSLHLYSP PFDTCHAFDQ RTGHKNKVTM
s*rr/4v /"fmn >• /T UTT^ _._<».*».» «k._*u ~*k.*b.,~. MM .k. __«._«.*.«.»,..•»« _MMMH «*. MM w«u _,-,.,.,-.„,,...,-,-.l» V VJLA. ^IIIJ. i. \ -I If***- ** "" *^ ** ** **• -.r-w^w-w-w-w-w-w-i*-* w>» n. n«'V«w«w'V-w«w ~r~f~f^f~- **f~*~~ -«_.—«——.-v^.n^n^n
cycbc_cele VSYMNDELGL HRMENLSHSN GAVSLHLYIP PYSTCNAFDE RTGKKTQCTV
cydx_sjap VTYMHDKIGI HRLHNPSTTE TAITLHLYFP PYTNSMIFEE STSRMKKMDV
cydx_human
cydx_rat
cydx_gmir
cydx_cele
cydx_sjap
201 221 
TFHSKFGIRT PNATSGSLEN N 
TFHSKFGIRT PFTTSGSLEN N
TFYSKYGKKV DYRGSKNGN- ~ 
TFHSKFGKQI PQ——————— -
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Figure A.8: Forward sequence of pET15b-hCDO construct
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Figure A.9: Reverse sequence of pET15b-hCDO construct
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Figure A. 10: sequence of pET15b-hCDO construct
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Figure A. 11: sequence of pETl 5b-hCDO construct
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PRETTYBOX of: pileup_53.msf{*} December 8, 2000 11:40:32.74
hcdo_cdna --ATGGAACA GACCGAAGTG CTGAAGCCAC 
forward_p_to_tl __________ __________ __________
reverse_p_to_tl __________ __________ __________
forward_p+to_t+ __________ __________ __________
reverse_p+_to_t+ ATATGGAACA GACCGAAGTG CTGAAGCCAC 
forward_p_to_t2 _--___--- __________ ______ ___
reverse_p_to_t2
Consensus
hcdo_cdna
forward_p_to_t1
reverse_p_to_t1
forward_p+to_t+
reverse_p+_to_t+
forward_p_to_t2
reverse_p_to_t2
Consensus
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_t1 
forward_p+to_t+ 
reverse_p»_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
hcdo_cdna
forward_p_to_t1
reverse_p_to_t1
forward_p+to_t +
reverse_p+_to_t +
forward_p_to_t2
reverse_p_to_t2
Consensus
C A T C 3
C AT C G
C AT C G
33
D
S
0
35
0
0
35
136 
:02
-08
30
138
101
98
140
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_t1 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
A G T G C- 
A G T G G 
AGTGGGCAAT
A 3TGGGCAA '-'
A 3TGGGCAA TG TACGCCAA G
AGTGGGCAA x
AGTGGGCAA T«G TACGCCAAG
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_tl 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
hcdo_cdna 
f orward__p_to_t 1 
reverse_p_to_t1 
f orward__p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
„ n . _„„--„ .._A T G G 
GATCAAGGA A| A T G^ G 
GATCAAGGAA 
GATCAAGGAA
Figure A. 14: Alignments of construct sequencing with consensus sequence 
(1/3)
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PRETTYBOX of: pileup_53.msf{*} December 8, 2000 11:40:32.74
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_tl 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t 2
Consensus
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_t1 
£orward_p+ to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t 2
Consensus
hcdo_cdna 
forvrard_p_to_tl 
reverse_p_to_tl 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_t1 
forward_p+ to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
hcdo_cdna 
forward_p_to_tl 
reverse_p_to_tl 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
hcdo_cdna 
forward_p_to_tl 
reverse_p_to_t1 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_tl 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Con s^n gi i«
AGGACATGGC 
AGGACATG3C 
AGGACATGGC 
; G A •'
AAAGGAGACA 
AAAGGAGACA 
AAAGGAGACA 
AAAGGAGACA
'AATGAGAT 
AATGAGAT 
AATGAGAT
TGAGGGAAA' 
TGAGGGAAAA
TGAGGGAAA A«C C A G T G T
TGAGGGAAA ABC C A G T G T
~ 3AGGGAAA A|~ r A G T G T
Figure A, 15: Alignments of construct sequencing with consensus sequence 
(2/3)
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PRETTYBOX of: pileup_53.msf{*} December 8, 2000 11:40:32.74
hcdo_cdna
fon»ard_p_to_t1
reverse_p_to_t1
forward_p+to_t+
reverse_p+_to_t+
forward_p_to_t2
reverse_p_to_t2
Consensus
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_tl 
forward_p+to_t+ 
reverse_p+_to_t+ 
forwardjp_to_t2 
reverse_p_to_t2
Consensus
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_t1 
forward_p+ to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
hcdo_cdna 
forward_p_to_tl 
reverse_p_to_tl 
forward_p+to_t-f 
reverse_p-f_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
A T A G i. A ** A^H _. T * G NJ
AT A G T A A AHT T T G G
T A G T A A A^T T T G G
T T T G G
T T
AA Tmc AGAA C T
AATHc AGAA C T
AA TMC AGAA C T
AA TMC AGAAC ~
hcdo_cdna
forward_p_to_tl
reverse_p_to_tl
forward_p+to_t+
reverse_p+_to_t+
forward_p_to_t2
reverse_p_to_t2
Consensus
NHCTANBG
GMTGGT THNAAA ACCC C
----- 603 
_____ 603
----- 591 
T T G G C 545 
_ _ _ _ 603
602
603
665
hcdo_cdna 
forward_p_to_t1 
reverse_p_to_t1 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2" 
reverse_p_to_t2
Consensus
TGCTGCCACC GCTGAGCAAT AACTAGCATG
----- 603 
_____ 603 
_____ 591 
A C C C C 580 
_____ 603 
_____ 602 
„_-,.,_ 603 
	700
hcdo_cdna 
£orward_p_to_tl 
reverse_p_to_t1 
forward_p+to_t+ 
reverse_p+_to_t+ 
forward_p_to_t2 
reverse_p_to_t2
Consensus
TTGGGGCNNC TAAACGGGNC
- - -603
- - -603
- - -591 
TTN603
- - -603
- - -602 
603 
723
Figure A. 16: Alignments of construct sequencing with consensus sequence 
(3/3)
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Amino Acid
Ala
Asx
Cys
Asp
Glu
Phe
Gly
His
He
Lys
Leu
Met
Asn
Pro
Gin
Arg
Ser
Thr
Val
Trp
Tyr
Glx
Total
No.
11
0
4
10
16
9
14
18
10
12
18
8
14
8
8
10
18
12
11
3
6
0
220
No. Nitrogen
1
1
1
1
1
1
1
3 (2x1°, 1x3°)
1
2 (1x1°, 1x2°)
1
1
2 (1x1°, 1x2°)
1
2 (1x1°, 1x2°)
3 (Ixl°,2x2°)
1
1
1
2(2x2°)
1
1
Total N
11
0
4
10
16
9
14
54
10
24
18
8
28
8
16
30
18
12
11
6
6
0
313
Table A.1: Breakdown of nitrogen content of recombinant cysteine dioxyge- 
nase
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Color Markers
High Range, (M.W. 29,000-205,000). Product Code C 3312 
Wide Range, (M.W. 6,500-205.000), Product Code C 3437 
Low Range, (M.W. 6,500-45.000), Product Code C 3187
Productlnformation
Product Description
Color Markers with high, low, and wide molecular 
weight ranges are specially designed for use as 
standards in the Laemmli SDS-PAGE system, the 
PhastSystem* etectrophoresis work station, and in 
protein transfer to solid phase supports such as 
nitrocellulose, nylon, and PVDF membranes. Color 
Markers consist of mixtures of 5-8 proteins with each 
protein conjugated to a different dye. These proteins 
provide a visual monitor of protein migration during 
etectrophoresis and/or protein transfer efficiency to a 
membrane.
Since the molecular weights of the proteins are altered 
by the attachment of dye. apparent molecular weights of 
the protein-dye conjugates are standardized using High, 
Low, and Wide Range SigmaMarkers (Product Codes 
M 3788, M 3913. and M 4038) on a 4-20% gradient gel 
in the Laemmli system. Molecular weights determined 
in this manner are available on lot specific Certificates 
of Analysis.
Each vial of Color Markers contains 500 ul of a mixture 
of the protein-dye conjugates in 62 mM Tris-HCI, 
pH 7.5, containing 2% SOS, 0.1 mM EDTA, 
100 mM dithiothreitol, 4 M urea, 0.005% bromophenol 
blue, and 30% grycerol. Distribution of the various 
proteins is indicated in Table 1.
Notes:
1. When precise molecular weight determinations are 
required, use Sigma Bkrtinylated Standards 
(Product Code SDS-6B) or High, Low. and Wide 
Range SigmaMarkers (Product Codes M 3788, 
M 3913. and M 4038, respectively).
2. The apparent molecular weight of the myosin-dye 
conjugate cannot be accurately determined since its 
molecular weight lies outside the range of the 
standard curve used for molecular weight 
determination.
3. Color Markers may be stained with Coomassie* 
Blue, but equal intensity bands will not be obtained.
Disclaimer
This product is for laboratory research use only. Please 
consult the Material Safety Data Sheet for information 
regarding hazards and safe handling practices.
Storage/Stability
Aliquot vial contents and store at -70 °C or below. 
Repeated freezing and thawing is not recommended. 
By eliminating multiple freeze/thaw cycles, the effective 
lifetime of these products will be prolonged.
Preparation Instructions
Do not heat the Color Markers. Simply thaw to room 
temperature and load the gel. For use in a mini gel 
(10 cm x 10 cm), load 10 ul for visualization directly on 
the gel or 5 ul when transferring to a membrane. For 
use in a standard size gel (16 cm x 18 cm), load 20 ul 
for visualization directly on the gel or 10 ul when 
transferring to a membrane. For use in the PhastGel 
system, load 1-4 ul.
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Table 1.
Distribution of Proteins in Color Markers
^— .. i _ »,, nproteins
Myosin, rabbit muscle
p-Galactosidase, E. coli
Albumin, bovine serum
Ovalbumin, 
chicken egg
Carbonic Anhydrase, 
bovine erythrocytes
Trypsin Inhibitor, 
soybean
a-Lactalbumin, 
bovine milk
Aprotinin, bovine milk
Native Md.Wt 
of Subunit (kOa)
205
116
66
45
29
20
14.2
6.5
Color of 
Conjugate
Blue
Turquoise
Pink
Yellow
Orange
Green
Purple
Blue
High Range* 
(C 3312)
X
X
X
X
X
Wide Range 
(C3437)
X
X
X
X
X
X
X
X
Low Range 
(C3187)
X
X
X
X
X
The light chain of myosin may appear as an additional blue band having a molecular weight approximately that of Trypsin 
Inhibitor from Soybean.
Reference
Laemmli, U.K., Nature, 227,680 (1970).
PhastGel is a registered trademark of Amersham 
Pharmacia Biotech Limited or its subsidiaries.
Coomassie is a registered trademark of Imperial 
Chemical Industries PLC.
MDS/MAM 6/03
Sigrna brand products are sold through S^jma-AMrich, Inc.
Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-AMrich publications. 
Purchaser must determine the suftabitty of the product(s) for their particular use. Additional terms and condWons may apply.
Please see reverse side of the invoice or packing slip.
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Figure A. 17: Comparison of human CDO according to topography and nitro­ 
gen content with relative secondary structures
APPENDIX A. SEQUENCE SPECIFIC DETAILS OF CDO 181
I Ql I I Q2 I
AD R H^^AGDEIJEE QA cydx_human
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Figure A. 18: Human CDO with predicted structural motifs and modification 
sites.
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Protein Concentration & Solubility Assays Using Surface 
Plasmon Resonance
Christopher H. Barry, Adrian C. Williams and David B. Ramsden* 
Department of Clinical Neuroscience. University of Birmingham, England 
t Department of Medicine, University of Birmingham. England
Surface plasmon resonance is a responsive and non-destructive alternative for measuring the concentration of pro­ 
teins in solution. Both the detection limits and resolution are unparallelled using non-destructive laboratory techniques. 
The method described in this experiment required minimal protein preparation and no chromophore to determine the 
concentration of a protein sample in solution. This method differentiates itself from other methods in that the analysis 
is performed on a planar interface with the sample; rather than a net analysis of the sample as a whole.
Spectroscopic and colorimetric methods have been devised to approximate protein concentration. Often these 
methods show a linear response to the concentration over a small range or require the destruction of the sample 
using a chromophore. It has already been established that there is a relation between the refractive index and the 
concentration of a sample! 1 ]. Increments in these values differ widely for different proteins and must be experimentally 
determined [2]. Surface plasmon resonance (SPR) is a physical method that measures a quantity proportional to the 
refractive index and is a technology used in new chip based bio-technologies(3). The only requirements for an accurate 
assay is a protein in solution and a sample of the buffer alone. SPR is a preferable measurement technique for microliter 
volumes or precious samples where accuracy and recovery are paramount.
Materials and Methods
An SPR device consists of a thin metal film deposited upon an optical substrate with an incident columnated light 
beam. The incident light, at a critical angle, induces a plasmon wave through the metal film. An analyte is exposed to 
the surface opposite the incident beam and optical substrate. Changes in the angular intensity of the reflected light are 
detected and are proportional to the refractive index of the sample, exposed to the planar surface.
A Biacore 3000 instrument was used for all measurements. An unmodified gold surface was used to detect changes 
in plasmon resonance (Biacore Pioneer Sensor Chip Jl, 99-1000-01). Data analysis was evaluated from the raw
1
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responses of Biacore unit The instrument was programmed to inject 10 /iL aliquots of sample, at a flow rate of 
10 uLlmm, through one micro-channel at 24°C.
Bovine serum albumin (BSA) and lysozyme were both purchased from Sigma (A-8022 and L-76S1). Sodium 
chloride gradients were diluted with distilled and de-ionised water from a 20% stock NaCl solution. Solutions of BSA 
were prepared by preparing a concentrate in 150 mM NaCl and diluting it in the same solution. Samples were filtered 
through a 0.22 fun syringe-top filter prior to dilution. To prevent adsorption of lysozyme to the plasmon surface, 
washing steps between protein injections consisted of ISOmM NaCl supplemented with lOOmM L-cysteine. Samples 
were intended to be solubilised only and were not buffered to simplify measurements [2].
Results and Discussion
The output units on the Biacore instrument are in terms of resonance units (RU) as opposed to refractive index units. 
To confirm that there is a linear relation between the refractive index and RU, a sodium chloride gradient was measured 
and compared to the standard index of refraction values at the same concentration taken from a CRC Handbook. Figure 
1 compares the linearity of the two methods. Sensorgraph readings (Figure 1 A) are plotted as a function of time to 
illustrate the raw resonance reading as each sample of the gradient is injected automatically in turn. The change in RU 
with respect to concentration can be approximateted by 1.517.6 ^^-(mL/mg) using a linear trend line (Figure 1C): 
Several orders of magnitude greater than a ^ of 0.00185 mL/mg over the same range.
The same method was applied for BSA. Figure 2A illustrates the measured changes in resonance units (RU) with 
the tabulated data. Due to small changes in baseline measurements between samples, changes from the baseline (ARU) 
were used to correlate protein concentration with RU in tabulated data. BSA shows a linear change in RU with protein 
concentration (Figure 2C).
The same method was applied to lysozyme. Initial results failed to bring the protein peak back to baseline. It 
was assumed that this was due to adsorption of free sulfhydryl groups of the protein to the gold surface of the sensor 
chip[4]. Supplementing the wash steps in the procedure with lOOmM L-cysteine and lOOmM NaCl was effective 
in bringing each measured sample to near baseline. Washing steps separate sample measurements. The additive in 
the lysozyme wash steps increase the refractive index for those intervals which explains the apparent negative RU 
at lysozyme concentrations of 0 and 250 /ig/mL (Figure 2B, indicated by arrows). Lysozyme shows a nearly linear 
change in RU with concentration from 0 to 9 mg/mL. There was a drop in RU at 10 mg/mL. Because the RU is 
a reflection of concentration as opposed to absolute density, the apparent decrease in RU at lOmg/mL is due to a
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decrease in the dispersion of the sample; Consistent with a protein dimerising at high concentrations.
A plot of the change in resonance (ARU) versus concentration, in mg/mL, between BSA and lysozyme differs 
substantially. Differences in response to concentration for BSA and lysozyme are nearly equal in magnitude to their 
individual molecular weights of the two species (Figure 2D). This indicates, while the refractive index is a function of 
density RI(/>)[5], plasmon resonance is a function of density and individual mass. RL'(p.m).
The results of this technique have been applied to two commonly available proteins and shows that approximate 
concentrations can be measured. Because the technique is a reflection of the number of particles in solution rather 
than the absolute mean in solution, it is possible to monitor aggregation of a samples. Changes in the refractive index 
for macromolecular systems have been cited in the literature and approximation of ^ values cannot be approxi­ 
mated for individual monomer components as is practised in analytical ultracentrifugation[2). SPR is an alternative 
or complementary technique to static or dynamic light scattering because the measurements do not require integration 
time, are not biased toward larger particle species, and are not influenced by flow. The technique could be adopted 
for use in tandem with spectroscopic analysis; It would be a valuable tool if the simultaneous measurement of two 
variables, concentration and aggregation state, could monitored in real-time during dialysis or other routine laboratory 
procedures.
References
[ 1 ] C. Hitscherich. Jr. J. Kaplan, M. Allaman, J. Wiencek, and P. J. Loll. Static light scattering studies of ompf porin: 
implications for integral membrane protein crystallization. Protein Sci, 9(8): 1559-66, August 2000.
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APPENDIX A. SEQUENCE SPECIFIC DETAILS OF CDO 185
49000
40000
35000 
30000
25000
20000
,-, AKC ———
-
-
-
-
-
— .
—
__
[1 ^_^
r-i -
15000 ———————————————————————————————————————————— 
200 400 «00 800 1000 1200 141
IAI 'n-e(t>
Conc.(%)
0
5
8
10
12
14
16
18
20
Resonance (RU)
15826.7
24576.7
29378.6
32364.2
35369.4
38229.1
40983.6
43757.5
46483.1
Ref.Index (n)
1.33054
1.3418
1.347
.3505
.3541
.3576
.3612
.3648
.3684
Rl
45000 
40000 
35000 
30000
25000
3QOQO
15000'(
iCl
, Ta»e<i)
SPR of Sodnm Chloride
Nad 0 _,
I517-59.X+1673S.7 —— _0---~- 
.-*"" 
.O--""
.O-""
.---°"~~
i i i
1 5 10 15 2
Cancemnuon (% w/r)
(B
W(»)
'' 1JC5
1J6 
1J55 
135 
1.345
134
1J35 
1334
0 C
ID)
CRC Values for Sodum Chloride
' Nad (») 0 ' ' .--•* 
O0018543*X+133MS —— --*" -
.-•*"" : _.«••"
.-*-""' i
.---*
~ .--•""
5 10 15 20
Oncenntion (% W/T)
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